

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12) Oversættelse af
europæisk patentskrift

(10) **DK/EP 2841578 T3**

-
- (51) Int.Cl.: **C 12 N 15/113 (2010.01)** **A 61 K 31/7115 (2006.01)** **A 61 K 31/712 (2006.01)**
A 61 K 31/7125 (2006.01) **A 61 P 25/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-07-31**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2017-06-07**
- (86) Europæisk ansøgning nr.: **13720617.3**
- (86) Europæisk indleveringsdag: **2013-04-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2015-03-04**
- (86) International ansøgning nr.: **NL2013050306**
- (87) Internationalt publikationsnr.: **WO2013162363**
- (30) Prioritet: **2012-04-23 EP 12165139** **2012-04-23 US 201261636914 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **BioMarin Technologies B.V., J.H. Oortweg 21, 2333 CH Leiden, Holland**
- (72) Opfinder: **DE VISSER, Peter Christian, Kurt Weillstraat 2, NL-2324 DS Leiden, Holland**
MULDERS, Susan Allegonda Maria, Bredeweg 75B, NL-6562 DC Groesbeek, Holland
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **RNA-modulerende oligonukleotider med forbedrede egenskaber til behandling af neuromuskulære sygdomme**
- (56) Fremdragne publikationer:
J. E. LEE ET AL: "RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 27 February 2012 (2012-02-27), XP055035228, ISSN: 0027-8424, DOI: 10.1073/pnas.1117019109
MELVIN M. EVERS ET AL: "Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide", PLOS ONE, vol. 6, no. 9, 1 September 2011 (2011-09-01), pages e24308-e24308, XP055007055, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0024308
JONATHAN J. MAGAÑA ET AL: "Perspectives on gene therapy in myotonic dystrophy type 1", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 89, no. 3, 16 December 2010 (2010-12-16), pages 275-285, XP055035164, ISSN: 0360-4012, DOI: 10.1002/jnr.22551
FRANCESCO MUNTONI ET AL: "Targeting RNA to treat neuromuscular disease", NATURE REVIEWS DRUG DISCOVERY, vol. 10, no. 8, 1 January 2011 (2011-01-01), pages 621-637, XP055035163, ISSN: 1474-1776, DOI: 10.1038/nrd3459
WO-A1-2008/018795
WO-A1-2009/099326
WO-A1-2011/097614
WO-A1-2011/097641

Fortsættes ...

WO-A2-03/004511

KEITH T. GAGNON ET AL: "Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat", **BIOCHEMISTRY**, vol. 49, no. 47, 28 October 2010 (2010-10-28), pages 10166-10178, XP055033274, ISSN: 0006-2960, DOI: 10.1021/bi101208k

AGNIESZKA FISZER ET AL: "An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases", **BMC MOLECULAR BIOLOGY**, vol. 13, no. 1, 7 March 2012 (2012-03-07), page 6, XP055033266, ISSN: 1471-2199, DOI: 10.1186/1471-2199-13-6

S. A. M. MULDER ET AL: "Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy", **PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES**, vol. 106, no. 33, 18 August 2009 (2009-08-18), pages 13915-13920, XP055007026, ISSN: 0027-8424, DOI: 10.1073/pnas.0905780106

S. A. M. MULDER ET AL: "Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function", **HUMAN MOLECULAR GENETICS**, vol. 19, no. R1, 20 April 2010 (2010-04-20), pages R90-R97, XP055007054, ISSN: 0964-6906, DOI: 10.1093/hmg/ddq161

DINAH W.Y. SAH ET AL: "Oligonucleotide therapeutic approaches for Huntington disease", **JOURNAL OF CLINICAL INVESTIGATION**, vol. 121, no. 2, 1 February 2011 (2011-02-01), pages 500-507, XP055033272, ISSN: 0021-9738, DOI: 10.1172/JCI45130

DESCRIPTION

Field

[0001] The invention relates to the field of human genetics, more specifically neuromuscular disorders. The invention in particular relates to the use of antisense oligonucleotides (AONs) with improved characteristics enhancing clinical applicability as further defined herein.

Background of the invention

[0002] Neuromuscular diseases are characterized by impaired functioning of the muscles due to either muscle or nerve pathology (myopathies and neuropathies). The neuropathies are characterized by neurodegeneration and impaired nerve control leading to problems with movement, spasticity or paralysis. Examples include Huntington's disease (HD), several types of spinocerebellar ataxia (SCA), Friedreich's ataxia (FA), Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD). A subset of neuropathies is caused by a cis-element repeat instability. For instance, HD is caused by a triplet (CAG)_n repeat expansion in exon 1 of the HTT gene. Expansion of these repeats results in expansion of a glutamine stretch at the N-terminal end of the 348 kDa cytoplasmic huntingtin protein. Huntingtin has a characteristic sequence of 6 to 29 glutamine amino acid residues in the normal form; the mutated huntingtin causing the disease has more than 38 residues. The continuous expression of mutant huntingtin molecules in neuronal cells results in the formation of large protein deposits which eventually give rise to cell death, especially in the frontal lobes and the basal ganglia (mainly in the caudate nucleus). The severity of the disease is generally proportional to the number of extra residues. AONs specifically targeting the expanded CAG repeats (such as PS57 (CUG)₇ as a 2'-O-methyl phosphorothioate RNA; SEQ ID NO:1 Evers et al.) can be applied to effectively reduce mutant huntingtin transcript and (toxic) protein levels in HD patient-derived cells. For treatment of neuropathies, systemically administered AONs need to pass the blood brain barrier. Thus, there is a need for optimization of oligochemistry allowing and/or exhibiting improved brain delivery.

[0003] The myopathies include genetic muscular dystrophies that are characterized by progressive weakness and degeneration of skeletal, heart and/or smooth muscle.

[0004] Examples of myopathies are Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and myotonic dystrophy type 2 (DM2). DM1 and DM2 are both also caused by cis-element repeat instability; DM1 by a trinucleotide (CTG)_n repeat expansion in the 3' untranslated region of exon 15 in the DMPK gene, and DM2 by a tetranucleotide (CCTG)_n repeat expansion in the DM2/ZNF9 gene. Also here, AONs specifically targeting the expanded repeats, such as PS58, (CAG)₇, a 2'-O-methyl phosphorothioate RNA for DM1

(Mulders et al.), have been shown to efficiently induce the specific degradation of the (toxic) expanded repeat transcripts. In contrast to DMD where the gene defect is associated with increased permeability of the muscle fiber membranes for small compounds as AONs, for most other myopathies an enhanced AON distribution to and uptake by muscle tissue is essential to obtain a therapeutic effect. Thus, also here there is a need for optimization of oligochemistry allowing and/or exhibiting improved muscle delivery.

[0005] The particular characteristics of a chosen chemistry at least in part affect the delivery of an AON to the target transcript: administration route, biostability, biodistribution, intra-tissue distribution, and cellular uptake and trafficking. In addition, further optimization of oligonucleotide chemistry is conceived to enhance binding affinity and stability, enhance activity, improve safety, and/or to reduce cost of goods by reducing length or improving synthesis and/or purification procedures. Multiple chemical modifications have become generally and/or commercially available to the research community (such as 2'-O-methyl RNA and 5-substituted pyrimidines and 2,6-diaminopurines), whereas most others still present significant synthetic effort to obtain. Especially preliminary encouraging results have been obtained using 2'-O-methyl phosphorothioate RNA containing modifications on the pyrimidine and purine bases as identified herein.

[0006] In conclusion, to enhance the therapeutic applicability of AONs for treating human cis-element repeat instability associated genetic disorders as exemplified herein, there is a need for AONs with further improved characteristics.

Description

Oligonucleotide

[0007] In a first aspect, the disclosure provides an oligonucleotide comprising 2'-O-methyl RNA nucleotide residues, having a backbone wherein at least one phosphate moiety is replaced by a phosphorothioate moiety, and comprising one or more 5-methylpyrimidine and/or one or more 2,6-diaminopurine bases; or an oligonucleotide of the invention consisting of 2'-O-methyl RNA nucleotide residues and having a backbone wherein all phosphate moieties are replaced by phosphorothioate moieties, and having a base sequence consisting of (XYG)₇ wherein each X is 5-methylcytosine and each Y is uracil (SEQ ID NO:70), preferably for use as a medicament for treating human cis-element repeat instability associated genetic disorders.

In this context, "backbone" is used to identify the chain of alternating ribose rings and internucleoside linkages, to which the nucleobases are attached. The term "linkage" is used for the connection between two ribose units (i.e. "internucleoside linkage"), which is generally a phosphate moiety. Thus, an oligonucleotide having 10 nucleotides may contain 9 linkages, linking the 10 ribose units together. Additionally, there may be one or more last linkage(s)

present at one or both sides of the oligonucleotide, which is only connected to one nucleotide. The terms "linkage" and "internucleoside linkage" are also meant to indicate such a pendant linkage. At least one of the linkages in the backbone of the oligonucleotide according to the disclosure consists of a phosphorothioate moiety, linking two ribose units. Thus, at least one of the naturally occurring 3' to 5' phosphodiester moieties present in RNA is replaced by a phosphorothioate moiety. Within the context of the disclosure and invention, "a" in each of the following expressions means "at least one": a 2'-O-methyl RNA nucleotide residue, a 2'-O-methyl RNA residue, a phosphorothioate moiety, a 2'-O-methyl phosphorothioate RNA residue, a 5-methylpyrimidine base, a 5-methylcytosine base, a 5-methyluracil base, a thymine base, a 2,6-diaminopurine base.

[0008] Preferably, the oligonucleotide according to the disclosure is an oligonucleotide with less than 37 nucleotides. Said oligonucleotide may have 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 nucleotides. Such oligonucleotide may also be identified as an oligonucleotide having from 12 to 36 nucleotides.

Accordingly, an oligonucleotide of the disclosure, comprising a 2'-O-methyl RNA nucleotide residue having a backbone wherein at least one phosphate moiety is replaced by a phosphorothioate moiety, comprises less than 37 nucleotides (i.e. it comprises 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides) and a 5-methylpyrimidine and/or a 2,6-diaminopurine base. Accordingly, an oligonucleotide of the invention, consisting of 2'-O-methyl RNA nucleotide residues and having a backbone wherein all phosphate moieties are replaced by phosphorothioate, and comprises less than 34 nucleotides (i.e. it comprises 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides) and a 5-methylpyrimidine and/or a 2,6-diaminopurine base.

[0009] In a preferred embodiment, the oligonucleotide of the disclosure comprises a 2'-O-methyl phosphorothioate RNA nucleotide residue, or consists of 2'-O-methyl phosphorothioate RNA nucleotide residues. Such oligonucleotide comprises a 2'-O-methyl RNA residue, which is connected through a phosphorothioate linkage to the next nucleotide in the sequence. This next nucleotide may be, but not necessarily, another 2'-O-methyl phosphorothioate RNA nucleotide residue. Alternatively, such oligonucleotide consists of 2'-O-methyl phosphorothioate RNA nucleotide residues, wherein all nucleotides comprise a 2'-O-methyl moiety and a phosphorothioate moiety. Preferably, such oligonucleotide consists of 2'-O-methyl phosphorothioate RNA nucleotide residues. Such chemistry is known to the skilled person. Throughout the application, an oligonucleotide comprising a 2'-O-methyl RNA residue and a phosphorothioate linkage may be replaced by an oligonucleotide comprising a 2'-O-methyl phosphorothioate RNA nucleotide residue or an oligonucleotide comprising a 2'-O-methyl phosphorothioate RNA residue. Throughout the application, an oligonucleotide consisting of 2'-O-methyl RNA residues linked by or connected through phosphorothioate linkages or an oligonucleotide consisting of 2'-O-methyl phosphorothioate RNA nucleotide residues may be replaced by an oligonucleotide consisting of 2'-O-methyl phosphorothioate RNA.

[0010] In addition, an oligonucleotide of the invention comprises at least one base

modification that increases binding affinity to target strands, increases melting temperature of the resulting duplex of said oligonucleotide with its target, and/or decreases immunostimulatory effects, and/or increases biostability, and/or improves biodistribution and/or intra-tissue distribution, and/or cellular uptake and trafficking. In an embodiment, an oligonucleotide of the invention comprises a 5-methylpyrimidine and/or a 2,6-diaminopurine base. A 5-methylpyrimidine base is selected from a 5-methylcytosine and/or a 5-methyluracil and/or a thymine, in which thymine is identical to 5-methyluracil. Where an oligonucleotide of the disclosure has two or more such base modifications, said base modifications may be identical, for example all such modified bases in the oligonucleotide are 5-methylcytosine, or said base modifications may be combinations of different base modifications, for example the oligonucleotide may have one or more 5-methylcytosines and one or more 5-methyluracils.

In a preferred embodiment, an oligonucleotide of the disclosure (i.e. an oligonucleotide comprising 2'-O-methyl RNA nucleotide residues, having a backbone wherein at least one phosphate moiety is replaced by a phosphorothioate moiety, and comprising one or more 5-methylpyrimidine and/or one or more 2,6-diaminopurine bases; or an oligonucleotide of the invention consisting of 2'-O-methyl RNA nucleotide residues and having a backbone wherein all phosphate moieties are replaced by phosphorothioate moieties, and comprising one or more 5-methylpyrimidine and/or one or more 2,6-diaminopurine bases) is such that it does not comprise a 2'-deoxy 2'-fluoro nucleotide (i.e. 2'-deoxy 2'-fluoro-adenosine, -guanosine, -uridine and/or -cytidine). Such oligonucleotide comprising a 2'-fluoro (2'-F) nucleotide has been shown to be able to recruit the interleukin enhancer-binding factor 2 and 3 (ILF2/3) and is thereby able to induce exon skipping in the targeted pre-mRNA (Rigo F, et al, WO2011/097614). In the current invention, the oligonucleotide used preferably does not recruit such factors and/or the oligonucleotide of the invention does not form heteroduplexes with RNA that are specifically recognized by the ILF2/3. The mechanism of action of the oligonucleotide of the current invention is assumed to be distinct from the one of an oligonucleotide with a 2'-F nucleotide: the oligonucleotide of the invention is expected to primarily induce the specific degradation of the (toxic) expanded repeat transcripts.

[0011] 'Thymine' and '5-methyluracil' may be interchanged throughout the document. In analogy, 2,6-diaminopurine is identical to 2-aminoadenine and these terms may be interchanged throughout the document.

[0012] The term "base modification" or "modified base" as identified herein refers to the modification of a naturally occurring base in RNA (i.e. pyrimidine or purine base) or to the de novo synthesis of a base. This de novo synthesized base could be qualified as "modified" by comparison to an existing base.

An oligonucleotide comprising a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine base means that at least one of the cytosine nucleobases of said oligonucleotide has been modified by substitution of the proton at the 5-position of the pyrimidine ring with a methyl group (i.e. a 5-methylcytosine), and/or that at least one of the uracil nucleobases of said oligonucleotide has been modified by substitution of the proton at the 5-position of the pyrimidine ring with a methyl group (i.e. a 5-methyluracil), and/or that at least one of the adenine nucleobases of said oligonucleotide has been modified by substitution

of the proton at the 2-position with an amino group (i.e. a 2,6-diaminopurine), respectively. Within this context, the expression "the substitution of a proton with a methyl group in position 5 of the pyrimidine ring" may be replaced by the expression "the substitution of a pyrimidine with a 5-methylpyrimidine," with pyrimidine referring to only uracil, only cytosine or both. Likewise, the expression "the substitution of a proton with an amino group in position 2 of adenine" may be replaced by the expression "the substitution of an adenine with a 2,6-diaminopurine." If said oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or more cytosines, uracils, and/or adenines, at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or more cytosines, uracils and/or adenines respectively have been modified this way. Preferably all cytosines, uracils and/or adenines have been modified this way or replaced by 5-methylcytosine, 5-methyluracil and/or 2,6-diaminopurine, respectively. No need to say that the AON's from the disclosure and invention could only be applied to oligonucleotides comprising at least one cytosine, uracil, or adenine, respectively, in their sequence.

[0013] We discovered that the presence of a 5-methylcytosine, 5-methyluracil and/or a 2,6-diaminopurine in an oligonucleotide of the invention has a positive effect on at least one of the parameters or an improvement of at least one parameters of said oligonucleotides. In this context, parameters may include: binding affinity and/or kinetics, silencing activity, biostability, (intra-tissue) distribution, cellular uptake and/or trafficking, and/or immunogenicity of said oligonucleotide, as explained below.

[0014] Binding affinity and kinetics depend on the AON's thermodynamic properties. These are at least in part determined by the melting temperature of said oligonucleotide (T_m ; calculated with e.g. the oligonucleotide properties calculator (<http://www.unc.edu/~cail/biotool/oligo/index.html>) or <http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/>) for single stranded RNA using the basic T_m and the nearest neighbor model), and/or the free energy of the oligonucleotide-target exon complex (using RNA structure version 4.5 or RNA mfold version 3.5). If a T_m is increased, the exon skipping activity typically increases, but when a T_m is too high, the AON is expected to become less sequence-specific. An acceptable T_m and free energy depend on the sequence of the oligonucleotide. Therefore, it is difficult to give preferred ranges for each of these parameters.

[0015] An activity of an oligonucleotide of the disclosure and invention is to inhibit the formation of a mutant protein and/or silence or reduce or decrease the quantity of a disease-associated or disease-causing or mutant transcript containing an extended or unstable number of repeats in a cell of a patient, in a tissue of a patient and/or in a patient as explained later herein. An oligonucleotide comprising or consisting of a 2'-O-methyl phosphorothioate RNA and a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine base is expected to be able to silence or reduce or decrease the quantity of said transcript more efficiently than what an oligonucleotide comprising or consisting of a 2'-O-methyl phosphorothioate RNA but without any 5-methylcytosine, without any 5-methyluracil and without any 2,6-diaminopurine base will do. This difference in terms of efficiency may be of at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%. The reduction or decrease may be assessed by Northern Blotting or (semi-) quantitative RT-

PCR for transcript levels (preferably as carried out in the experimental part) or by Western blotting for protein levels. An oligonucleotide may first be tested in the cellular system like patient-derived fibroblasts as described in Example 1.

[0016] Biodistribution and biostability are preferably at least in part determined by a validated hybridization ligation assay adapted from Yu et al., 2002. In an embodiment, plasma or homogenized tissue samples are incubated with a specific capture oligonucleotide probe. After separation, a DIG-labeled oligonucleotide is ligated to the complex and detection followed using an anti-DIG antibody-linked peroxidase. Non-compartmental pharmacokinetic analysis is performed using WINNONLIN software package (model 200, version 5.2, Pharsight, Mountainview, CA). Levels of AON (ug) per mL plasma or mg tissue are monitored over time to assess area under the curve (AUC), peak concentration (C_{max}), time to peak concentration (T_{max}), terminal half life and absorption lag time (t_{lag}). Such a preferred assay has been disclosed in the experimental part.

AONs may stimulate an innate immune response by activating the Toll-like receptors (TLR), including TLR9 and TLR7 (Krieg et al., 1995). The activation of TLR9 typically occurs due to the presence of non-methylated CG sequences present in oligodeoxynucleotides (ODNs), by mimicking bacterial DNA which activates the innate immune system through TLR9-mediated cytokine release. The 2'-O-methyl modification is however suggested to markedly reduce such possible effect. TLR7 has been described to recognize uracil repeats in RNA (Diebold et al., 2006).

Activation of TLR9 and TLR7 result in a set of coordinated immune responses that include innate immunity (macrophages, dendritic cells (DC), and NK cells)(Krieg et al., 1995; Krieg, 2000). Several chemo- and cytokines, such as IP-10, TNF α , IL-6, MCP-1 and IFN α (Wagner, 1999; Popovic et al., 2006) have been implicated in this process. The inflammatory cytokines attract additional defensive cells from the blood, such as T and B cells. The levels of these cytokines can be investigated by *in vitro* testing. In short, human whole blood is incubated with increasing concentrations of AONs after which the levels of the cytokines are determined by standard commercially available ELISA kits. A decrease in immunogenicity preferably corresponds to a detectable decrease of concentration of at least one of the cytokines mentioned above by comparison to the concentration of corresponding cytokine in an assay in a cell treated with an oligonucleotide comprising at least one 5-methylcytosine and/or 5-methyluracil, and/or 2,6-diaminopurine compared to a cell treated with a corresponding oligonucleotide having no 5-methylcytosines, 5-methyluracils, or 2,6-diaminopurines.

[0017] Accordingly, a preferred oligonucleotide of the invention has an improved parameter, such as an acceptable or a decreased immunogenicity and/or a better biodistribution and/or acceptable or improved RNA binding kinetics and/or thermodynamic properties by comparison to a corresponding oligonucleotide consisting of a 2'-O-methyl phosphorothioate RNA without a 5-methylcytosine, without a 5-methyluracil and without a 2,6-diaminopurine. Each of these parameters could be assessed using assays known to the skilled person or preferably as disclosed herein.

[0018] Below other chemistries and modifications of the oligonucleotide of the disclosure are

defined. These additional chemistries and modifications may be present in combination with the chemistry already defined for said oligonucleotide, *i.e.* the presence of a 5-methylcytosine, a 5-methyluracil and/or a 2,6-diaminopurine, and the oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA.

[0019] A preferred oligonucleotide of the invention comprises or consists of an RNA molecule or a modified RNA molecule. In a preferred embodiment, an oligonucleotide is single stranded. The skilled person will understand that it is however possible that a single stranded oligonucleotide may form an internal double stranded structure. However, this oligonucleotide is still named a single stranded oligonucleotide in the context of this invention. A single stranded oligonucleotide has several advantages compared to a double stranded siRNA oligonucleotide: (i) its synthesis is expected to be easier than two complementary siRNA strands; (ii) there is a wider range of chemical modifications possible to enhance uptake in cells, a better (physiological) stability and to decrease potential generic adverse effects; (iii) siRNAs have a higher potential for non-specific effects (including off-target genes) and exaggerated pharmacology (e.g. less control possible of effectiveness and selectivity by treatment schedule or dose) and (iv) siRNAs are less likely to act in the nucleus and cannot be directed against introns.

In addition to the modifications described above, the oligonucleotide of the disclosure may comprise further modifications such as different types of nucleic acid nucleotide residues or nucleotides as described below. Different types of nucleic acid nucleotide residues may be used to generate an oligonucleotide of the disclosure. Said oligonucleotide may have at least one backbone modification (internucleoside linkage and/or sugar modification) and/or at least one base modification compared to an RNA-based oligonucleotide.

A base modification includes a modified version of the natural purine and pyrimidine bases (e.g. adenine, uracil, guanine, cytosine, and thymine), such as hypoxanthine (e.g. inosine), orotic acid, agmatidine, lysidine, pseudouracil, 2-thiopyrimidine (e.g. 2-thiouracil, 2-thiothymine), G-clamp and its derivatives, 5-substituted pyrimidine (e.g. 5-halouracil, 5-propynyluracil, 5-propynylcytosine, 5-aminomethyluracil, 5-hydroxymethyluracil, 5-aminomethylcytosine, 5-hydroxymethylcytosine, Super T), 7-deazaguanine, 7-deazaadenine, 7-aza-2,6-diaminopurine, 8-aza-7-deazaguanine, 8-aza-7-deazaadenine, 8-aza-7-deaza-2,6-diaminopurine, Super G, Super A, and N⁴-ethylcytosine, or derivatives thereof; N²-cyclopentylguanine (cPent-G), N²-cyclopentyl-2-aminopurine (cPent-AP), and N²-propyl-2-aminopurine (Pr-AP), or derivatives thereof; and degenerate or universal bases, like 2,6-difluorotoluene or absent bases like abasic sites (e.g. 1-deoxyribose, 1,2-dideoxyribose, 1-deoxy-2-O-methylribose; or pyrrolidine derivatives in which the ring oxygen has been replaced with nitrogen (azaribose)). Examples of derivatives of Super A, Super G and Super T can be found in US patent 6,683,173 (Epoch Biosciences), which is incorporated here entirely by reference. cPent-G, cPent-AP and Pr-AP were shown to reduce immunostimulatory effects when incorporated in siRNA (Peacock H. *et al.*).

In an embodiment, an oligonucleotide of the disclosure comprises an abasic site or an abasic monomer. Within the context of the disclosure, such monomer may be called an abasic site or an abasic monomer. An abasic monomer or abasic site is a nucleotide residue or building block that lacks a nucleobase by comparison to a corresponding nucleotide residue comprising

oligonucleotide as in SEQ ID NO:210 and 213.

In tables 1 and 2, an abasic monomer is identified using the letter Q.

Depending on its length an oligonucleotide of the invention may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base modifications. It is also encompassed by the disclosure to introduce more than one distinct base modification in said oligonucleotide.

[0022] A "sugar modification" indicates the presence of a modified version of the ribosyl moiety as naturally occurring in RNA (i.e. the furanosyl moiety), such as bicyclic sugars, tetrahydropyrans, morpholinos, 2'-modified sugars, 4'-modified sugars, 5'-modified sugars, and 4'-substituted sugars. Examples of suitable sugar modifications include, but are not limited to, 2'-O-modified RNA nucleotide residues, such as 2'-O-alkyl or 2'-O-(substituted)alkyl e.g. 2'-O-methyl, 2'-O-(2-cyanoethyl), 2'-O-(2-methoxy)ethyl (2'-MOE), 2'-O-(2-thiomethyl)ethyl, 2'-O-butyryl, 2'-O-propargyl, 2'-O-allyl, 2'-O-(2-amino)propyl, 2'-O-(2-(dimethylamino)propyl), 2'-O-(2-amino)ethyl, 2'-O-(2-(dimethylamino)ethyl); 2'-deoxy (DNA); 2'-O-(haloalkoxy)methyl (Arai K. *et al.*) e.g. 2'-O-(2-chloroethoxy)methyl (MCEM), 2'-O-(2,2-dichloroethoxy)methyl (DCEM); 2'-O-alkoxycarbonyl e.g. 2'-O-[2-(methoxycarbonyl)ethyl] (MOCE), 2'-O-[2-(*N*-methylcarbamoyl)ethyl] (MCE), 2'-O-[2-(*N,N*-dimethylcarbamoyl)ethyl] (DCME); 2'-halo e.g. 2'-F, FANA (2'-F arabinosyl nucleic acid); carbasugar and azasugar modifications; 3'-O-alkyl e.g. 3'-O-methyl, 3'-O-butyryl, 3'-O-propargyl, 5'-alkyl e.g. 5'-methyl; and their derivatives.

Another sugar modification includes "bridged" or "bicyclic" nucleic acid (BNA), e.g. locked nucleic acid (LNA), *xylo*-LNA, α -L-LNA, β -D-LNA, cEt (2'-O,4'-C constrained ethyl) LNA, cMOEt (2'-O,4'-C constrained methoxyethyl) LNA, ethylene-bridged nucleic acid (ENA), BNA^{NC}[*N*-Me] (as described in Chem. Commun. 2007, 3765, which is incorporated in its entirety by reference); tricyclo DNA (tcDNA); unlocked nucleic acid (UNA); 5'-methyl substituted BNAs (as described in US patent application 13/530,218, which is incorporated in its entirety by reference); cyclohexenyl nucleic acid (CeNA), altrial nucleic acid (ANA), hexitol nucleic acid (HNA), fluorinated HNA (F-HNA), pyranosyl-RNA (p-RNA), 3'-deoxypyranosyl-DNA (p-DNA); morpholino (as e.g. in PMO, PMOPlus, PMO-X) and their derivatives, preferably locked nucleic acid (LNA), *xylo*-LNA, α -L-LNA, β -D-LNA, cEt (2'-O,4'-C constrained ethyl) LNA, cMOEt (2'-O,4'-C constrained methoxyethyl) LNA, ethylene-bridged nucleic acid (ENA), tricyclo DNA (tcDNA); cyclohexenyl nucleic acid (CeNA), altrial nucleic acid (ANA), hexitol nucleic acid (HNA), fluorinated HNA (F-HNA), pyranosyl-RNA (p-RNA), 3'-deoxypyranosyl-DNA (p-DNA); morpholino (as e.g. in PMO, PMOPlus, PMO-X) and their derivatives. A preferred tcDNA is tc-PS-DNA (tricyclo DNA comprising phosphorothioate internucleoside linkage). Depending on its length, an oligonucleotide of the disclosure may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 sugar modifications. It is also encompassed to introduce more than one distinct sugar modification in said oligonucleotide. In an embodiment, an oligonucleotide as defined herein comprises or consists of an LNA or a derivative thereof. BNA derivatives are for example described in WO 2011/097641. In a more preferred embodiment, an oligonucleotide is fully 2'-O-methyl modified. Examples of PMO-X are described in WO2011150408, which is incorporated here in its entirety by reference.

In a preferred embodiment, the oligonucleotide according to the disclosure comprises, apart

from the mandatory 2'-O-methyl sugar modification, at least one other sugar modification selected from 2'-O-methyl, 2'-O-(2-methoxy)ethyl, morpholino, a bridged nucleotide or BNA, or the oligonucleotide comprises both bridged nucleotides and 2'-deoxy modified nucleotides (BNA/DNA mixmers). More preferably, the oligonucleotide is modified over its full length with a sugar modification selected from 2'-O-methyl, 2'-O-(2-methoxy)ethyl, morpholino, bridged nucleic acid (BNA) or BNA/DNA mixmer.

In a more preferred embodiment, the oligonucleotide according to the invention comprises is fully 2'-O-methyl modified, preferably fully 2'-O-methyl phosphorothioate modified.

A "backbone modification" indicates the presence of a modified version of the ribosyl moiety ("sugar modification"), as indicated above, and/or the presence of a modified version of the phosphodiester as naturally occurring in RNA ("internucleoside linkage modification"). Examples of internucleoside linkage modifications, which are compatible with the present invention, are phosphorothioate (PS), chirally pure phosphorothioate, phosphorodithioate (PS₂), phosphonoacetate (PACE), phosphonoacetamide (PACA), thiophosphonoacetate, thiophosphonoacetamide, phosphorothioate prodrug, H-phosphonate, methyl phosphonate, methyl phosphonothioate, methyl phosphate, methyl phosphorothioate, ethyl phosphate, ethyl phosphorothioate, boranophosphate, boranophosphorothioate, methyl boranophosphate, methyl boranophosphorothioate, methyl boranophosphonate, methyl boranophosphonothioate, and their derivatives. Another modification includes phosphoramidite, phosphoramidate, N3'→P5' phosphoramidate, phosphordiamidate, phosphorothiodiamidate, sulfamate, dimethylenesulfoxide, sulfonate, triazole, oxalyl, carbamate, methyleneimino (MMI), and thioacetamido nucleic acid (TANA); and their derivatives. Depending on its length, an oligonucleotide of the disclosure may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 backbone modifications. It is also encompassed by the disclosure to introduce more than one distinct backbone modification in said oligonucleotide.

An oligonucleotide of the disclosure comprises at least one phosphorothioate modification. In a more preferred embodiment, an oligonucleotide of the invention is fully phosphorothioate modified.

[0023] Other chemical modifications of an oligonucleotide of the disclosure include peptide-base nucleic acid (PNA), boron-cluster modified PNA, pyrrolidine-based oxy-peptide nucleic acid (POPNA), glycol- or glycerol-based nucleic acid (GNA), threose-based nucleic acid (TNA), acyclic threoninol-based nucleic acid (aTNA), morpholino-based oligonucleotide (PMO, PPMO, PMO-X), cationic morpholino-based oligomers (PMOPlus), oligonucleotides with integrated bases and backbones (ONIBs), pyrrolidine-amide oligonucleotides (POMs); and their derivatives.

In another embodiment, an oligonucleotide comprises a peptide nucleic acid and/or a morpholino phosphorodiamidate or a derivative thereof.

[0024] Thus, the preferred oligonucleotide according to one aspect of the disclosure comprises:

1. (a) at least one base modification selected from 5-methylpyrimidine and 2,6-

diaminopurine; and/or

2. (b) at least one sugar modification, which is 2'-O-methyl, and/or
3. (c) at least one backbone modification, which is phosphorothioate.

[0025] Thus, a preferred oligonucleotide according to this aspect of the disclosure comprises a base modification (a) and no sugar modification (b) and no backbone modification (c). Another preferred oligonucleotide according to this aspect of the disclosure comprises a sugar modification (b) and no base modification (a) and no backbone modification (c). Another preferred oligonucleotide according to this aspect of the disclosure comprises a backbone modification (c) and no base modification (a) and no sugar modification (b). Also oligonucleotides having none of the above-mentioned modifications are understood to be covered by the present disclosure, as well as oligonucleotides comprising two, i.e. (a) and (b), (a) and (c) and/or (b) and (c), or all three of the modifications (a), (b) and (c) as in the present invention. In another preferred embodiment, any of the oligonucleotides as described in the previous paragraph may comprise:

1. (a) at least one (additional) base modification selected from 2-thiouracil, 2-thiothymine, 5-methylcytosine, 5-methyluracil, thymine, 2,6-diaminopurine; and/or
2. (b) at least one (additional) sugar modification selected from 2'-O-methyl, 2'-O-(2-methoxy)ethyl, 2'-deoxy (DNA), morpholino, a bridged nucleotide or BNA, or the oligonucleotide comprises both bridged nucleotides and 2'-deoxy modified nucleotides (BNA/DNA mixmers); and/or
3. (c) at least one (additional) backbone modification selected from (another) phosphorothioate or phosphordiamidate.

In another preferred embodiment, the oligonucleotide according to the invention is modified over its entire length with one or more of the same modification, selected from (a) one of the base modifications; and/or (b) one of the sugar modifications; and/or (c) one of the backbone modifications.

[0026] With the advent of nucleic acid mimicking technology, it has become possible to generate molecules that have a similar, preferably the same hybridization characteristics in kind not necessarily in amount as nucleic acid itself. Such functional equivalents are of course also suitable for use in the invention.

[0027] The skilled person will understand that not each sugar, base, and/or backbone may be modified the same way. Several distinct modified sugars, bases and/or backbones may be combined into one single oligonucleotide of the invention.

[0028] A person skilled in the art will also recognize that there are many synthetic derivatives of oligonucleotides.

Preferably, said oligonucleotide comprises RNA, as RNA/RNA duplexes are very stable. It is preferred that an RNA oligonucleotide comprises a modification providing the RNA with an

additional property, for instance resistance to endonucleases, exonucleases, and RNaseH, additional hybridisation strength, increased stability (for instance in a bodily fluid), increased or decreased flexibility, increased activity, reduced toxicity, increased intracellular transport, tissue-specificity, etc. In addition, the mRNA complexed with the oligonucleotide of the invention is preferably not susceptible to RNaseH cleavage. Preferred modifications have been identified above. Oligonucleotides containing at least in part naturally occurring DNA nucleotides are useful for inducing degradation of DNA-RNA hybrid molecules in the cell by RNase H activity (EC.3.1.26.4).

Naturally occurring RNA ribonucleotides or RNA-like synthetic ribonucleotides comprising oligonucleotides are encompassed herein to form double stranded RNA-RNA hybrids that act as enzyme-dependent antisense through the RNA interference or silencing (RNAi/siRNA) pathways, involving target RNA recognition through sense-antisense strand pairing followed by target RNA degradation by the RNA-induced silencing complex (RISC).

Alternatively or in addition, an oligonucleotide can interfere with the processing or expression of precursor RNA or messenger RNA (steric blocking, RNaseH independent processes) in particular but not limited to RNA splicing and exon skipping, by binding to a target sequence of RNA transcript and getting in the way of processes such as translation or blocking of splice donor or splice acceptor sites. Moreover, the oligonucleotide may inhibit the binding of proteins, nuclear factors and others by steric hindrance and/or interfere with the authentic spatial folding of the target RNA and/or bind itself to proteins that originally bind to the target RNA and/or have other effects on the target RNA, thereby contributing to the destabilization of the target RNA, preferably pre-mRNA, and/or to the decrease in amount of diseased or toxic transcript and/or protein in diseases like HD as identified later herein.

[0029] As herein defined, an oligonucleotide may comprise nucleotides with (RNaseH resistant) chemical substitutions at least one of its 5' or 3' ends, to provide intracellular stability, and comprises less than 9, more preferably less than 6 consecutive (RNaseH-sensitive) deoxyribose nucleotides in the rest of its sequence. The rest of the sequence is preferably the center of the sequence. Such oligonucleotide is called a gapmer. Gapmers have been extensively described in WO 2007/089611. Gapmers are designed to enable the recruitment and/or activation of RNaseH. Without wishing to be bound by theory, it is believed that RNaseH is recruited and/or activated via binding to the central region of the gapmer made of deoxyriboses. An oligonucleotide of the invention which is preferably substantially independent of or independent of RNaseH is designed in order to have a central region which is substantially not able or is not able to recruit and/or activate RNaseH. In a preferred embodiment, the rest of the sequence of said oligonucleotide, more preferably its central part comprises less than 9, 8, 7, 6, 5, 4, 3, 2, 1, or no deoxyribose. Accordingly, this oligonucleotide of the invention is preferably partly to fully replaced as earlier defined herein. "Partly replaced" means that the oligonucleotide comprises at least some of nucleotides that have been replaced, preferably at least 50% of its nucleotides have been replaced, or at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% have been replaced. 100% replacement of nucleotides corresponds to "fully replaced".

[0030] Accordingly, the invention provides an oligonucleotide comprising a 2'-O-methyl

phosphorothioate RNA residue or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylpyrimidine and/or a 2,6-diaminopurine base. Most preferably, this oligonucleotide consists of 2'-O-methyl RNA residues connected through a phosphorothioate backbone and all of its cytosines and/or all of its uracils and/or all of its adenines, independently, have been replaced by 5-methylcytosine, 5-methyluracil and/or 2,6-diaminopurine, respectively. Thus, an oligonucleotide may have:

At least one and preferably all cytosines replaced with 5-methylcytosines as in the present invention,

At least one and preferably all cytosines replaced with 5-methylcytosines and at least one and preferably all uracils replaced with 5-methyluracils,

At least one and preferably all cytosines replaced with 5-methylcytosines and at least one and preferably all adenines replaced with 2,6-diaminopurines,

At least one and preferably all cytosines replaced with 5-methylcytosines and at least one and preferably all uracils replaced with 5-methyluracils and at least one and preferably all adenines replaced with 2,6-diaminopurines,

At least one and preferably all uracils replaced with 5-methyluracils,

At least one and preferably all uracils replaced with 5-methyluracils and at least one and preferably all adenines replaced with 2,6-diaminopurines, or At least one and preferably all adenines replaced with 2,6-diaminopurines.

[0031] An oligonucleotide of the invention is for use as a medicament for preventing delaying and/or treating a human cis-element repeat instability associated genetic disorders preferably as exemplified herein. A human cis-element repeat instability associated genetic disorders as identified herein is preferably a neuromuscular disorder. Preferably said oligonucleotide is for use in therapeutic RNA modulation. Therefore, the oligonucleotide according to the invention may be described as an antisense oligonucleotide (AON). An antisense oligonucleotide is an oligonucleotide which binds (or is able to bind), targets, hybridizes to (or is able to hybridize to) and/or is reverse complementary to a specific sequence of a transcript of a gene which is known to be associated with or involved in a human cis-element repeat instability associated genetic neuromuscular disorder.

[0032] According to the disclosure, an antisense oligonucleotide comprising or consisting of 2'-O-methyl RNA nucleotide residues, having a backbone wherein at least one phosphate moiety is replaced by a phosphorothioate moiety, and further comprising at least one of a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a repetitive element in a RNA transcript having as repetitive nucleotide unit a repetitive nucleotide unit,

which is selected from the $(CAG)_n$, $(GCG)_n$, $(CGG)_n$, $(GAA)_n$, $(GCC)_n$, $(CCG)_n$, $(AUUCU)_n$, $(GGGGCC)_n$ or $(CCUG)_n$. Said oligonucleotide is preferably a single stranded oligonucleotide.

Although it is to be understood that an oligonucleotide of the disclosure binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a repetitive element present in a RNA transcript as identified above, it can not be ruled out that such oligonucleotide may also interfere with or bind (or is able to bind) or hybridize to (or is able to hybridize) a corresponding DNA, this RNA transcript is derived from.

[0033] A repeat or repetitive element or repetitive sequence or repetitive stretch is herein defined as a repetition of at least 3, 4, 5, 10, 100, 1000 or more, of a repetitive unit or repetitive nucleotide unit or repeat nucleotide unit (as $(CAG)_n$, $(GCG)_n$, $(CGG)_n$, $(GAA)_n$, $(GCC)_n$, $(CCG)_n$, $(AUUCU)_n$, $(GGGGCC)_n$ or $(CCUG)_n$), comprising a trinucleotide repetitive unit, or alternatively a 4, 5 or 6 nucleotide repetitive unit, in a transcribed gene sequence in the genome of a subject, including a human subject. Accordingly, n is an integer and may be at least 3, 4, 5, 10, 100, 1000 or more. The disclosure is not limited to exemplified repetitive nucleotide units. Other repetitive nucleotide unit could be found on the following site <http://neuromuscular.wustl.edu/mother/dnarep.htm>. In the majority of patients, a "pure" repeat or repetitive element or repetitive sequence or repetitive stretch as identified above (as $(CAG)_n$, $(GCG)_n$, $(CGG)_n$, $(GAA)_n$, $(GCC)_n$, $(CCG)_n$, $(AUUCU)_n$, $(GGGGCC)_n$ or $(CCUG)_n$) is present in a transcribed gene sequence in the genome of said patient. However, it is also encompassed by the disclosure and invention, that in some patients, said repeat or repetitive element or repetitive sequence or repetitive stretch as identified above is not qualified as "pure" or is qualified as a "variant" when for example said repeat or repetitive element or repetitive sequence or repetitive stretch as identified above is interspersed with at least 1, 2, or 3 nucleotide(s) that do not fit the nucleotide(s) of said repeat or repetitive element or repetitive sequence or repetitive stretch (Braida C., et al.).

An oligonucleotide according to the disclosure and invention therefore may not need to be 100% reverse complementary to a targeted repeat. Usually an oligonucleotide of the invention may be at least 90%, 95%, 97%, 99% or 100% reverse complementary to a targeted repeat.

[0034] In an embodiment, an antisense oligonucleotide comprises or consists of 2'-O-methyl phosphorothioate RNA, comprises a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a $(CAG)_n$ tract in a transcript and is particularly useful for the treatment, delay, amelioration and/or prevention of the human genetic diseases Huntington's disease (HD), spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, 12 or 17, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), X-linked spinal and bulbar muscular atrophy (SBMA) and/or dentatorubropallidoluysian atrophy (DRPLA) caused by CAG repeat expansions in the transcripts of the HTT (SEQ ID NO: 80), ATXN1 (SEQ ID NO:81), ATXN2 (SEQ ID NO: 82) ATXN3 (SEQ ID NO: 83), CACNA1A (SEQ ID NO:84), ATXN7 (SEQ ID NO: 85), PPP2R2B (SEQ ID NO: 86), TBP (SEQ ID NO: 87), AR (SEQ ID NO: 88) or ATN1 (SEQ ID NO: 89) genes. Preferably, these genes are from human origin. In this embodiment, an oligonucleotide

comprises or consists of 2'-O-methyl phosphorothioate RNA, comprises a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a $(CAG)_n$ repeat as identified above and has as repetitive nucleotide unit $(CUG)_m$. The m in $(CUG)_m$ is preferably an integer which is 4, 5, 6, 7, 8, 9, 10, 11, 12.. In a preferred embodiment, m is 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12. It is to be noted that for ALS and FTD, it is known that at least two distinct repeats in at least two distinct transcripts may be involved or may be responsible or linked with the disease. One has been identified in the previous paragraph (i.e. $(CAG)_n$ in a ATXN2 transcript). Another one is being identified later as a $(GGGGCC)_n$ repeat or tract in a C9ORF72 transcript. It means that for each of these two diseases, one may envisage to use either one of these two distinct oligonucleotides of the invention and disclosure, respectively, to specifically induce the specific degradation of the corresponding (toxic) expanded repeat transcripts.

[0035] Throughout the application, an oligonucleotide defined as being reverse complementary to, binding (being able to bind), hybridizing (being able to hybridize) or targeting a repeat as identified above and has or comprises a repetitive nucleotide unit may have any length comprised from 12 to 36 nucleotides. If we take the example of CUG as repetitive nucleotide unit comprised within said oligonucleotide, any oligonucleotide comprising UGC or GCU as repetitive nucleotide unit is also encompassed by the present invention. Depending on the length of said oligonucleotide (for example from 12 to 36 nucleotides), the given repetitive nucleotide unit may not be complete at the 5' and/or at the 3'side of said oligonucleotide. Each of said oligonucleotide is encompassed within the scope of said invention.


[0036] Alternatively, if we still take as an example the oligonucleotide having CUG as repetitive nucleotide unit, it may be represented by $H-(P)_p-(CUG)_m-(Q)_q-H$, wherein m is an integer as defined above. Each occurrence of P and Q is, individually, an abasic monomer as defined above or a nucleotide, such as A, C, G, U or an analogue or equivalent thereof and p and q are each individually an integer, preferably 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or higher up to 100. Thus, p and q are each individually an integer from 0 to 100, preferably an integer from 0 to 20, more preferably an integer from 0 to 10, more preferably from 0 to 6, even more preferably from 0 to 3. Thus, when p is 0, P is absent and when q is 0, Q is absent. The skilled person will appreciate that an oligonucleotide will always start with and end with a hydrogen atom (H), regardless of the amount and nature of the nucleotides present in the oligonucleotide.

It will be appreciated that herein $(CUG)_m$ may be replaced by any repeating nucleotide unit within the context of the disclosure. Thus, a preferred oligonucleotide according to the disclosure may be represented by $H-(P)_p-(R)_r-(Q)_q-H$, wherein $(R)_r$ is a repeating nucleotide unit within the context of the disclosure and P , Q , p and q are as defined above.

In the context of the present invention, an "analogue" or an "equivalent" of a nucleotide is to be understood as a nucleotide which comprises at least one modification with respect to the nucleotides naturally occurring in RNA, such as A, C, G and U. Such a modification may be a

internucleoside linkage modification and/or a sugar modification and/or a base modification, as explained and exemplified above.



Again taking the oligonucleotide having CUG as repetitive nucleotide unit, it is to be understood that the repeating sequence may start with either a C, a U or a G. Thus, in a preferred embodiment, p is not 0, and $(P)_p$ is represented by $(P')_p\text{UG}$ or $(P')_p\text{G}$, wherein each occurrence of P' is, individually, an abasic site or a nucleotide, such as A, C, G, U or an analogue or equivalent thereof, and p' is $p - 2$ and p'' is $p - 1$. Such oligonucleotides may be represented as:





or



In an equally preferred embodiment, q is not 0, and $(Q)_q$ is represented by $\text{CU}(Q')_{q'}$ or $\text{C}(Q')_{q''}$ and each occurrence of Q' is, individually, an abasic site or a nucleotide, such as A, C, G, U or an analogue or equivalent thereof, and q' is $q - 2$ and q'' is $q - 1$. Such oligonucleotides may be represented as:



[0037] In another preferred embodiment, both p and q are not 0, and both $(P)_p$ and $(Q)_q$ are represented by $(P')_p\text{UG}$ or $(P')_p\text{G}$ and $\text{CU}(Q')_{q'}$ or $\text{C}(Q')_{q''}$ respectively, wherein P' , Q' , p' , p'' , q' and q'' are as defined above. Such oligonucleotides may be represented as:



It is to be understood that p' , p'' , q' and q'' may not be negative integers. Thus, when $(P)_p$ is represented by $(P')_p\text{UG}$ or $(P')_p\text{G}$, p is at least 1 or at least 2 respectively, and when $(Q)_q$ is represented by $\text{CU}(Q')_{q'}$ or $\text{C}(Q')_{q''}$, q is at least 1 or at least 2 respectively. It is to be understood that all said here regarding the CUG repeat unit can be extended to any repeat

unit within the context of the disclosure.

[0038] In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a $(CAG)_n$ repeat comprises or consists of a repetitive nucleotide unit $(XYG)_m$ and has a length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil. m is an integer. In the context of this embodiment, m may be 4, 5, 6, 7, 8, 9, 10, 11, 12. A preferred value for m is 7.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XYG)_m$, wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil, and m is an integer from 4 to 12 (SEQ ID NO:2 to 12).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XYG)_m$, wherein each X is 5-methylcytosine, and/or each Y is 5-methyluracil, and m is an integer from 4 to 12 (SEQ ID NO:2 to 12).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XYG)_5$, $(XYG)_6$ or $(XYG)_7$, $(XYG)_8$, or $(XYG)_9$ wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil. More preferred is an oligonucleotide comprising or consisting of $(XYG)_7$, wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil (SEQ ID NO:7).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XYG)_7$, wherein each X is 5-methylcytosine and each Y is a uracil (SEQ ID NO: 2), or each X is a cytosine and each Y is 5-methyluracil (SEQ ID NO:3). An even more preferred oligonucleotide comprises SEQ ID NO:2 or 3 and has a length of 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit $(XYG)_m$ have been identified in table 2 as SEQ ID NO:90-118.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 90-106 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 90-106 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 90-106 and has a length of 21 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 107 or 108 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate

RNA and comprises one of the base sequences SEQ ID NO: 107 or 108 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 107 or 108 and has a length of 21 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 107 or 108, has a length of 21 nucleotides and additionally comprises 4 abasic monomers at one of its termini, preferably at the 3' terminus. Said most preferred oligonucleotide is represented by a base sequence consisting of SEQ ID NO: 220 or 221.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 109 or 110 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 109 or 110 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 109 or 110 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 111 or 112 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 111 or 112 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 111 or 112 and has a length of 27 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 113 or 114 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 113 or 114 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 113 or 114 and has a length of 30 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 115 or 116 and has a length from 33-36 nucleotides, more preferably 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 115 or 116 and has a length from 33-36 nucleotides, more preferably 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 115 or 116 and has a length of 33 nucleotides.

[0039] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 117 or 118 and has a length of 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 117 or 118 and has a length of 36 nucleotides.

[0040] In another embodiment of the disclosure, an antisense oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA, and comprising a 5-methylcytosine is represented by a nucleotide sequence comprising or consisting of a sequence that binds to (or is able to bind to), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a (GCG)_n repeat in a transcript and is particularly useful for the treatment, delay, amelioration and/or prevention of the human genetic diseases: infantile spasm syndrome, deidocranial dysplasia, blepharophimosis, hand-foot-genital disease, synpolydactyly, oculopharyngeal muscular dystrophy and/or holoprosencephaly, which are caused by repeat expansions in the ARX, CBFA1, FOXL2, HOXA13, HOXD13, OPDM/PABP2, TCFBR1 or ZIC2 genes. Preferably, these genes are from human origin.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a (GCG)_n repeat comprises or consists of a repetitive nucleotide unit (XGX)_m and has a length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine, such that at least one X is 5-methylcytosine. m is an integer. In the context of this embodiment, m may be 4, 5, 6, 7, 8, 9, 10, 11, 12. A preferred value for m is 7.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (XGX)_m, wherein at least one X is 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 13 to 21). An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (XGX)_m, wherein each X is 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 13 to 21).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (XGX)₇ (SEQ ID NO: 16), wherein at least one X is 5-methylcytosine. An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (XGX)₇ (SEQ ID NO: 16), wherein each X is 5-methylcytosine.

[0041] Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit (XGX)_m have been identified in table 2 as SEQ ID NO: 119-132.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 119 or 120 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 119 or 120 and has a length from 16-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 119 or 120 and has a length of 12

nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 121 or 122 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 90-106 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 121 or 122 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 123 or 124 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 123 or 124 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 123 or 124 and has a length of 18 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 125 or 126 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 125 or 126 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 125 or 126 and has a length of 21 nucleotides. A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 127 or 128 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 127 or 128 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 127 or 128 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 129 or 130 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 129 or 130 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 129 or 130 and has a length of 27

nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 131 or 132 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 131 or 132 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 131 or 132 and has a length of 30 nucleotides.

[0042] In another embodiment of the disclosure, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylcytosine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), targets, hybridizes (or is able to hybridize) and/or is reverse complementary to a $(CGG)_n$ repeat in a transcript and is particularly useful for the treatment, delay, amelioration and/or prevention of human fragile X syndromes, caused by repeat expansion in the FMR1 gene. Preferably, these genes are from human origin. In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or is able to bind), hybridizing (or is able to hybridize) or targeting a $(CGG)_n$ repeat comprises or consists of a repetitive nucleotide unit $(XXG)_m$ and has a length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine, such that at least one X is 5-methylcytosine.

m is an integer. In the context of this embodiment, m may be 4, 5, 6, 7, 8, 9, 10, 11, 12. A preferred value for m is 7.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XXG)_m$, wherein each X is C or 5-methylcytosine, such that at least one X is 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 22 to 30). An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XXG)_m$, wherein each X is 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 22 to 30).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XXG)_7$ (SEQ ID NO: 25), wherein each X is C or 5-methylcytosine, such that at least one X is 5-methylcytosine.

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XXG)_7$ (SEQ ID NO: 25), wherein each X is 5-methylcytosine.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit $(XXG)_m$ have been identified in table 2 as SEQ ID NO: 133-146.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 133 or 134 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 133 or 134 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence

that consists of one of the base sequences SEQ ID NO: 133 or 134 and has a length of 12 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 135 or 136 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 135 or 136 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 135 or 136 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 137 or 138 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 137 or 138 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 137 or 138 and has a length of 18 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 139 or 140 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 139 or 140 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 139 or 140 and has a length of 21 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 141 or 142 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 141 or 142 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 141 or 142 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 143 or 144 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 143 or 144 and has a length from 27-36 nucleotides,

more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 143 or 144 and has a length of 27 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 145 or 146 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 145 or 146 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 145 or 146 and has a length of 30 nucleotides.

[0043] In another embodiment of the disclosure, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylcytosine and/or a 5-methyluracil, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), targets, hybridizes (or is able to hybridize) and/or is reverse complementary to a $(GAA)_n$ repeat in a transcript and is particularly useful for the treatment, delay and/or prevention of the human genetic disorder Friedreich's ataxia.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a $(GAA)_n$ repeat comprises or consists of a repetitive nucleotide unit $(YYX)_m$ and has a length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil. m is an integer. In the context of this embodiment, m may be 4, 5, 6, 7, 8, 9, 10, 11, 12. A preferred value for m is 7.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(YYX)_m$, wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil, and m is an integer from 4 to 12 (SEQ ID NO: 31 to 39).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(YYX)_m$, wherein each X is 5-methylcytosine, and/or each Y is 5-methyluracil, and m is an integer from 4 to 12 (SEQ ID NO: 31 to 39).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(YYX)_7$ (SEQ ID NO: 34), wherein each X is C or 5-methylcytosine, and each Y is U or 5-methyluracil such that at least one X is 5-methylcytosine and/or at least one Y is 5-methyluracil.

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(YYX)_7$ (SEQ ID NO: 34), wherein each X is 5-methylcytosine, and/or each Y is 5-methyluracil.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit $(XYG)_m$ have been identified in table 2 as SEQ ID NO: 147-167.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 147 or 148 and has a length from 12-36

nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 147 or 148 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 147 or 148 and has a length of 12 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 149 or 150 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 149 or 150 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 149 or 150 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 151 or 152 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 151 or 152 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 151 or 152 and has a length of 18 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 153-157 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 153-157 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 153-157 and has a length of 21 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 158 or 159 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 158 or 159 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 158 or 159 and has a length

of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 160 or 161 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 160 or 161 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 160 or 161 and has a length of 27 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 162 or 163 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 162 or 163 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 162 or 163 and has a length of 30 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 164 or 165 and has a length from 33-36 nucleotides, more preferably 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 164 or 165 and has a length from 33-36 nucleotides, more preferably 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has a base sequence that consists of one of the base sequences SEQ ID NO: 164 or 165 and has a length of 33 nucleotides.

[0044] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 166 or 167 and has a length of 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and has a base sequence that consists one of the base sequences SEQ ID NO: 166 or 167 and has a length of 36 nucleotides.

[0045] In another embodiment of the disclosure, an antisense oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylcytosine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds to (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a (CCG)_n or (GCC)_n repeat in a transcript and is particularly useful for the treatment, delay, amelioration and/or prevention of the human genetic disorder fragile XE mental retardation, caused by repeat expansion in the FMR2 gene. Preferably, these genes are from human origin.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a (CCG)_n repeat comprises or consists of a repetitive nucleotide unit (XGG)_m or (GGX)_m and has a

length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine. m is an integer. In the context of this embodiment, m may be 4, 5, 6, 7, 8, 9, 10, 11, 12. A preferred value for m is 7.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XGG)_m$ or $(GGX)_m$, wherein each X is C or 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 49 to 57) or (SEQ ID NO: 40 to 48).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XGG)_m$ or $(GGX)_m$, wherein each X is 5-methylcytosine, and m is an integer from 4 to 12 (SEQ ID NO: 49 to 57) or (SEQ ID NO: 40 to 48).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit $(XGG)_7$ (SEQ ID NO: 52) or $(GGX)_7$ (SEQ ID NO: 43), wherein each X is C or 5-methylcytosine.

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit $(XGG)_7$ (SEQ ID NO: 52) or $(GGX)_7$ (SEQ ID NO: 43), wherein each X is 5-methylcytosine.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit $(GGX)_m$ have been identified in table 2 as SEQ ID NO: 168-177.

[0046] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 168 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequences SEQ ID NO: 168 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequences SEQ ID NO: 168 and has a length of 12 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 169 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 169 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 169 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 170 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 170 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 170 and has a length of 18

nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 171-174 has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 171-174 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 171-174 and has a length of 21 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 175 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 175 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 175 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 176 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 176 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 176 and has a length of 27 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 177 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 177 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 177 and has a length of 30 nucleotides.

[0047] Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit (XGG)_m have been identified in table 2 as SEQ ID NO: 178-184.

[0048] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 178 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 178 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,

24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 178 and has a length of 12 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 179 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 179 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 179 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequences SEQ ID NO: 180 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 180 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 180 and has a length of 18 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 181 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 181 and has a length from 21-36 nucleotides, more preferably 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 181 and has a length of 21 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 182 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 182 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 182 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 183 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 183 and has a length from 27-36 nucleotides, more preferably 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO:

183 and has a length of 27 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 184 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 184 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 184 and has a length of 30 nucleotides.

[0049] In another embodiment of the disclosure, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylcytosine and/or a 2,6-diaminopurine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a (CCUG)_n repeat in a transcript and is particularly useful for the treatment, delay and/or prevention of the human genetic disorder myotonic dystrophy type 2 (DM2), caused by repeat expansions in the DM2/ZNF9 gene. Preferably, these genes are from human origin.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a (CCUG)_n repeat comprises or consists of a repetitive nucleotide unit (XZGG)_m and has a length comprised from 12 to 36 nucleotides and wherein each X is C or 5-methylcytosine, and each Z is A or 2,6-diaminopurine such that at least one X is 5-methylcytosine and/or at least one Z is 2,6-diaminopurine.

m is an integer. In the context of this embodiment, m may be 3, 4, 5, 6, 7, 8, 9. A preferred value for m is 5.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (XZGG)_m, wherein each X is C or 5-methylcytosine, and each Z is A or 2,6-diaminopurine such that at least one X is 5-methylcytosine and/or at least one A is 2,6-diaminopurine, and m is an integer from 3 to 9 (SEQ ID NO: 63 to 69).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (XZGG)_m, wherein each X is 5-methylcytosine, and/or each Z is 2,6-diaminopurine, and m is an integer from 3 to 9 (SEQ ID NO: 63 to 69).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (XZGG)₅ (SEQ ID NO: 65), wherein each X is C or 5-methylcytosine, and each Z is A or 2,6-diaminopurine such that at least one X is 5-methylcytosine and/or at least one Z is 2,6-diaminopurine.

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (XZGG)₅ (SEQ ID NO: 65), wherein each X is 5-methylcytosine, and/or each Z is 2,6-diaminopurine.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit (XZGG)_m have been identified in table 2 as SEQ ID NO: 193-208.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA

comprises one of base sequences SEQ ID NO: 193 or 194 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 193 or 194 and has a length from 12-36 nucleotides, more preferably 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 193 or 194 and has a length of 12 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 195 or 196 and has a length from 16-36 nucleotides, more preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 195 or 196 and has a length from 16-36 nucleotides, more preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 195 or 196 and has a length of 16 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 197-200 and has a length from 20-36 nucleotides, more preferably 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 197-200 and has a length from 20-36 nucleotides, more preferably 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 197-200 and has a length of 20 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 201 or 202 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 201 or 202 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 201 or 202 and has a length of 24 nucleotides.

[0050] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 203 or 204 and has a length from 28-36 nucleotides, more preferably 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 203 or 204 and has a length from 28-36 nucleotides, more preferably 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of

the base sequences SEQ ID NO: 203 or 204 and has a length of 28 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 205 or 206 and has a length from 32-36 nucleotides, more preferably 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 205 or 206 and has a length from 32-36 nucleotides, more preferably 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 205 or 206 and has a length of 32 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 207 or 208 and has a length of 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and has its base sequence that consists of one of the base sequences SEQ ID NO: 207 or 208 and has a length of 36 nucleotides.

[0051] In another embodiment of the disclosure, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methyluracil and/or a 2,6-diaminopurine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a (AUUCU)_n repeat in an intron and is particularly useful for the treatment, delay, amelioration and/or prevention of the human genetic disorder spinocerebellar ataxia type 10 (SCA10). Preferably, this gene is from human origin.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a (AUUCU)_n repeat comprises or consists of a repetitive nucleotide unit (ZGZZY)_m and has a length comprised from 12 to 36 nucleotides and wherein each Y is U or 5-methyluracil, and each Z is A or 2,6-diaminopurine such that at least one Y is 5-methyluracil and/or at least one Z is 2,6-diaminopurine.

m is an integer. In the context of this embodiment, m may be 3, 4, 5, 6, 7. A preferred value for m is 4.

A more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (ZGZZY)_m, wherein each Y is U or 5-methyluracil, and each Z is A or 2,6-diaminopurine such that at least one Y is 5-methyluracil and/or at least one Z is 2,6-diaminopurine, and m is an integer from 3 to 7 (SEQ ID NO: 58 to 62).

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (ZGZZY)_m, wherein each Y is 5-methyluracil, and/or each Z is 2,6-diaminopurine, and m is an integer from 3 to 7 (SEQ ID NO: 58 to 62).

An even more preferred oligonucleotide therefore comprises or consists of a repetitive nucleotide unit (ZGZZY)₄ (SEQ ID NO: 59), wherein each Y is C or 5-methyluracil, and each Z is A or 2,6-diaminopurine such that at least one Y is 5-methyluracil and/or at least one Z is 2,6-diaminopurine.

An even more preferred oligonucleotide comprises or consists of a repetitive nucleotide unit (ZGZZY)₄ (SEQ ID NO: 59), wherein each Y is 5-methyluracil, and/or each Z is 2,6-

diaminopurine.

Most preferred oligonucleotides sequences comprising or consisting of a repetitive nucleotide unit (ZGZZY)_m have been identified in table 2 as SEQ ID NO:185-192.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 185 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 185 and has a length from 15-36 nucleotides, more preferably 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 185 and has a length of 15 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 186-189 and has a length from 20-36 nucleotides, more preferably 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 186-189 and has a length from 20-36 nucleotides, more preferably 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 186-189 and has a length of 20 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 190 and has a length from 25-36 nucleotides, more preferably 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 190 and has a length from 25-36 nucleotides, more preferably 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 190 and has a length of 25 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 191 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 191 and has a length from 30-36 nucleotides, more preferably 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 191 and has a length of 30 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 192 and has a length from 35-36 nucleotides, more preferably 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 192 and has a length from 35-36 nucleotides, more preferably 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 192 and has a length of 35 nucleotides.

[0052] In another embodiment of the disclosure, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA and comprising a 5-methylcytosine and/or an abasic monomer, and/or an inosine, is represented by a nucleotide sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a (GGGGCC)_n repeat present in a C9ORF72 human transcript and is particularly useful for the treatment, delay, amelioration and/or prevention of the human genetic disorder amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Preferably, this gene is from human origin.

In a preferred embodiment, an oligonucleotide defined as being reverse complementary to, binding (or being able to bind), hybridizing (or being able to hybridize) or targeting a (GGGGCC)_n repeat comprises or consists of a repetitive nucleotide unit (GGXUXX)_m, (GGXQXX)_m, (GGXIXX)_m, or (GGCCUC)_m, and has a length comprised from 17 to 36 nucleotides and wherein each X is C or 5-methylcytosine such that at least one X is 5-methylcytosine, wherein each Q is an abasic monomer, wherein each I is an inosine, and wherein m is an integer. In the context of this embodiment, m may be 3, 4, 5, 6, 7. A preferred value for m is 3 or 4.

More preferably, said oligonucleotide comprises or consists of a repetitive nucleotide unit SEQ ID NO: 216-219 as defined in table 1. Even more preferred oligonucleotide sequences comprising or consisting of a repetitive nucleotide unit (GGXUXX)_m, (GGXQXX)_m, (GGXIXX)_m, or (GGCCUC)_m, have been identified in table 2 as SEQ ID NO: 209-215.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 209 or 211 and has a length from 17-36 nucleotides, more preferably 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 209 or 211 and has a length from 17-36 nucleotides, more preferably 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 209 or 211 and has a length of 17 or 18 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 210 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 210 and has a length from 18-36 nucleotides, more preferably 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequence SEQ ID NO: 210 and has a length of 18 nucleotides.

[0053] A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises one of base sequences SEQ ID NO: 212 or 215 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides.

An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises one of the base sequences SEQ ID NO: 212 or 215 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of one of the base sequences SEQ ID NO: 212 or 215 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 213 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 213 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequences SEQ ID NO: 213 and has a length of 24 nucleotides.

A preferred oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA comprises base sequence SEQ ID NO: 214 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. An even more preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA and comprises base sequence SEQ ID NO: 214 and has a length from 24-36 nucleotides, more preferably 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36 nucleotides. Most preferred oligonucleotide consists of 2'-O-methyl phosphorothioate RNA, has its base sequence that consists of base sequences SEQ ID NO: 214 and has a length of 24 nucleotides.

[0054] In an embodiment, an oligonucleotide preferably comprises or consists of 2'-O-methyl phosphorothioate RNA, comprises a 5-methylcytosine and/or a 5-methyluracil and/or a 2,6-diaminopurine base, is represented by a nucleotide sequence comprising or consisting of at least 12 to 36 consecutive nucleotides, said oligonucleotide targeting, hybridizing (or is able to hybridize), binding (or is able to bind) and/or being reverse complementary to a repeat as earlier defined herein. More preferably, said nucleotide sequence comprising or consisting of at least 12 to 36 nucleotides, even more preferably 15 to 24, and most preferably 20 or 21 nucleotides. The length of said oligonucleotide may be 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 nucleotides. Said oligonucleotide may be reverse complementary to and/or capable of hybridizing to and/or capable of targeting and/or capable of binding to a repeat in a coding region of a transcript, preferably a polyglutamine (CAG)_n coding tract. Said oligonucleotide may also be reverse complementary to and/or capable of hybridizing to and/or capable of targeting and/or capable of binding to a non-coding region for instance 5' or 3' untranslated regions, or intronic sequences present in precursor RNA molecules.

In the context of the invention, the expression "capable of" may be replaced with "is able to".

[0055] In a second aspect, the present disclosure relates to an oligonucleotide, which comprises one or more abasic sites, as defined further below, at one or both termini. Preferably 1 to 10, more preferably 2, 3, 4, 5, 6, 7, 8, 9 or 10 and most preferably 4 abasic sites are present at a single terminus or at both termini of the oligonucleotide. One or more

abasic sites may be present and both free termini of the oligonucleotide (5' and 3'), or at only one. The oligonucleotide according to this aspect of the disclosure preferably is represented by a nucleotide or a base sequence comprising or consisting of a sequence that binds (or is able to bind), hybridizes (or is able to hybridize), targets and/or is reverse complementary to a repetitive element in a RNA transcript selected from the (CAG)_n, (GCG)_n, (CGG)_n, (GAA)_n, (GCC)_n, (CCG)_n, (AUUCU)_n, (GGGGCC)_n or (CCUG)_n, as indicated above. Said oligonucleotide is preferably a single stranded oligonucleotide, and may further optionally comprise any of the modifications as discussed herein, such as one or more base modifications, sugar modifications and/or backbone modifications, such as 5-methyl-C, 5-methyl-U, 2,6-diaminopurine, 2'-O-methyl, phosphorothioate, and combinations thereof. It is to be understood that in this aspect of the disclosure, these modification are not compulsory.

The oligonucleotide according to this aspect of the disclosure, comprising one or more abasic sites at one or both termini has an improved parameter over the oligonucleotides without such abasic sites. In this context, parameters may include: binding affinity and/or kinetics, silencing activity, allelic selectivity, biostability, (intra-tissue) distribution, cellular uptake and/or trafficking, and/or immunogenicity of said oligonucleotide, as explained earlier herein in connection with the improved parameter of an oligonucleotide of the invention of the first aspect. Each of the assays and definitions provided herein in connection with the improvement of a parameter of an oligonucleotide of the first aspect also hold for an oligonucleotide of the second aspect.

[0056] Below, an oligonucleotide comprising or consisting of 2'-O-methyl phosphorothioate RNA, comprising a 5-methylcytosine and/or a 5-methyluracil base and being represented by a nucleotide or a base sequence comprising (CUG)_m and thus binding to (or being able to bind to), hybridizing (or being able to hybridize), targeting and/or being reverse complementary to (CAG)_n is taken as an example to further illustrate the invention. Similar parameters defined in the context of such oligonucleotide could be defined by the skilled person for other oligonucleotides falling under the scope of the invention and binding to (or being able to bind to), hybridizing (or being able to hybridize), targeting and/or being reverse complementary to other repeats as identified herein. Other or similar symptoms may be identified by the skilled person concerning other diseases as identified herein.

In a preferred embodiment, in the context of the invention, an oligonucleotide as designed herein is able to delay and/or cure and/or treat and/or prevent and/or ameliorate a human genetic disorder as Huntington's disease (HD), spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, 12 or 17, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), X-linked spinal and bulbar muscular atrophy (SBMA) and/or dentatorubropallidoluysian atrophy (DRPLA) caused by CAG repeat expansions in the transcripts of a HTT (SEQ ID NO: 80), ATXN1 (SEQ ID NO: 81), ATXN2 (SEQ ID NO: 82) ATXN3 (SEQ ID NO: 83), CACNA1A (SEQ ID NO: 84), ATXN7 (SEQ ID NO: 85), PPP2R2B (SEQ ID NO: 86), TBP (SEQ ID NO: 87), AR (SEQ ID NO: 88), ATN1 (SEQ ID NO: 89) genes when this oligonucleotide is able to reduce or decrease the amount of (toxic) transcript of a diseased allele of a HTT, ATXN1, ATXN2 ATXN3, CACNA1A, ATXN7, PPP2R2B, TBP, AR or ATN1 gene in a cell of a patient, in a tissue of a patient and/or in a patient. In an embodiment, said HTT, ATXN1, ATXN2 ATXN3, CACNA1A, ATXN7, PPP2R2B, TBP, AR or ATN1 genes are human genes.

In the case of HD, an expanded CAG repeat region is present in exon 1 of the HTT gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 38 to 180 repetitive units comprising a CAG trinucleotide, in a transcribed sequence of the HTT gene.

In the case of SCA1, an expanded CAG repeat region is present in exon 8 of the ATXN1 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 41 to 83 repetitive units comprising a CAG trinucleotide, in a transcribed sequence of the ATXN1 gene.

In the case of SCA2, an expanded CAG repeat region is present in exon 1 of the ATXN2 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 32 to 200 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the ATXN2 gene.

In the case of SCA3, an expanded CAG repeat region is present in exon 8 of the ATXN3 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 52 to 86 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the ATXN3 gene.

In the case of SCA6, an expanded CAG repeat region is present in exon 47 of the CACNA1A gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 20 to 33 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the CACNA1A gene.

In the case of SCA7, an expanded CAG repeat region is present in exon 3 of the ATXN7 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 36 to at least 460 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the ATXN7 gene.

In the case of SCA12, an expanded CAG repeat region may be present in the 5' untranslated region (UTR), in an intron or within an open reading frame of the PPP2R2B gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 66 to 78 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the PPP2R2B gene.

In the case of SCA17, an expanded CAG repeat region is present in exon 3 of the TBP gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 45 to 66 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the TBP gene.

In the case of ALS or FTD, an expanded CAG repeat region is present in exon 1 of the ATXN2 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 27 to 33 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the ATXN2 gene.

In the case of ALS or FTD, an expanded GGGGCC repeat region is present in the first intron of the C9orf72 gene in the genome of a patient. An expanded GGGGCC repeat region may be defined herein as comprising a consecutive repetition of >30 repetitive units comprising a GGGGCC hexanucleotide in a transcribed sequence of the C9orf72 gene.

[0057] In the case of SBMA, an expanded CAG repeat region is present in exon 1 of the AR gene in the genome of a patient. An expanded CAG repeat region may be defined herein as

comprising a consecutive repetition of 40 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the AR gene.

In the case of DRPLA, an expanded CAG repeat region is present in exon 5 of the ATN1 gene in the genome of a patient. An expanded CAG repeat region may be defined herein as comprising a consecutive repetition of 49 to 88 repetitive units comprising a CAG trinucleotide in a transcribed sequence of the ATN1 gene.

[0058] Throughout the invention, the term CAG repeat may be replaced by $(CAG)_n$, and vice versa, wherein n is an integer that may be 6 to 29 when the repeat is present in exon 1 of the HTT transcript of a healthy individual, 6 to 39 when the repeat is present in exon 8 of the ATXN1 gene of a healthy individual, less than 31 when the repeat is present in exon 1 of the ATXN2 gene of a healthy individual, 12 to 40 when the repeat is present in exon 8 of the ATXN3 gene of a healthy individual, less than 18 when the repeat is present in exon 47 of the CACNA1A gene of a healthy individual, 4 to 17 when the repeat is present in exon 3 of the ATXN7 gene of a healthy individual, 7 to 28 when the repeat is present in the 5'UTR of the PPP2R2B gene of a healthy individual, 25 to 42 when the repeat is present in exon 3 of the TBP gene of a healthy individual, 13 to 31 when the repeat is present in exon 1 of the AR gene of a healthy individual, 12 to 40 when the repeat is present in exon 8 of the ATXN3 gene of a healthy individual, or 6 to 35 when the repeat is present in exon 5 of the ATN1 gene of a healthy individual.

It preferably means that an oligonucleotide of the invention reduces a detectable amount of disease-associated or disease-causing or mutant transcript containing an extending or unstable number of CAG repeats in a cell of said patient, in a tissue of said patient and/or in a patient. Alternatively or in combination with previous sentence, said oligonucleotide may reduce the translation of said mutant transcript and thus the amount of mutant (toxic) protein. The reduction or decrease of the amount of expanded CAG repeat transcripts may be at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by comparison to the amount of expanded CAG repeat transcripts before the treatment. Another parameter may be the decrease in $(CAG)_n$ transcript or of the quantity of said mutant transcript. This may be of at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by comparison to the quantity of said transcript detected at the onset of the treatment

The reduction or decrease may be assessed by Northern Blotting or Q-RT-PCR, preferably as carried out in the experimental part. An oligonucleotide of the invention may first be tested in the cellular system as described in Example 1 in the experimental part.

[0059] Alternatively or in combination with previous preferred embodiment, in the context of the invention, an oligonucleotide as designed herein is able to delay and/or cure and/or treat and/or prevent and/or ameliorate a human genetic disorder as Huntington's disease (HD), spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, 12 or 17, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), X-linked spinal and bulbar muscular atrophy (SBMA) and/or dentatorubropallidoluysian atrophy (DRPLA) caused by CAG repeat expansions in the transcripts of the HTT, ATXN1, ATXN2 ATXN3, CACNA1A, ATXN7, PPP2R2B, TBP, AR or ATN1 genes when this oligonucleotide is able to alleviate one or more symptom(s) and/or

characteristic(s) and/or to improve a parameter linked with or associated with Huntington's disease (HD), spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, 12 or 17, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), X-linked spinal and bulbar muscular atrophy (SBMA) and/or dentatorubropallidoluysian atrophy (DRPLA) in an individual. An oligonucleotide as defined herein is able to improve one parameter or reduce a symptom or characteristic if after at least one week, one month, six month, one year or more of treatment using a dose of said oligonucleotide of the invention as identified herein said parameter is said to have been improved or said symptom or characteristic is said to have been reduced.

Improvement in this context may mean that said parameter had been significantly changed towards a value of said parameter for a healthy person and/or towards a value of said parameter that corresponds to the value of said parameter in the same individual at the onset of the treatment.

Reduction or alleviation in this context may mean that said symptom or characteristic had been significantly changed towards the absence of said symptom or characteristic which is characteristic for a healthy person and/or towards a change of said symptom or characteristic that corresponds to the state of the same individual at the onset of the treatment.

[0060] In this context, symptoms for Huntington's Disease are choreiform movements, progressive dementia and psychiatric manifestations (depression, psychosis, etc.). Choreiform movements consist of involuntary, rapid, irregular, jerky motor actions including facial twitching or writhing and twitching of distal extremities, and later more generalized forms that may impair gait (Ropper and Brown, 2005). Each of these symptoms may be assessed by the physician using known and described methods. A preferred method is monitoring of total functional capacity (TFC), a validated scale or symptom progression regarding the three main symptomatic areas of HD, measured by validated rating scales. These areas are specifically progression of motor signs, progression of neuropsychiatric symptoms and progression of cognitive decline. Another preferred scale therefore is the Unified HD Rating Scale (UHDRS; Huntington Study Group (Kiebertz K. et al. 1996;11:136-142).

[0061] Huntington's disease (HD), spinocerebellar ataxia (SCA) type 1, 2, 3, 6, 7, or 17, X-linked spinal and bulbar muscular atrophy (SBMA) and dentatorubropallidoluysian atrophy (DRPLA) are all caused by CAG triplet repeat expansions in the coding region of the gene. Although the disease causing proteins in these diseases are different, in each case the resulting expanded stretch of glutamines results in a toxic-gain-of function of the protein and this leads to neurodegeneration. Protein aggregates are found in the nucleus and cytoplasm of cells, indicating that protein misfolding is a common feature of these disorders. A common preferred parameter is therefore (mutant) protein levels which can be determined by western blot analysis (Evers et al.), or the presence of protein aggregates in the nucleus and/or cytoplasm which can be monitored by *in situ* hybridization. An improvement of a HD parameter may be the decrease in the detection of the quantity or amount of protein aggregate. Such decrease may be at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% by comparison to the quantity or amount of protein aggregate before the onset of the treatment.

In the context of HD, various other proteins have been found to co-localize with htt aggregates,

i.e. TATA box binding protein (TBP), CREB binding protein (CBP) and several molecular chaperones (Huang et al.; Muchowski et al.; Roon-Mom et al.; Steffan et al.). Also many affected cellular processes have been identified in HD, such as transcriptional de-regulation, mitochondrial dysfunction, and impaired vesicle transport, which may provide alternative parameters for HD (Bauer et al., 2009; Ross et al.). An improvement of each of these possible alternative HD parameters (i.e. TATA box binding protein (TBP), CREB binding protein (CBP) and several molecular chaperones) may be defined as for the improvement of protein aggregate as defined above.

Composition

[0062] In a second aspect, there is provided a composition comprising an oligonucleotide as described in the previous section entitled "Oligonucleotide". This composition preferably comprises or consists of or essentially consists of an oligonucleotide as described above.

As explained in the first aspect of the invention for ALS and FTD, it is known that at least two distinct repeats in at least two distinct transcripts may be involved in, responsible for, or linked with the disease. All preferred features relating to each of these oligonucleotides have been disclosed in the section entitled "oligonucleotide". In a preferred embodiment, said composition is for use as a medicament. Said composition is therefore a pharmaceutical composition. A pharmaceutical composition usually comprises a pharmaceutically accepted carrier, diluent and/or excipient. In a preferred embodiment, a composition of the current invention comprises a compound as defined herein and optionally further comprises a pharmaceutically acceptable formulation, filler, preservative, solubilizer, carrier, diluent, excipient, salt, adjuvant and/or solvent. Such pharmaceutically acceptable carrier, filler, preservative, solubilizer, diluent, salt, adjuvant, solvent and/or excipient may for instance be found in Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2000. The compound as described in the invention possesses at least one ionizable group. An ionizable group may be a base or acid, and may be charged or neutral. An ionizable group may be present as ion pair with an appropriate counterion that carries opposite charge(s). Examples of cationic counterions are sodium, potassium, cesium, Tris, lithium, calcium, magnesium, trialkylammonium, triethylammonium, and tetraalkylammonium. Examples of anionic counterions are chloride, bromide, iodide, lactate, mesylate, acetate, trifluoroacetate, dichloroacetate, and citrate. Examples of counterions have been described [e.g. Kumar L. et al, 2008]. A pharmaceutical composition may be further formulated to further aid in enhancing the stability, solubility, absorption, bioavailability, pharmacokinetics and cellular uptake of said compound, in particular formulations comprising excipients capable of forming complexes, nanoparticles, microparticles, nanotubes, nanogels, hydrogels, poloxamers or pluronics, polymersomes, colloids, microbubbles, vesicles, micelles, lipoplexes, and/or liposomes. Examples of nanoparticles include polymeric nanoparticles, gold nanoparticles, magnetic nanoparticles, silica nanoparticles, lipid nanoparticles, sugar particles, protein nanoparticles and peptide nanoparticles.

[0063] A preferred composition comprises at least one excipient that may further aid in

enhancing the targeting and/or delivery of said composition and/or said oligonucleotide to and/or into muscle and/or brain tissue and/or to a neuronal tissue and/or a cell. A cell may be a muscular or a neuronal cell.

[0064] Many of these excipients are known in the art (e.g. see Bruno, 2011) and may be categorized as a first type of excipient. Examples of first type of excipients include polymers (e.g. polyethyleneimine (PEI), polypropyleneimine (PPI), dextran derivatives, butylcyanoacrylate (PBCA), hexylcyanoacrylate (PHCA), poly(lactic-co-glycolic acid) (PLGA), polyamines (e.g. spermine, spermidine, putrescine, cadaverine), chitosan, poly(amido amines) (PAMAM), poly(ester amine), polyvinyl ether, polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG) cyclodextrins, hyaluronic acid, colominic acid, and derivatives thereof), dendrimers (e.g. poly(amidoamine)), lipids {e.g. 1,2-dioleoyl-3-dimethylammonium propane (DODAP), dioleoyldimethylammonium chloride (DODAC), phosphatidylcholine derivatives [e.g. 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)], lyso-phosphatidylcholine derivatives [e.g. 1-stearoyl-2-lyso-sn-glycero-3-phosphocholine (S-LysoPC)], sphingomyeline, 2- {3-[bis-(3-amino-propyl)-amino]-propylamino}-*N*-ditetradecyl carbamoyl methylacetamide (RPR209120), phosphoglycerol derivatives [e.g. 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol sodium salt (DPPG-Na), phosphatidic acid derivatives [1,2-distearoyl-sn-glycero-3-phosphatidic acid, sodium salt (DSPA), phosphatidylethanolamine derivatives [e.g. dioleoyl--phosphatidylethanolamine (DOPE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE).], *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium (DOTAP), *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium (DOTMA), 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamid (DOSPER), (1,2-dimyristyloxypropyl-3-dimethylhydroxy ethyl ammonium (DMRIE), (N1-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine (CDAN), dimethyldioctadecylammonium bromide (DDAB), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), (b-L-arginyl-2,3-L-diaminopropionic acid-*N*-palmityl-*N*-oleyl-amide trihydrochloride (AtuFECT01), *N,N*-dimethyl-3-aminopropane derivatives [e.g. 1,2-distearoyloxy-*N,N*-dimethyl-3-aminopropane (DSDMA), 1,2-dioleoyloxy-*N,N*-dimethyl-3-aminopropane (DoDMA), 1,2-dilinoleyloxy-*N,N*-3-dimethylaminopropane (DLinDMA), 2,2-dilinoley-4-dimethylaminomethyl [1,3]-dioxolane (DLin-K-DMA), phosphatidylserine derivatives [1,2-dioleoyl-sn-glycero-3-phospho-L-serine, sodium salt (DOPS)], cholesterol}proteins (e.g. albumin, gelatins, atellocollagen), and peptides (e.g. protamine, PepFects, NickFects, polyarginine, polylysine, CADY, MPG).

[0065] Another preferred composition may comprise at least one excipient categorized as a second type of excipient. A second type of excipient may comprise or contain a conjugate group as described herein to enhance targeting and/or delivery of the composition and/or of the oligonucleotide of the invention to a tissue and/or cell and/or into a tissue and/or cell, as for example muscle or neuronal tissue or cell. Both types of excipients may be combined together into one single composition as identified herein.

[0066] The skilled person may select, combine and/or adapt one or more of the above or other alternative excipients and delivery systems to formulate and deliver a compound for use in the present invention.

[0067] Such a pharmaceutical composition of the invention may be administered in an effective concentration at set times to an animal, preferably a mammal. More preferred mammal is a human being. An oligonucleotide or a composition as defined herein for use according to the invention may be suitable for direct administration to a cell, tissue and/or an organ *in vivo* of individuals affected by or at risk of developing a disease or condition as identified herein, and may be administered directly *in vivo*, *ex vivo* or *in vitro*. Administration may be *via* systemic and/or parenteral routes, for example intravenous, subcutaneous, intraventricular, intrathecal, intramuscular, intranasal, enteral, intravitreal, intracerebral, epidural or oral route.

[0068] Preferably, such a pharmaceutical composition of the invention may be encapsulated in the form of an emulsion, suspension, pill, tablet, capsule or soft-gel for oral delivery, or in the form of aerosol or dry powder for delivery to the respiratory tract and lungs. In an embodiment an oligonucleotide of the invention may be used together with another compound already known to be used for the treatment of said disease. Such other compounds may be used for slowing down progression of disease, for reducing abnormal behaviors or movements, for reducing muscle tissue inflammation, for improving muscle fiber and/or neuronal function, integrity and/or survival and/or improve, increase or restore cardiac function. Examples are, but not limited to, a steroid, preferably a (gluco)corticosteroid, an ACE inhibitor (preferably perindopril), an angiotensin II type 1 receptor blocker (preferably losartan), a tumor necrosis factor-alpha (TNF α) inhibitor, a TGF β inhibitor (preferably decorin), human recombinant biglycan, a source of mIGF-1, a myostatin inhibitor, mannose-6-phosphate, dantrolene, halofuginone, an antioxidant, an ion channel inhibitor, a protease inhibitor, a phosphodiesterase inhibitor (preferably a PDE5 inhibitor, such as sildenafil or tadalafil, and/or PDE10A inhibitors and/or MP-10), L-arginine, dopamine blockers, amantadine, tetrabenazine, co-enzyme Q10, antidepressants, antipsychotics, anti-epileptics, mood-stabilizers in general, omega-3-fatty acids, creatine monohydrate, KMO inhibitors (Kynurenine mono oxygenase) such as CHDI246, or HDAC4 inhibitors such as PBT2. Such combined use may be a sequential use: each component is administered in a distinct composition. Alternatively each compound may be used together in a single composition.

Use

[0069] In a further aspect, there is provided the use of a composition or an oligonucleotide as described in the previous sections for use as a medicament or part of therapy, or applications in which said oligonucleotide exerts its activity intracellularly. Preferably, an oligonucleotide or composition of the invention is for use as a medicament or part of a therapy for preventing, delaying, curing, ameliorating and/or treating a human cis-element repeat instability associated genetic disorder. A human cis-element repeat instability associated genetic disorder is preferably a neuromuscular genetic disorder, more preferably as identified earlier herein.

Method

[0070] In a further aspect, there is provided a method for preventing, treating, curing, ameliorating and/or delaying a condition or disease as defined in the previous section in an individual, in a cell, tissue or organ of said individual. The method comprising administering an oligonucleotide or a composition of the invention to said individual or a subject in the need thereof.

The method according to the invention wherein an oligonucleotide or a composition as defined herein may be suitable for administration to a cell, tissue and/or an organ *in vivo* of individuals affected by any of the herein defined diseases or at risk of developing said disease, and may be administered *in vivo*, *ex vivo* or *in vitro*. An individual or a subject in need is preferably a mammal, more preferably a human being.

In a further aspect, there is provided a method for diagnosis wherein the oligonucleotide of the invention is provided with a radioactive label or fluorescent label. In this method, an oligonucleotide of the invention may be used as an *in situ* probe to detect foci (RNA/protein aggregates resulting from the repeat expansion) in a sample from a subject. Said sample comprises cells from said subject.

In an embodiment, in a method of the invention, a concentration of an oligonucleotide or composition is ranged from 0.01 nM to 1 μ M. More preferably, the concentration used is from 0.05 to 500 nM, or from 0.1 to 500 nM, or from 0.02 to 500 nM, or from 0.05 to 500 nM, even more preferably from 1 to 200 nM.

[0071] Dose ranges of an oligonucleotide or composition according to the invention are preferably designed on the basis of rising dose studies in clinical trials (*in vivo* use) for which rigorous protocol requirements exist. An oligonucleotide as defined herein may be used at a dose which is ranged from 0.01 to 200 mg/kg or 0.05 to 100 mg/kg or 0.1 to 50 mg/kg or 0.1 to 20 mg/kg, preferably from 0.5 to 10 mg/kg.

Dose ranges of an oligonucleotide or composition according to the invention may also be used at a dose which is

Ranged from 100 to 300 μ g/week, 8 to 12 injections in total or

Ranged from 150 to 250 μ g/week, 9 to 11 injections in total or

200 μ g/week, 11 injections in total or

Ranged from 10 to 350 μ g/day during two weeks or

Ranged from 50 to 250 μ g/day during two weeks or

Ranged from 100 to 200 μ g/day during two weeks or

Ranged from 20 to 80 μ g/day during two weeks or

Ranged from 200 to 320 μ g/day during two weeks or

320 μ g/day, during two weeks or

30 μ g/day, during two weeks.

[0072] The ranges of concentration or dose of oligonucleotide or composition as given above are preferred concentrations or doses for *in vitro* or *ex vivo* uses. The skilled person will understand that depending on the identity of the oligonucleotide used, the target cell to be treated, the gene target and its expression levels, the medium used and the transfection and

incubation conditions, the concentration or dose of oligonucleotide used may further vary and may need to be optimised any further.

[0073] In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. The verb "to comprise" is synonymous with the verb "to have" unless otherwise indicated. In addition the verb "to consist" may be replaced by "to consist essentially of" meaning that an oligonucleotide or a composition as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".

[0074] Each embodiment as identified herein may be combined together unless otherwise indicated.

Definitions

[0075] Throughout the application, the word "binds", "targets", "hybridizes" could be used interchangeably when used in the context of an antisense oligonucleotide which is reverse complementary to a part of a pre-mRNA as identified herein. In the context of the invention, "hybridizes" or "binds" is used under physiological conditions in a cell, preferably a human cell unless otherwise indicated.

As used herein, "hybridization" refers to the pairing of complementary oligomeric compounds (e.g., an antisense compound and its target nucleic acid). While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases). For example, the natural base adenine is nucleobase complementary to the natural nucleobases thymine, 5-methyluracil and uracil which pair through the formation of hydrogen bonds. The natural base guanine is nucleobase complementary to the natural bases cytosine and 5-methyl-cytosine. Hybridization can occur under varying circumstances. In particular, hybridization of an oligonucleotide of the invention with a targeted pre-mRNA can occur under varying circumstances. Similarly, binding of an oligonucleotide of the invention to a targeted pre-mRNA can occur under varying circumstances. Preferably, said hybridization or said binding is assessed under physiological conditions in a cell, more preferably in a human cell. An oligonucleotide of the invention is preferably said to be able to bind to, or capable of binding to, or able to hybridize with, or capable of hybridizing with, when said binding or hybridization occurs under physiological conditions in a cell, preferably a human cell.

As used herein, "nucleotide" refers to a nucleoside further comprising a modified or unmodified phosphate linking group or a non-phosphate internucleoside linkage.

[0076] As used herein, "nucleotide analogue" or "nucleotide equivalent" refers to a nucleotide, which comprises at least one modification with respect to the nucleotides naturally occurring in RNA, such as A, C, G and U. Such a modification may be an internucleoside linkage modification and/or a sugar modification and/or a base modification.

As used herein, "monomer" refers to a precursor in the synthesis of an oligomeric or polymeric compound. Also the monomeric unit or residue within such an oligomeric or polymeric compound is encompassed in the term "monomer". Thus, "monomer" and "nucleotide residue" may be used interchangeably throughout the description. Within the context of the present invention, a monomer is preferably a nucleotide. Preferred monomers to be incorporated in the oligonucleotides according to the invention are nucleotides comprising a 2'-O-methyl substituent, a phosphorothioate internucleoside linkage and a 5-methylpyrimidine and/or a 2,6-diaminopurine nucleobase.

As used herein, "nucleobase" refers to the heterocyclic base portion of a nucleoside. Nucleobases may be naturally occurring or may be modified and therefore include, but are not limited to adenine, cytosine, guanine, uracil, thymine and analogues thereof such as 5-methylcytosine. In certain embodiments, a nucleobase may comprise any atom or group of atoms capable of hydrogen bonding to a base of another nucleic acid. As used herein, " T_m " means melting temperature which is the temperature at which the two strands of a duplex nucleic acid separate. T_m is often used as a measure of duplex stability or the binding affinity of an antisense compound toward a complementary RNA molecule.

[0077] As used herein, "2'-modified" or "2'-substituted" refers to a nucleoside comprising a pentose sugar comprising a substituent at the 2' position other than H or OH. 2'-modified nucleosides include, but are not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring connects the 2' carbon and another carbon of the sugar ring; and nucleosides with non-bridging 2'-substituents, such as allyl, amino, azido, thio, O-allyl, O- C_1 - C_{10} alkyl, $-OCF_3$, O- $(CH_2)_2$ -O- CH_3 , 2'-O $(CH_2)_2$ SCH $_3$, O- $(CH_2)_2$ -O-N(R_m)(R_n), or O- CH_2 -C(=O)-N(R_m)(R_n), wherein each R_m and R_n is, independently, H or substituted or unsubstituted C_1 - C_{10} alkyl. 2'-modified nucleosides may further comprise other modifications, for example at other positions of the sugar and/or at the nucleobase.

[0078] As used herein, "2'-O-Me", "2'-OMe" or "2'-OCH $_3$ " or "2'-O-methyl" each refers to a nucleoside comprising a sugar comprising an -OCH $_3$ group at the 2' position of the sugar ring. As used herein, "MOE" or "2'-MOE" or "2'-OCH $_2$ CH $_2$ OCH $_3$ " or "2'-O-methoxyethyl" each refers to a nucleoside comprising a sugar comprising a -OCH $_2$ CH $_2$ OCH $_3$ group at the 2' position of the sugar ring.

As used herein, the term "adenine analogue" means a chemically-modified purine nucleobase that, when incorporated into an oligomer, is capable of forming a base pair with either a thymine or uracil of a complementary strand of RNA or DNA. Preferably, such base pair is a Watson-Crick base pair, but analogues and slight deviations thereof are also considered allowable within the context of the present invention.

As used herein, the term "uracil analogue" means a chemically-modified pyrimidine nucleobase that, when incorporated into an oligomer, is capable of forming a base pair with either a

adenine of a complementary strand of RNA or DNA. Preferably, such base pair is a Watson-Crick base pair, but analogues and slight deviations thereof are also considered allowable within the context of the present invention.

As used herein, the term "thymine analogue" means a chemically-modified pyrimidine nucleobase that, when incorporated into an oligomer, is capable of forming a base pair with an adenine of a complementary strand of RNA or DNA. Preferably, such base pair is a Watson-Crick base pair, but analogues and slight deviations thereof are also considered allowable within the context of the present invention.

As used herein, the term "cytosine analogue" means a chemically-modified pyrimidine nucleobase that, when incorporated into an oligomer, is capable of forming a base pair with a guanine of a complementary strand of RNA or DNA. For example, cytosine analogue can be a 5-methylcytosine. Preferably, such base pair is a Watson-Crick base pair, but analogues and slight deviations thereof are also considered allowable within the context of the present invention.

As used herein, the term "guanine analogue" means a chemically-modified purine nucleobase that, when incorporated into an oligomer, is capable of forming a base pair with a cytosine of a complementary strand of RNA or DNA. Preferably, such base pair is a Watson-Crick base pair, but analogues and slight deviations thereof are also considered allowable within the context of the present invention.

As used herein, the term "guanosine" refers to a nucleoside or sugar-modified nucleoside comprising a guanine or guanine analog nucleobase.

[0079] As used herein, the term "uridine" refers to a nucleoside or sugar-modified nucleoside comprising a uracil or uracil analog nucleobase.

As used herein, the term "thymidine" refers to a nucleoside or sugar-modified nucleoside comprising a thymine or thymine analog nucleobase.

As used herein, the term "cytidine" refers to a nucleoside or sugar-modified nucleoside comprising a cytosine or cytosine analog nucleobase.

As used herein, the term "adenosine" refers to a nucleoside or sugar-modified nucleoside comprising an adenine or adenine analog nucleobase.

As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA).

As used herein, "internucleoside linkage" refers to a covalent linkage between adjacent nucleosides. An internucleoside linkage may be a naturally occurring internucleoside linkage, i.e. a 3' to 5' phosphodiester linkage, or a modified internucleoside linkage.

As used herein, "modified internucleoside linkage" refers to any internucleoside linkage other than a naturally occurring internucleoside linkage.

As used herein, "backbone" refers to the chain of alternating sugar moieties and internucleoside linkages, as it occurs in an oligonucleotide. The oligonucleotide of the invention comprises at least one phosphorodithioate internucleoside linkage, but it has to be understood that more backbone modifications, such as sugar modifications and/or internucleoside linkage modifications may be present in the backbone.

As used herein, "oligomeric compound" refers to a polymeric structure comprising two or more sub-structures. In certain embodiments, an oligomeric compound is an oligonucleotide. In certain embodiments, an oligomeric compound is a single-stranded oligonucleotide. In certain embodiments, an oligomeric compound is a double-stranded duplex comprising two oligonucleotides. In certain embodiments, an oligomeric compound is a single-stranded or double-stranded oligonucleotide comprising one or more conjugate groups and/or terminal groups.

As used herein, "conjugate" refers to an atom or group of atoms bound to an oligonucleotide or oligomeric compound. In general, conjugate groups modify one or more properties of the compound to which they are attached, including, but not limited to pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and clearance. Conjugate groups are routinely used in the chemical arts and are linked directly or via an optional linking moiety or linking group to the parent compound such as an oligomeric compound. In certain embodiments, conjugate groups includes without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterol, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes. In certain embodiments, conjugates are terminal groups. In certain embodiments, conjugates are attached to a 3' or 5' terminal nucleoside or to an internal nucleoside of an oligonucleotide.

As used herein, "conjugate linking group" refers to any atom or group of atoms used to attach a conjugate to an oligonucleotide or oligomeric compound. Linking groups or bifunctional linking moieties such as those known in the art are amenable to the present invention.

As used herein, "antisense compound" refers to an oligomeric compound, at least a portion of which is at least partially complementary to, or at least partially directed to, a target nucleic acid to which it hybridizes and modulates the activity, processing or expression of said target nucleic acid.

As used herein, "expression" refers to the process by which a gene ultimately results in a protein. Expression includes, but is not limited to, transcription, splicing, post-transcriptional modification, and translation.

As used herein, "antisense oligonucleotide" refers to an antisense compound that is an oligonucleotide.

As used herein, "antisense activity" refers to any detectable and/or measurable activity attributable to the hybridization of an anti sense compound to its target nucleic acid. In certain embodiments, such activity may be an increase or decrease in an amount of a nucleic acid or protein. In certain embodiments, such activity may be a change in the ratio of splice variants of a nucleic acid or protein. Detection and/or measuring of antisense activity may be direct or indirect. In certain embodiments, antisense activity is assessed by observing a phenotypic change in a cell or animal.

As used herein, "target nucleic acid" refers to any nucleic acid molecule the expression, amount, or activity of which is capable of being modulated by an antisense compound. In certain embodiments, the target nucleic acid is DNA or RNA. In certain embodiments, the target RNA is miRNA, mRNA, pre-mRNA, non-coding RNA, or natural antisense transcripts. For example, the target nucleic acid can be a cellular gene (or mRNA transcribed from the

gene) whose expression is associated with a particular disorder or disease state,

As used herein, "target mRNA" refers to a pre-selected RNA molecule that encodes a protein.

As used herein, "targeting" or "targeted to" refers to the association of an antisense compound to a particular target nucleic acid molecule or a particular region of nucleotides within a target nucleic acid molecule. An antisense compound targets a target nucleic acid if it is sufficiently reverse complementary to the target nucleic acid to allow hybridization under physiological conditions. In this context "sufficiently reverse complementary" may be at least 90%, 95%, 97%, 99% or 100% reverse complementary with said targeted nucleic acid molecule.

As used herein, "target site" refers to a region of a target nucleic acid that is bound by an antisense compound. In certain embodiments, a target site is at least partially within the 3' untranslated region of an RNA molecule. In certain embodiments, a target site is at least partially within the 5' untranslated region of an RNA molecule. In certain embodiments, a target site is at least partially within the coding region of an RNA molecule. In certain embodiments, a target site is at least partially within an exon of an RNA molecule. In certain embodiments, a target site is at least partially within an intron of an RNA molecule. In certain embodiments, a target site is at least partially within a miRNA target site of an RNA molecule. In certain embodiments, a target site is at least partially within a repeat region of an RNA molecule.

As used herein, "target protein" refers to a protein, the expression of which is modulated by an antisense compound. In certain embodiments, a target protein is encoded by a target nucleic acid. In certain embodiments, expression of a target protein is otherwise influenced by a target nucleic acid.

As used herein, "complementarity" in reference to nucleobases refers to a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair. Nucleobases comprising certain modifications may maintain the ability to pair with a counterpart nucleobase and thus, are still capable of nucleobase complementarity.

As used herein, "non-complementary" in reference to nucleobases refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization.

As used herein, "complementary" in reference to linked nucleosides, oligonucleotides, or nucleic acids, refers to the capacity of an oligomeric compound to hybridize to another oligomeric compound or nucleic acid through nucleobase complementarity. In certain embodiments, an antisense compound and its target are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleobases that can bond with each other to allow stable association between the antisense compound and the target. One skilled in the art recognizes that the inclusion of mismatches is possible without eliminating the ability of the oligomeric compounds to remain in association. Therefore, described herein are antisense compounds that may comprise up to about 20% nucleotides

that are mismatched (i.e., are not nucleobase complementary to the corresponding nucleotides of the target). Preferably the antisense compounds contain no more than about 15%, more preferably not more than about 10%, most preferably not more than 5% or no mismatches. The remaining nucleotides are nucleobase complementary or otherwise do not disrupt hybridization (e.g., universal bases). One of ordinary skill in the art would recognize the compounds provided herein are at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to a target nucleic acid or reverse complementarity to a target nucleic acid.

As used herein, "modulation" refers to a perturbation of amount or quality of a function or activity when compared to the function or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression. As a further example, modulation of expression can include perturbing splice site selection of pre-mRNA processing, resulting in a change in the amount of a particular splice-variant present compared to conditions that were not perturbed. As a further example, modulation includes perturbing translation of a protein.

[0080] As used herein, "motif" refers to a pattern of modifications in an oligomeric compound or a region thereof. Motifs may be defined by modifications at certain nucleosides and/or at certain linking groups of an oligomeric compound.

As used herein, "the same modifications" refer to modifications relative to naturally occurring molecules that are the same as one another, including absence of modifications. Thus, for example, two unmodified DNA nucleoside have "the same modification," even though the DNA nucleoside is unmodified.

As used herein, "type of modification" in reference to a nucleoside or a nucleoside of a "type" refers to the modification of a nucleoside and includes modified and unmodified nucleosides. Accordingly, unless otherwise indicated, a "nucleoside having a modification of a first type" may be an unmodified nucleoside.

As used herein, "pharmaceutically acceptable salts" refers to salts of active compounds that retain the desired biological activity of the active compound and do not impart undesired toxicological effects thereto.

As used herein, the term "independently" means that each occurrence of a repetitive variable within a claimed oligonucleotide is selected independent of one another. For example, each repetitive variable can be selected so that (i) each of the repetitive variables are the same, (ii) two or more are the same, or (iii) each of the repetitive variables can be different.

General Chemistry Definitions

[0081] As used herein, "alkyl" refers to a saturated straight or branched hydrocarbon substituent or radical, typically containing up to twenty four carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like. Alkyl groups typically include from 1 to 24 carbon atoms, more typically from 1 to 12 carbon atoms (C₁-C₁₂ alkyl) with from 1 to 6 carbon atoms (C₁-C₆ alkyl) being more preferred. The term "lower alkyl" as used herein includes from 1 to 6 carbon atoms

(C₁-C₆ alkyl). Alkyl groups as used herein may optionally contain one or more further substituents.

As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain radical or substituent, typically containing up to twenty four carbon atoms, and having at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadienyl and the like. Alkenyl groups typically include from 2 to 24 carbon atoms, more typically from 2 to 12 carbon atoms with from 2 to 6 carbon atoms being more preferred. Alkenyl groups as used herein may optionally contain one or more further substituents.

As used herein, "alkynyl" refers to a straight or branched hydrocarbon radical or substituent, typically containing up to twenty four carbon atoms, and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 1-butyne, and the like. Alkynyl groups typically include from 2 to 24 carbon atoms, more typically from 2 to 12 carbon atoms with from 2 to 6 carbon atoms being more preferred. Alkynyl groups as used herein may optionally contain one or more further substituents.

As used herein, "aminoalkyl" refers to an amino substituted alkyl radical or substituent. This term is meant to include C₁-C₁₂ alkyl groups having an amino substituent at any position and wherein the aminoalkyl group is attached to the parent molecule via its alkyl moiety. The alkyl and/or amino portions of the aminoalkyl group may optionally be further substituted with further substituents.

As used herein, "aliphatic" refers to a straight or branched hydrocarbon radical or substituent, typically containing up to twenty four carbon atoms, wherein the saturation between any two carbon atoms is a single, double or triple bond. An aliphatic group preferably contains from 1 to 24 carbon atoms, more typically from 1 to 12 carbon atoms with from 1 to 6 carbon atoms being more preferred. The straight or branched chain of an aliphatic group may be interrupted with one or more heteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groups interrupted by heteroatoms include without limitation polyalkoxys, such as polyalkylene glycols, polyamines, and polyimines. Aliphatic groups as used herein may optionally contain further substituents.

As used herein, "alicyclic" or "alicyclicyl" refers to a cyclic radical or substituent, wherein the ring system is aliphatic. The ring system can comprise one or more rings wherein at least one ring is aliphatic. Preferred alicyclic moieties include rings having from 5 to 9 carbon atoms in the ring. Alicyclic groups as used herein may optionally contain further substituents.

As used herein, "alkoxy" refers to a radical or substituent comprising an alkyl group and an oxygen atom, wherein the alkoxy group is attached to a parent molecule via its oxygen atom. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein may optionally contain further substituents.

As used herein, "halo", "halide" and "halogen" refer to an atom, radical or substituent selected from fluorine, chlorine, bromine and iodine.

As used herein, "aryl" and "aromatic" refer to a radical or substituent comprising a mono- or polycyclic carbocyclic ring system having one or more aromatic rings. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like. Preferred aryl ring systems have from 5 to 20 carbon atoms in one or more rings. Aryl groups

as used herein may optionally contain further substituents.

As used herein, "aralkyl" and "arylalkyl" refer to a radical or substituent comprising an alkyl group and an aryl group, wherein the aralkyl or arylalkyl group is attached to a parent molecule via its alkyl moiety. Examples include, but are not limited to, benzyl, phenethyl and the like. Aralkyl groups as used herein may optionally contain further substituents attached to the alkyl, the aryl or both moieties that form the radical or substituent.

As used herein, "heterocyclyl" refers to a radical or substituent comprising a mono- or polycyclic ring system that includes at least one heteroatom and is unsaturated, partially saturated or fully saturated, thereby including heteroaryl groups. Heterocyclyl is also meant to include fused ring system moieties wherein one or more of the fused rings contain at least one heteroatom and the other rings can contain one or more heteroatoms or optionally contain no heteroatoms. A heterocyclic group typically includes at least one atom selected from sulfur, nitrogen or oxygen. Examples of heterocyclic groups include [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and the like. Heterocyclic groups as used herein may optionally contain further substituents. As used herein, "heteroaryl" and "heteroaromatic" refer to a radical or substituent comprising a mono- or polycyclic aromatic ring, ring system or fused ring system wherein at least one of the rings is aromatic and includes one or more heteroatom. Heteroaryl is also meant to include fused ring systems including systems where one or more of the fused rings contain no heteroatoms. Heteroaryl groups typically include one ring atom selected from sulfur, nitrogen or oxygen. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like. Heteroaryl radicals or substituents can be attached to a parent molecule directly or through a linking moiety such as an aliphatic group or a heteroatom. Heteroaryl groups as used herein may optionally contain further substituents.

As used herein, "heteroarylalkyl" refers to a radical or substituent comprising a heteroaryl group as previously defined and an alkyl moiety, wherein the heteroarylalkyl group is attached to a parent molecule via its alkyl moiety. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl, naphthyridinylpropyl and the like. Heteroarylalkyl groups as used herein may optionally contain further substituents on one or both of the heteroaryl or alkyl portions.

As used herein, "mono or polycyclic" refers to any ring systems, such as a single ring or a polycyclic system having rings that are fused or linked, and is meant to be inclusive of single and mixed ring systems individually selected from aliphatic, alicyclic, aryl, heteroaryl, aralkyl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic and heteroarylalkyl. Such mono and polycyclic structures can contain rings that have a uniform or varying degree of saturation, including fully saturated, partially saturated or fully unsaturated rings. Each ring can comprise ring atoms selected from C, N, O and S to give rise to heterocyclic rings as well as rings comprising only C ring atoms. Heterocyclic and all-carbon rings can be present in a mixed motif, such as for example benzimidazole wherein one ring of the fused ring system has only carbon ring atoms and the other ring has two nitrogen atoms. The mono or polycyclic structures can be further substituted with substituents such as for example phthalimide which

has two oxo groups (=O) attached to one of the rings. In another aspect, mono or polycyclic structures can be attached to a parent molecule directly through a ring atom, through a substituent or a bifunctional linking moiety.

As used herein, "acyl" refers to a radical or substituent comprising a carbonyl moiety (C=O or -C(O)-) and a further substituent X, wherein the acyl group is attached to a parent molecule via its carbonyl moiety. As such, an acyl group is formally obtained by removal of a hydroxyl group from an organic acid and has the general formula -C(O)-X, wherein X is typically aliphatic, alicyclic or aromatic. The term "acyl" is also meant to include heteroacyl radicals or substituents with general formula -Y(O)_n-X, wherein X is as defined above and Y(O)_n is typically sulfonyl, sulfinyl or phosphate. Examples of acyl groups include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphatic phosphates and the like. Acyl groups as used herein may optionally contain further substituents.

As used herein, "substituent" and "substituent group" include groups that are typically added to other substituents or parent compounds to enhance desired properties or give desired effects. Substituent groups can be protected or unprotected and can be attached to one available site or to many available sites in a parent compound. Substituent groups may also be further substituted with other substituent groups and may be attached directly or via a linking group such as an alkyl or hydrocarbyl group to a parent compound. Herein, "hydrocarbyl" refers to any group comprising C, O and H. Included are straight, branched and cyclic groups having any degree of saturation. Such hydrocarbyl groups can include one or more heteroatoms selected from N, O and S and can be further substituted with one or more substituents.

[0082] Unless otherwise indicated, the term "substituted" or "optionally substituted" refers to the (optional) presence of any of the following substituents: halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (-C(O)R_{aa}), carboxyl (-C(O)O-R_{aa}), aliphatic groups, alicyclic groups, alkoxy, substituted oxo (-O-R_{aa}), aryl, aralkyl, heterocyclic, heteroaryl, heteroarylalkyl, amino (-NR_{bb}R_{cc}), imino (=NR_{bb}), amido (-C(O)NR_{bb}R_{cc} or -N(R_{bb})C(O)R_{aa}), azido (-N₃), nitro (-NO₂), cyano (-CN), carbamido (-OC(O)NR_{bb}R_{cc} or -N(R_{bb})C(O)OR_{aa}), ureido (-N(R_{bb})C(O)NR_{bb}R_{cc}), thioureido (-N(R_{bb})C(S)NR_{bb}R_{cc}), guanidiny (-N(R_{bb})C(=NR_{bb})NR_{bb}R_{cc}), amidiny (-C(=NR_{bb})NR_{bb}R_{cc} or -N(R_{bb})C(NR_{bb})R_{aa}), thiol (-SR_{bb}), sulfinyl (-S(O)R_{bb}), sulfonyl (-S(O)₂R_{bb}), sulfonamidyl (-S(O)₂NR_{bb}R_{cc} or -N(R_{bb})S(O)₂R_{bb}) and conjugate groups. Herein, each R_{aa}, R_{bb} and R_{cc} is, independently, H, an optionally linked chemical functional group or a further substituent, preferably but without limitation chosen from the group consisting of H, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. Selected substituents within the compounds described herein are present to a recursive degree.

In this context, "recursive substituent" means that a substituent may recite another instance of itself. Because of the recursive nature of such substituents, theoretically, a large number may be present in any given claim. One of ordinary skill in the art of medicinal chemistry and organic chemistry understands that the total number of such substituents is reasonably limited by the desired properties of the compound intended. Such properties include, by way of example and not limitation, physical properties such as molecular weight, solubility or log P,

application properties such as activity against the intended target and practical properties such as ease of synthesis.

Recursive substituents are an intended aspect of the invention. One of ordinary skill in the art of medicinal and organic chemistry understands the versatility of such substituents. To the degree that recursive substituents are present in a claim of the invention, the total number will be determined as set forth above.

As used herein, a zero (0) in a range indicating number of a particular unit means that the unit may be absent. For example, an oligomeric compound comprising 0-2 regions of a particular motif means that the oligomeric compound may comprise one or two such regions having the particular motif, or the oligomeric compound may not have any regions having the particular motif. In instances where an internal portion of a molecule is absent, the portions flanking the absent portion are bound directly to one another. Likewise, the term "none" as used herein, indicates that a certain feature is not present. As used herein, "analogue" or "derivative" means either a compound or moiety similar in structure but different in respect to elemental composition from the parent compound regardless of how the compound is made. For example, an analogue or derivative compound does not need to be made from the parent compound as a chemical starting material.

[0083] The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Legends to the figure

[0084]

Figure 1. *In vitro* activity assay for (XYG)₇ in which X = 5-methylcytosine and Y=U (PS659 SEQ ID NO:90; derived from SEQ ID NO:2) and (XYG)₇ in which X=C and Y is 5-methyluracil (PS661 SEQ ID NO: 97; derived from SEQ ID NO:3). PS659 (**1a**) and PS661 (**1b**) were transfected into HD fibroblasts (GM04022) at increasing concentrations (0.5 - 200 nM). Efficacy and selectivity was determined with RT-PCR and lab-on-a-chip analysis. Silencing of the expanded ((CAG)₄₄) and healthy ((CAG)₁₈) HTT transcripts were compared to the relative HTT transcript levels in mock samples. For all AONs n=2 except for mock (n=3).

Figure 2. *In vivo* efficacy of PS659 ((XYG)₇ in which X = 5-methylcytosine and Y=U; SEQ ID NO:2) in a transgenic HD rat model. Transgenic HD rats ((CAG)₅₁ repeat) received 15 times an intraventricular injection with PS659 (SEQ ID NO:90 derived from SEQ ID NO: 2), during 18 weeks at a final dose of 200 µg per injection, control HD rats received vehicle only. Rats were sacrificed one week after the final injection. From all rats tissue was isolated and HTT levels were determined with Q-RT-PCR analysis. Reduced levels of HTT transcript were found in (**A**) cortex, (**B**) hippocampus, (**C**) olfactory bulb and (**D**) thalamus after PS659 treatment compared to control.

TABLE 1. General structures of AONs. X = C or 5-methylcytosine Y = U or 5-methyluracil, Z = A

or 2,6-diaminopurine, I = inosine, and Q = abasic monomer.

Target Repeat	AON Sequence (5'→3')	SEQ ID NO
	(XYG) ₇ (PS57)	1
	X=C, Y=U	
	(XYG) ₇ (PS659)	2
	X=5-methylcytosine, Y=U	
	(XYG) ₇ (PS661)	3
	X=C, Y=5-methyluracil	
	(XYG) ₄	4
	(XYG) ₅	5
(CAG) _n	(XYG) ₆	6
	(XYG) ₇	7
	(XYG) ₈	8
	(XYG) ₉	9
	(XYG) ₁₀	10
	(XYG) ₁₁	11
	(XYG) ₁₂	12
(GCG) _n	(XGX) ₄	13
	(XGX) ₅	14
	(XGX) ₆	15
	(XGX) ₇	16
	(XGX) ₈	17
	(XGX) ₉	18
	(XGX) ₁₀	19
	(XGX) ₁₁	20
	(XGX) ₁₂	21
(CGG) _n	(XXG) ₄	22
	(XXG) ₅	23
	(XXG) ₆	24
	(XXG) ₇	25
	(XXG) ₈	26
	(XXG) ₉	27
	(XXG) ₁₀	28
	(XXG) ₁₁	29
	(XXG) ₁₂	30

Target Repeat	AON Sequence (5'→3')	SEQ ID NO
(GAA)n	(YYX)4	31
	(YYX)5	32
	(YYX)6	33
	(YYX)7	34
	(YYX)8	35
	(YYX)9	36
	(YYX)10	37
	(YYX)11	38
	(YYX)12	39
(GCC)n	(GGC)4	40
	(GGX)5	41
	(GGX)6	42
	(GGX)7	43
	(GGX)8	44
	(GGC)9	45
	(GGX)10	46
	(GGX)11	47
	(GGX)12	48
(CCG)n	(XGG)4	49
	(XGG)5	50
	(XGG)6	51
	(XGG)7	52
	(XGG)8	53
	(XGG)9	54
	(XGG)10	55
	(XGG)11	56
	(XGG)12	57
(AUUCU)n	(ZGZZY)3	58
	(ZGZZY)4	59
	(ZGZZY)5	60
	(ZGZZY)6	61
	(ZGZZY)7	62
	(XZGG)3	63
	(XZGG)4	64
	(XZGG)5	65

Target Repeat	AON Sequence (5'→3')	SEQ ID NO
(CCUG) _n	(XZGG)6	66
	(XZGG)7	67
	(XZGG)8	68
	(XZGG)9	69
(GGGGCC) _n	(GGXUXX)3	216
	(GGXUXX)4	217
	(GGXIXX)4	218
	(GGXQXX)4	219

Note: All AONs with SEQ ID NO: 4-69, or 216-219 comprise at least one base modification selected from 5-methylcytosine, 5-methyluracil, and 2,6-diaminopurine.

TABLE 2. General structures of AONs. All AONs are 2'-O- methyl phosphorothioate AONs wherein C is 5-methylcytosine, U is 5-methyluracil, A is 2,6-diaminopurine, I is inosine and Q is an abasic monomer.

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
	PS659	<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	90
		<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	91
		CUG <u>C</u> UG CUG <u>C</u> UG CUG <u>C</u> UG CUG	92
		<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	93
		CUG CUG <u>C</u> UG <u>C</u> UG <u>C</u> UG CUG CUG	94
		CUG CUG CUG <u>C</u> UG CUG CUG CUG	95
		<u>C</u> UG CUG CUG CUG CUG CUG <u>C</u> UG	96
	PS661	<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	97
		<u>C</u> UG CUG CUG CUG CUG CUG CUG	98
(CAG) _n		CUG <u>C</u> UG CUG <u>C</u> UG CUG <u>C</u> UG CUG	99
		<u>C</u> UG CUG <u>C</u> UG CUG <u>C</u> UG CUG <u>C</u> UG	100
		CUG CUG <u>C</u> UG <u>C</u> UG <u>C</u> UG CUG CUG	101
		<u>C</u> UG CUG CUG CUG CUG CUG <u>C</u> UG	102
		CUG CUG <u>C</u> UG CUG <u>C</u> UG CUG CUG	103
	PS660	<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	104
		CUG CUG <u>C</u> UG <u>C</u> UG <u>C</u> UG CUG CUG	105
		<u>C</u> UG CUG CUG CUG CUG CUG <u>C</u> UG	106
	PS684	<u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG <u>C</u> UG	107

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
		<u>CUG CUG CUG CUG CUG CUG CUG</u> QQQQ	220
		<u>CUG CUG CUG CUG CUG CUG CUG</u>	108
		<u>CUG CUG CUG CUG CUG CUG CUG</u> QQQQ	221
		<u>CUG CUG CUG CUG CUG CUG CUG CUG</u>	109
		<u>CUG CUG CUG CUG CUG CUG CUG CUG</u>	110
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	111
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	112
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	113
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	114
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	115
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	116
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	117
		<u>CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG</u>	118
		<u>CGC CGC CGC CGC</u>	119
		<u>CGC CGC CGC CGC</u>	120
		<u>CGC CGC CGC CGC CGC</u>	121
		<u>CGC CGC CGC CGC CGC</u>	122
		<u>CGC CGC CGC CGC CGC CGC</u>	123
		<u>CGC CGC CGC CGC CGC CGC</u>	124
(GCG)n		<u>CGC CGC CGC CGC CGC CGC CGC</u>	125
		<u>CGC CGC CGC CGC CGC CGC CGC</u>	126
		<u>CGC CGC CGC CGC CGC CGC CGC CGC</u>	127
		<u>CGC CGC CGC CGC CGC CGC CGC CGC</u>	128

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
		<u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u>	129
		<u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u>	130
		<u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u>	131
		<u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u> <u>CGC</u>	132
(CGG) _n		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	133
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	134
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	135
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	136
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	137
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	138
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	139
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	140
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	141
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	142
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	143
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	144
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	145
		<u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u> <u>CCG</u>	146
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	147
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	148
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	149
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	150
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	151
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	152
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	153
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	154
(GAA) _n		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	155
		<u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u> <u>UUC</u>	156

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
		<u>UUC UUC UUC UUC UUC UUC UUC</u>	157
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u>	158
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u>	159
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC</u>	160
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC</u>	161
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC UUC</u>	162
		<u>UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC UUC</u>	163
		<u>UUC UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC</u>	164
		<u>UUC UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC</u>	165
		<u>UUC UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC UUC</u>	166
		<u>UUC UUC UUC UUC UUC UUC UUC UUC UUC</u> <u>UUC UUC</u>	167
(GCC)n		<u>GGC GGC GGC GGC</u>	168
		<u>GGC GGC GGC GGC GGC</u>	169
		<u>GGC GGC GGC GGC GGC GGC</u>	170
		<u>GGC GGC GGC GGC GGC GGC GGC</u>	171
		<u>GGC GGC GGC GGC GGC GGC GGC</u>	172
		<u>GGC GGC GGC GGC GGC GGC GGC</u>	173
		<u>GGC GGC GGC GGC GGC GGC GGC</u>	174
		<u>GGC GGC GGC GGC GGC GGC GGC GGC</u>	175
		<u>GGC GGC GGC GGC GGC GGC GGC GGC</u> <u>GGC</u>	176
		<u>GGC GGC GGC GGC GGC GGC GGC GGC</u> <u>GGC GGC</u>	177
		<u>CGG CGG CGG CGG</u>	178

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
(CCG) _n		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	179
		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	180
		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	181
		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	182
		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	183
		C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G C <u>G</u> G	184
(AUUCU) _n		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	185
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	186
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	187
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	188
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	189
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	190
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU	191
		A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU A <u>G</u> AAU <u>A</u> GAAU	192
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	193
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	194
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	195
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	196
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	197
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	198
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	199
		C <u>A</u> G G CAGG C <u>A</u> G G CAGG C <u>A</u> G G	200
(CCUG) _n		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	201
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	202
		C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	203
		CAGG CAGG CAGG CAGG CAGG CAGG C <u>A</u> G G	204
		CAGG C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G C <u>A</u> G G	205

Target Repeat	AON ID	AON Sequence (5'→3')	SEQ ID NO
		CAGG CAGG CAGG CAGG CAGG CAGG CAGG CAGG	206
		CAGG CAGG CAGG CAGG CAGG CAGG CAGG CAGG CAGG	207
		CAGG CAGG CAGG CAGG CAGG CAGG CAGG CAGG CAGG	208
(GGGGCC) _n	PS1252	GGCUC ₂ GGCUC ₂ GGCUC	209
		GGCQCC GGCQCC GGCQCC	210
		GGCUC ₂ GGCUC ₂ GGCUC ₂	211
		GGCUC ₂ GGCUC ₂ GGCUC ₂ GGCUC ₂	212
		GGCQCC GGCQCC GGCQCC GGCQCC	213
		GGCIC ₂ GGCIC ₂ GGCIC ₂ GGCIC ₂	214
		GGCCUC ₂ GGCCUC ₂ GGCCUC ₂ GGCCUC ₂	215

Examples

EXAMPLE 1.

Introduction

[0085] The particular characteristics of a chosen antisense oligonucleotide (AON) chemistry may at least in part enhance binding affinity and stability, enhance activity, improve safety, and/or reduce cost of goods by reducing length or improving synthesis and/or purification procedures. This example describes the comparative analysis of the activity of AONs designed to target the expanded (CAG)_n repeat in HTT transcripts in HD fibroblasts *in vitro*, and includes AONs with either 5-methylcytosines (XYG)₇, wherein X is 5-methylcytosine and Y = U being also identified as SEQ ID NO:90 (and derived from SEQ ID NO:2), or 5-methyluracils (XYG)₇, wherein X = C and Y= 5-methyluracil being also identified as SEQ ID NO: 97 (and derived from SEQ ID NO:3).

Materials and Methods

[0086] Cell culture. Patient derived HD fibroblasts (GM04022) (purchased from Coriell Cell Repositories, Camden, USA) were cultured at 37°C and 5% CO₂ in Minimal Essential Medium (MEM) (Gibco Invitrogen, Carlsbad, USA) with 15% heat inactivated Fetal Bovine Serum (FBS) (Clontech, Palo Alto USA), 1% Glutamax (Gibco) and 100 U/ml penicillin/streptomycin (P/S) (Gibco).

[0087] Oligonucleotides. The AONs were fully 2'-O-methyl phosphorothioate modified: PS659; (XYG)₇, wherein X is 5-methylcytosine and Y = U being also identified as SEQ ID NO: 90 (and derived from SEQ ID NO:2), and PS661; (XYG)₇, wherein X = C and Y= 5-methyluracil being also identified as SEQ ID NO:97 (and derived from SEQ ID NO:3).

[0088] Transfection. Cells were transfected with AONs complexed with PEI (2 µL per µg AON, in 0.15 M NaCl). AON-PEI complex was added in MEM medium with 5% FBS to cells to a final AON concentration varying from 0.5 - 200 nM. Fresh medium was supplemented after four hours and after 24 hours RNA was isolated.

[0089] RNA isolation. RNA from cultured cells was isolated using the Aurum Total RNA Mini Kit (Bio-Rad, Hercules, CA) according to the manufacturer's protocol.

[0090] RT-PCR and Lab-on-a-chip analysis. Approximately 200 ng RNA was subjected to cDNA synthesis with random hexamers using the SuperScript first-strand synthesis system (Invitrogen) in a total volume of 20 µL. PCR was performed with primers for HTT (across the CAG repeat) and β-actin. The PCR program started with a 4 min initial denaturation at 95°C, followed by 35 cycles of 30 sec denaturation at 94°C, 30 sec annealing at 60°C, 45 sec elongation at 72°C, after which a final elongation step was performed at 72°C for 7 min. Lab-on-a-Chip was performed on the Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany), using the Agilent DNA 1000 Kit. Expression levels were normalized for β-actin levels and relative to transcript levels without transfection. The following primers were used:

HTT forward; 5'-ATGGCGACCCTGGAAAAGCTGAT-3' (SEQ ID NO: 70)

HTT reverse: 5'-TGAGGCAGCAGCGGCTG-3' (SEQ ID NO: 71)

β-actin forward; 5'-GGACTTCGAGCAAGAGATGG-3' (SEQ ID NO: 72)

β-actin reverse; 5'- AGCACTGTGTTGGCGTACAG-3' (SEQ ID NO: 73)

Results

[0091] Both PS659 (SEQ ID NO: 90 derived from SEQ ID NO:2) and PS661 (SEQ ID NO: 97

derived from SEQ ID NO:3) were highly effective and reduced the HTT transcripts in HD fibroblasts in a dose-dependent manner (**Figure 1a, b**). Both AONs also showed a preference for the allele with the expanded CAG repeats. PS659 (SEQ ID NO: 90 derived from SEQ ID NO:2) was more effective and more allele-specific at lower concentrations (strongest effect at 5 nM) (**1a**) than PS661 (SEQ ID NO: 97 derived from SEQ ID NO:3) (strongest effect at 20 nM) (**1b**).

EXAMPLE 2.

Introduction

[0092] PS659 (XYG)₇, wherein X is 5-methylcytosine and Y = U also identified as SEQ ID NO: 90 (derived from SEQ ID NO:2), was selected from *in vitro* studies as most efficient and safe candidate. This example describes its activity in a transgenic HD rat model after a series of direct intraventricular injections.

Materials and Methods

[0093] Animals. Transgenic HD rats carry a truncated Huntington cDNA fragment with 51 CAG repeats under the control of the native rat Huntington promoter. The expressed gene product is about 75 kDa, corresponding to 22% of the full-length Huntington (cDNA position 324-2321, amino acid position 1-709/825, corresponding to exon 1-16), under the control of 886 bp of the rat Huntington promoter (von Hörsten S. *et al.*). All animal experiments were approved by the Institutional Animal Care and Use Committees of the Maastricht University, Maastricht.

[0094] Oligonucleotides. PS659 (XYG)₇, wherein X is 5-methylcytosine and Y = U also identified as SEQ ID NO: 90 (derived from SEQ ID NO:2), is a fully 2'-O-methyl phosphorothioate modified AON.

[0095] *In vivo* treatment. Transgenic HD rats received 15 times an intraventricular injection at a final dose of 200 µg PS659 also identified as SEQ ID NO: 90 (derived from SEQ ID NO:2) during 18 weeks. Control HD rats received vehicle only. Rats were sacrificed one week after the final injection.

[0096] RNA isolation. RNA from brain tissue was isolated using RNA-Bee reagent (Tel Test, Inc). In brief, tissue samples were homogenized in MagNA Lyser green bead tubes (Roche) by adding RNA-Bee (50 mg tissue/mL RNA-Bee) and homogenizing using a MagNA Lyser instrument (Roche). Lysate was transferred to a new tube, chloroform (SIGMA) was added (0.2 mL per mL RNA-Bee), mixed, incubated on ice for 5 minutes and centrifuged at 13,000

rpm for 15 minutes at 4°C. The upper aqueous phase was collected and an equal volume isopropanol (SIGMA) was added, followed by a 1 hour incubation period at 4°C and centrifugation (13,000 rpm, 15 min, 4°C). The RNA precipitate was washed with 70% (v/v) ethanol (BioSolve), air dried and dissolved in MilliQ.

[0097] Quantitative RT-PCR analysis. Approximately 200 ng was subjected to cDNA synthesis with random hexamers using the SuperScript first-strand synthesis system (Invitrogen) in a total volume of 20 µL. 3 µL of 1/40 cDNA dilution preparation was subsequently used in a quantitative PCR analysis according to standard procedures in presence of iQ™ SYBR® Green Supermix (Bio-Rad). Quantitative PCR primers were designed based on NCBI database sequence information. Product identity was confirmed by DNA sequencing. The signal for Rab2 and YWHAZ was used for normalization. The following primers were used:

Rat Htt-F; 5'- CGCCGCCTCCTCAGCTTC -3' (SEQ ID NO: 74)

Rat Htt-R; 5'- GAGAGTTCCTTCTTTGGTCGGTGC -3' (SEQ ID NO: 75)

Rab2-F; 5'- TGGGAAACAGATAAACTCCAGA-3'(SEQ ID NO: 76)

Rab2-R; 5'- AATATGACCTTGTGATAGAACGAAAG-3' (SEQ ID NO: 77)

YWHAZ-F; 5'- AAATGAGCTGGTGCAGAAGG-3' (SEQ ID NO: 78)

YWHAZ -R; 5'- GGCTGCCATGTCATCGTAT -3' (SEQ ID NO: 79)

Results

[0098] PS659 (also identified as SEQ ID NO: 90 or derived from SEQ ID NO: 2) reduced transgenic Htt transcript levels in cortex (**Figure 2a**), hippocampus (**Figure 2b**), olfactory bulb (**Figure 2c**) as well as in thalamus (**Figure 3d**) when compared to saline treated rats. These results demonstrate that PS659 (also identified as SEQ ID NO: 90 or derived from SEQ ID NO: 2) is effective *in vivo* after direct intraventricular injection.

List of references

[0099]

Aartsma-Rus et al., Hum Mol Gen 2003; 12(8):907-14.

Arai K et al.Bioorg. Med. Chem. 2011, 21, 6285

Bauer et al., 2009; J Neurochem. 110:1737-65

- Braida C., et al, Human Molecular Genetics, 2010, vol 9: 1399-1412
- Bruno et al., Adv Drug Deliv Rev. 2011;63(13):1210-26
- Diebold et al., 2006, Eur J Immunol; 36(12): 3256-67
- Evers et al. PLoS ONE 2011, 6 (9) e24308
- Huang et al., 1998 Somat Cell Molec Gen 24:217-33;
- Krieg AM. et al., Nature 1995; 374: 546-549.
- Krieg, A. M., Curr. Opin. Immunol. 2000; 12: 35-43.
- Kumar L, Pharm. Technol. 2008, 3, 128.
- Muchowski et al., 2002 PNAS 99: 727-32
- Mulders et al. PNAS 2009 106(33); p13915-20
- Peacock H et al. J. Am. Chem. Soc. 2011, 133, 9200
- Popovic PJ. et al. J of Immunol 2006; 177: 8701-8707.
- Roon-Mom et al., 2002 Mol Brain Res 109: 1-10
- Ropper AH. and Brown RH., 2005 Principles of neurology. 8th Ed. New York: McGraw-Hill, 2005.
- Ross et al., 2011; Lancet Neurol. 10:83-98
- Rigo, F, et al, 2012, Nature chemical biology, 8: 555-561.
- Steffan et al., 2000 PNAS 97: 6763-68
- von Horsten S. et al. Hum Mol Genet. 2003;12(6):617-24
- Wagner, H., Adv. Immunol. 1999; 73: 329-368.
- Yu RZ., Anal Biochem 2002; 304: 19-25.

SEQUENCE LISTING

[0100]

<110> Prosensa Technologies B.V.

<120> RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

<130> P6040090pct

<150> EP 12165139.2

<151> 2012-04-23

<150> US 61/636,914

<151> 2012-04-23

<160> 221

<170> PatentIn version 3.3

<210> 1

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<400> 1

cugcugcugc ugcugcugcu g 21

<210> 2

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<400> 2
 nugnugnugn ugnugnugnu g 21

<210> 3
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

<220>

<221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methyluracil

<400> 3
 cngcngcngc ngcngcngcn g 21

<210> 4
 <211> 12
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<400> 4

nngnngnngn ng 12

<210> 5

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<400> 5

nngnngnngn ngngg 15

<210> 6

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<400> 6

nngnngnngn ngngnng 18

<210> 7

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<400> 7
nngnngnngn ngngnngnngn g 21

<210> 8
<211> 24
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (11)..(11)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is U or 5-methyluracil

 <400> 8
 nngnngnngn ngngnngnngn gngg

<210> 9

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

<400> 9

nnngnnngnn ngngnnngnn gnnngng 27

<210> 10

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (26) .. (26)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (28) .. (28)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (29) .. (29)
 <223> n is U or 5-methyluracil

<400> 10
 nngnngnngn ngnngnngnn gnnngnngng 30

<210> 11
 <211> 33
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (4) .. (4)
 <223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (5)..(5)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is U or 5-methyluracil

<400> 11
nngnngnngn ngngnngnngn gngnngnng nng 33

<210> 12

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (11)..(11)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (23)..(23)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is U or 5-methyluracil

<400> 12

nngnngnngn ngngnngnngn gngngnngng nngnng 36

<210> 13

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<400> 13
 ngngngngnn gn 12

<210> 14
 <211> 15
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is C or 5-methylcytosine

<400> 14
 ngngngngnn gnggn 15

<210> 15
 <211> 18
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<400> 15
ngnngnngnn gnnngnngn 18

<210> 16
<211> 21
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature

<222> (3)..(3)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<400> 16

ngnngnngnn gnnngnngng n 21

<210> 17

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<400> 17

ngnngnngnn gnnngnngng nngn 24

<210> 18

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<400> 18

ngnngnngnn gnnngnngng nngnngn 27

<210> 19

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21)..(21)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24)..(24)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25)..(25)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27)..(27)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (28)..(28)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (30)..(30)
 <223> n is C or 5-methylcytosine

<400> 19
 ngngngngnn gngngngng ngngngngnn 30

<210> 20
 <211> 33
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide
 <220>

<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is C or 5-methylcytosine

<400> 20

ngnngnngnn gnnngnngng nngnngnngn ngn 33

<210> 21

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (36)..(36)
 <223> n is C or 5-methylcytosine

 <400> 21
 ngngngngnn gngngngng ngngngngnn ngngnn 36

 <210> 22
 <211> 12
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is C or 5-methylcytosine

 <220>

<221> misc_feature
 <222> (10)..(10)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is C or 5-methylcytosine

<400> 22
 nngnngnngn ng 12

<210> 23
 <211> 15
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature

<222> (8)..(8)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is C or 5-methylcytosine

<400> 23
 nngnnngnngn ngngng 15

<210> 24
 <211> 18
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<400> 24
nngnngnngn ngngnng 18

<210> 25
<211> 21
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (11)..(11)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is C or 5-methylcytosine

<400> 25
 nngnngnngn ngngnngnngn g 21

<210> 26
 <211> 24
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature

<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is C or 5-methylcytosine

<400> 26
 nngnngnngn ngngnngnngn gngg 24

<210> 27
 <211> 27
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (2)..(2)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is C or 5-methylcytosine

<400> 27

nnngnnngnn ngnnngnnngn gnnngng 27

<210> 28

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature

<222> (14)..(14)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (23)..(23)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (25)..(25)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (26)..(26)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (28)..(28)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is C or 5-methylcytosine

<400> 28

nngnngnngn ngngnngnngn gnnngnngng 30

<210> 29

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (23)..(23)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is C or 5-methylcytosine

<400> 29

nngnngnngn ngngnngnngn gngngnngng nng 33

<210> 30

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (23)..(23)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (25)..(25)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (26)..(26)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (28)..(28)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (29)..(29)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is C or 5-methylcytosine

<400> 30

nngnngnngn ngnnngnnngn gnnngnngng nngnng 36

<210> 31

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (4)..(4)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is U or 5-methyluracil

 <220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

 <400> 31
 nnnnnnnnnn nn 12

<210> 32

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is C or 5-methylcytosine

<400> 32
 nnnnnnnnnnn nnnnn 15

<210> 33
 <211> 18
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>

<221> misc_feature
 <222> (1)..(1)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is U or 5-methyluracil

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<400> 34

nnnnnnnnnnnn nnnnnnnnnnn n 21

<210> 35

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<400> 35

nnnnnnnnnnnn nnnnnnnnnnnn nnnnn 24

<210> 36

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (7)..(7)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<400> 36

oooooooooooo ooooooooooooo ooooooooo 27

<210> 37

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is C or 5-methylcytosine

<220>

<221> misc feature

$\langle 222 \rangle$ (25) .. (25)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

 $\langle 220 \rangle$

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<220>

<221> misc feature

<222> (28) .. (28)

<223> n is U or 5-methyluracil

<220>

<221> misc feature

<222> (29) .. (29)

<223> n is U or 5-methyluracil

 $\langle 220 \rangle$

<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<400> 37

oooooooooooo oooooooooooooo oooooooooooooo 30

<210> 38

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

 $\langle 220 \rangle$

<221> misc_feature

$\langle 222 \rangle$ (1) .. (1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature
<222> (2)..(2)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (21) .. (21)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (22) .. (22)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (23) .. (23)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (24) .. (24)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (25) .. (25)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (26) .. (26)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (27) .. (27)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (28) .. (28)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (29) .. (29)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is C or 5-methylcytosine

<400> 38

oooooooooooo oooooooooooooo oooooooooooooo oooo

33

<210> 39

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (36)..(36)

<223> n is C or 5-methylcytosine

<400> 39

oooooooooooo ooooooooooooo ooooooooooooo ooooooooo

36

<210> 40

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<400> 40
 ggnggnggng gn 12

<210> 41
 <211> 15
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is C or 5-methylcytosine

<400> 41
 ggnggnggng gnggn 15

<210> 42
 <211> 18
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<400> 42

ggnggnggng gnggnggn 18

<210> 43

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is C or 5-methylcytosine

<400> 43

ggnggnggng gnggnggngg n 21

<210> 44

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24) .. (24)
 <223> n is C or 5-methylcytosine

<400> 44
 ggnggnggng gnggnggngg nggn 24

<210> 45
 <211> 27
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide
 <220>

<221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24)..(24)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27) .. (27)
 <223> n is C or 5-methylcytosine

<400> 45

ggnggnggng gnggnggngg nggnggn

<210> 46

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is C or 5-methylcytosine

<400> 46

ggnggnggng gnggnggngg nggnggnggn 30

<210> 47

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (18)..(18)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24) .. (24)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27)..(27)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (30)..(30)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (33)..(33)
 <223> n is C or 5-methylcytosine

<400> 47
 ggnggnggng gnggnggngg nggnggnggn ggn 33

<210> 48
 <211> 36
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature

<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (21) .. (21)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (24)..(24)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (27)..(27)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (30)..(30)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (33)..(33)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (36)..(36)

<223> n is C or 5-methylcytosine

<400> 48

ggnggnggng gnggnggngg nggnggnggn ggnggn 36

<210> 49

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<400> 49

nggnggnggn gg 12

<210> 50

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<400> 50
nggnggnggn ggngg 15

<210> 51
<211> 18
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is C or 5-methylcytosine

<400> 51
nggnggnggn ggnggngg 18

<210> 52
<211> 21
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is C or 5-methylcytosine

<400> 52

nggnggnggn ggnggnggng g 21

<210> 53

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<400> 53

ngngngngngn ggngngngng gngg 24

<210> 54

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is C or 5-methylcytosine

<400> 54

ngngngngngn ggngngngng gngngng 27

<210> 55

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (4)..(4)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25)..(25)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (28) .. (28)
 <223> n is C or 5-methylcytosine

<400> 55

ngngngngngn ggngngngng gngngngngg

<210> 56

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (28) .. (28)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is C or 5-methylcytosine

<400> 56

nggngggnggn ggngggngng gngggngngg ngg 33

<210> 57

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (28) .. (28)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (31)..(31)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (34)..(34)
 <223> n is C or 5-methylcytosine

<400> 57
 nggnggnggn gnggnggng gnggnggng nggngg

36

<210> 58
 <211> 15
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is U or 5-methyluracil

<400> 58

ngnnnnngnnn ngnnn 15

<210> 59

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature
<222> (6)..(6)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is U or 5-methyluracil

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<400> 59

ngnnnnngnnn ngnnnnngnnn 20

<210> 60

<211> 25

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is U or 5-methyluracil

<400> 60

ngnnnnngnnn ngnnnnngnnn ngnnn 25

<210> 61

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is U or 5-methyluracil

<400> 61

ngnnnnngnnn ngnnnnngnnn ngnnnnngnnn 30

<210> 62

<211> 35

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (28) .. (28)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is U or 5-methyluracil

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is U or 5-methyluracil

<400> 62

ngnnnnngnnn ngnnnnngnnn ngnnnnngnnn ngnnnn 35

<210> 63

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is A or 2,6-diaminopurine

<400> 63

nnggnngggn gg 12

<210> 64

<211> 16

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is A or 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is A or 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is A or 2,6-diaminopurine

<400> 64
 nnggnngggn ggnggg 16

<210> 65
 <211> 20
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<400> 65

nnggnnggnn ggnggnngg 20

<210> 66

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is A or 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (21)..(21)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is A or 2,6-diaminopurine

 <400> 66
 nnggnnggnn ggnggngngg nngg 24

 <210> 67
 <211> 28
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is A or 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is C or 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is A or 2,6-diaminopurine

 <220>

<221> misc_feature

<222> (9) .. (9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is A or 2,6-diaminopurine

<400> 67
nnggnngggnn ggnggngngg nnggnggg 28

<210> 68
<211> 32
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is A or 2,6-diaminopurine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is A or 2,6-diaminopurine

<400> 68

nnggnngggnn ggngngngngg nnggnngggn gg

<210> 69

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is A or 2,6-diaminopurine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is A or 2,6-diaminopurine

<400> 69

nnggnngggnn ggngngngng nnggnngggn ggngng 36

<210> 70

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 70

atggcgaccc tggaaaagct gat 23

<210> 71

<211> 17

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 71

tgaggcagca gcggctg 17

<210> 72

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 72

ggacttcgag caagagatgg 20

<210> 73

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 73

agcactgtgt tggcgtacag 20

<210> 74

<211> 18

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 74

cgccgcctcc tcagcttc 18

<210> 75

<211> 24

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 75

gagagttcct tctttggtcg gtgc 24

<210> 76

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 76

tgggaaacag ataaaactcc aga 23

<210> 77

<211> 26

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 77

aatatgacct tgtgatagaa cgaaag 26

<210> 78

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 78

aaatgagctg gtcagaagg 20

<210> 79

<211> 19

<212> DNA

<213> Artificial

<220>

<223> Primer

<400> 79

ggctgccatg tcatcgtat 19

<210> 80

<211> 13481

<212> DNA

<213> Homo sapiens

<400> 80

```

gctgccggga cgggtccaag atggacggcc gctcaggttc tgcttttacc tgcggcccag 60
agccccattc attgccccgg tgctgagcgg cgccgcgagt cggcccagagg cctccgggga 120
ctgccgtgcc gggcgggaga ccgccatggc gaccctggaa aagctgatga aggccttcga 180
gtccctcaag tccttccagc agcagcagca gcagcagcag cagcagcagc agcagcagca 240
gcagcagcag cagcagcagc aacagccgcc accgccgccg ccgccgccgc cgcctcctca 300
gttctctcag ccgccgccgc aggcacagcc gctgctgcct cagccgcagc cgcctccgcc 360
gccgccccgc ccgccccccg gcccggtgtg ggctgaggag ccgctgcacc gaccaaagaa 420
agaactttca gctaccaaga aagaccgtgt gaatcattgt ctgacaatat gtgaaaacat 480
agtggcacag tctgtcagaa attctccaga atttcagaaa cttctgggca tcgctatgga 540
actttttctg ctgtgcagtg atgacgcaga gtcagatgtc aggatggtgg ctgacgaatg 600
cctcaacaaa gttatcaaag ctttgatgga ttctaattct ccaaggttac agctcgagct 660
ctataaggaa attaaaaaga atggtgcccc tcggagtttg cgtgctgccc tgtggaggtt 720
tgctgagctg gctcacctgg ttcggcctca gaaatgcagg ccttacctgg tgaaccttct 780
gccgtgcctg actcgaacaa gcaagagacc cgaagaatca gtccaggaga ccttggctgc 840
agctgttccc aaaattatgg cttcttttgg caattttgca aatgacaatg aaattaaggt 900
tttgtaaaag gccttcatag cgaacctgaa gtcaagctcc cccaccattc ggccgacagc 960
ccctccatca ccactgagca tctgccagca ctcaagaagg acacaatatt tctataattc 1020

```

```

gctactaaat gtgctcttag gcttactcgt tctgtctgag gatgaacact ccactctgct 1080
gattcttggc gtgctgtctca ccctgaggta ttigtgtgcc ttgctgcagc agcagggtcaa 1140
ggacacaagc ctgaaaggca gcttcggagt gacaaggaaa gaaatggaag tctctccttc 1200
tgcagagcag cttgtccagg tttatgaact gacgttacat catacacagc accaagacca 1260
caatgttgtg accggagccc tggagctgtt gcagcagctc ttcagaacgc ctccaccoga 1320
gcttctgcaa accctgaccg cagtcggggg cattgggcag ctcaccgctg ctaaggagga 1380
gtctgtgtgc cgaagccgta gtgggagtat tgtggaactt atagctggag ggggttcctc 1440
atgcagccct gtcctttcaa gaaaacaaaa aggc aaagtg ctcttaggag aagaagaagc 1500
cttgaggat gactctgaat cgagatcgga tgtcagcagc tctgccttaa cagcctcagt 1560
gaaggatgag atcagtggag agctggctgc ttcttcaggg gtttccactc cagggtcagc 1620
aggtcatgac atcatcacag aacagccacg gtcacagcac aactgcagg cggactcagt 1680
ggatctggcc agctgtgact tgacaagctc tgccactgat ggggatgagg aggatatctt 1740

gagccacagc tccagccagg tcagcgcgt cccatctgac cctgccatgg acctgaatga 1800
tgggaccacg gcctcgtcgc ccacagcga cagctcccag accaccaccg aagggcctga 1860
ttcagctgtt accccttcag acagttctga aattgtgtta gacggtaccg acaaccagta 1920
tttgggcctg cagattggac agcccagga tgaagatgag gaagccacag gtattcttcc 1980
tgatgaagcc tcggaggcct tcaggaactc ttccatggcc cttcaacagg cacatctatt 2040
gaaaaacatg agtcaactgca ggcagccttc tgacagcagt gttgataaat ttgtgttgag 2100
agatgaagct actgaaccgg gtgatcaaga aaacaagcct tgccgcacat aaggtgacat 2160
tggacagtc actgatgatg actctgcacc tcttgtccat tgtgtccgc ttttatctgc 2220
ttcgtttttg ctaacagggg gaaaaaatgt gctgggtccg gacagggatg tgagggtcag 2280
cgtgaaggcc ctggccctca gctgtgtggg agcagctgtg gcctccacc cggaatcttt 2340
cttcagcaaa ctctataaag ttctcttga caccacgga taccctgagg aacagtatgt 2400
ctcagacatc ttgaactaca tcgatcatgg agaccacag gttcaggag ccactgccat 2460
tctctgtggg acctcatct gctccatcct cagcaggctc cgttccacc tgggagattg 2520
gatgggcacc attagaacct tcacaggaaa tacatcttct ttggcggatt gcattccttt 2580
gctgcggaaa aactgaagg atgagtcttc tgttacttgc aagttagctt gtacagctgt 2640
gaggaactgt gtcatgagtc tctgcagcag cagctacagt gagttaggac tgcagctgat 2700
catcgatgtg ctgactctga ggaacagttc ctattggctg gtgaggacag agcttctgga 2760
aacccttgca gagattgact tcaggctggt gagctttttg gaggcaaaag cagaaaactt 2820
acacagaggg gctcatcatt atacagggct tttaaaactg caagaacgag tgctcaataa 2880
tgttgtcatc catttgcttg gagatgaaga cccagggtg cgacatgttg ccgcagcatc 2940
actaattagc cttgtcccaa agctgtttta taaatgtgac caaggacaag ctgatccagt 3000
agtggcctg gcaagagatc aaagcagtgt ttacctgaaa cttctcatgc atgagacgca 3060
gcctccatct catttctccg tcagcacaat aaccagaata tatagaggct ataacctact 3120
accaagcata acagacgtca ctatggaaaa taacctttca agagttattg cagcagtttc 3180
tactgactta ctgacttaa cccggggggg actgactttt actgacttgc ccccttttgc 3240

```

tcatgaacta atcacatcaa ccaccagagc actcacattt ggatgctgtg aagctttgtg 3240
 tcttctttcc actgccttcc cagtttgcat ttggagtta ggttggcact gtggagtgcc 3300
 tccactgagt gcctcagatg agtctaggaa gagctgtacc gttgggatgg ccacaatgat 3360
 tctgacctg ctctcgtcag cttggttccc attggatctc tcagcccatc aagatgcttt 3420
 gattttggcc ggaaacttgc ttgcagccag tgctccaaa tctctgagaa gttcatgggc 3480
 ctctgaagaa gaagccaacc cagcagccac caagcaagag gaggtctggc cagccctggg 3540
 ggacggggcc ctggtgcca tggtaggaca gctcttctct cacctgctga aggtgattaa 3600

 catttgtgcc cactcctgg atgacgtggc tcctggaccc gcaataaagg cagccttgcc 3660
 ttctctaaca aacccccctt ctctaagtc catccgacga aaggggaagg agaaagaacc 3720
 aggagaacaa gcatctgtac cgttgagtcc caagaaaggc agtgaggcca gtgcagcttc 3780
 tagacaatct gatacctcag gtctgttac aacaagtaaa tcctcatcac tggggagtgt 3840
 ctatcatctt ccttcatacc tcaaaactgca tgatgtcctg aaagctacac acgctaacta 3900
 caaggtcacg ctggatcttc agaacagcac ggaaaagtgt ggagggttc tccgctcagc 3960
 cttggatgtt ctttctcaga tactagagct ggccacactg caggacattg ggaagtgtgt 4020
 tgaagagatc ctaggatacc tgaaatcctg ctttagtoga gaaccaatga tggcaactgt 4080
 ttgtgttcaa caattgttga agactctctt tggcaciaac ttggcctccc agtttgatgg 4140
 cttatcttcc aaccccagca agtcacaagg ccgagcacag cgccttggct cctccagtgt 4200
 gaggccaggc ttgtaccact actgcttcat ggcctcgtac acccacttca ccagggccct 4260
 cgctgacgcc agcctgagga acatgggtgca ggcggagcag gagaacgaca cctcgggatg 4320
 gtttgatgtc ctccagaag tgtctacca gttgaagaca aacctcagca gtgtcacaaa 4380
 gaaccgtgca gataagaatg ctattcataa tcacattcgt ttgtttgaac ctcttgttat 4440
 aaaagcttta aaacagtaca cgactacaac atgtgtgcag ttacagaagc aggttttaga 4500
 tttgctggcg cagctggttc agttacgggt taattactgt cttctggatt cagatcaggt 4560
 gtttattggc ttgtattga aacagtttga atacattgaa gtgggccagt tcagggaatc 4620
 agaggcaatc attccaaaca tcttttctt cttggtatta ctatcttatg aacgctatca 4680
 ttcaaaacag atcattggaa ttctaaaat cattcagctc tgtgatggca tcatggccag 4740
 tggaaaggaa gctgtgacac atgccatacc ggcctctgag cccatagtcc acgacctctt 4800
 tgtattaaga ggaacaaata aagctgatgc aggaaaagag cttgaaaccc aaaaagaggt 4860
 ggtggtgtca atgttactga gactcatcca gtaccatcag gtgttgaga tgttcattct 4920
 tgtcctgcag cagtgcaca aggagaatga agacaagtgg aagcgactgt ctcgacagat 4980
 agctgacatc atcctcccaa tgttagccaa acagcagatg cacattgact ctcatgaagc 5040
 ccttggagtg ttaaatacat tatttgagat ttgggccct tcctccctcc gtccggtaga 5100
 catgctttta cggagtatgt tcgtcactcc aaacacaatg gcgtccgtga gcaactgtca 5160
 actgtggata tcgggaattc tggccatttt gagggttctg atttccagc caactgaaga 5220
 tattgttctt tctcgtatcc aggagctctc cttctctccg tatttaatct cctgtacagt 5280
 aattaatagg ttaagagatg gggacagtac ttcaacgcta gaagaacaca gtgaagggaa 5340
 acaataaag aatttgccag aagaacatt ttcaaggttt ctattacaac tggttggtat 5400
 tcttttagaa gacattgtta caaacagct gaaggtggaa atgagtgagc agcaacatac 5460
 tttctattcc caggaaatag ccacactgct aatctctctg atccacatct tcaagtctcc 5520

```

.....
aatgttccgg agaatcacag cagctgccac taggtgttcc cgcagtgatg gctgtggcgg 5580
cagtttctac accctggaca gcttgaactt gcgggctcgt tccatgatca ccacccaccc 5640
ggccctgggtg ctgctctggt gtcagatact gctgcttgtc aaccacaccg actaccgctg 5700
gtgggcagaa gtgcagcaga ccccgaaaag acacagtctg tccagcaca agttacttag 5760
tccccagatg tctggagaag aggaggattc tgacttggca gccaaacttg gaatgtgcaa 5820
tagagaaata gtacgaagag gggctctcat tctcttctgt gattatgtct gtcagaacct 5880
ccatgactcc gagcacttaa cgtggctcat tgtaaatcac attcaagatc tgatcagcct 5940
tccccacgag cctccagtac aggacttcat cagtgcctgt catcggaact ctgctgccag 6000
cggcctgttc atccaggcaa ttcagtctcg ttgtgaaaac ctttcaactc caaccatgct 6060
gaagaaaact cttcagtgtc tggaggggat ccatctcagc cagtggggag ctgtgctcac 6120
gctgtatgtg gacaggcttc tgtgcacccc tttccgtgtg ctggctcgca tggctgacat 6180
ccttgcttgt cgcgggtag aatgtcttct ggctgcaaat ttacagagca gcatggccca 6240
gttgccaatg gaagaactca acagaatcca ggaatacctt cagagcagcg ggtctgctca 6300
gagacaccaa aggtctctatt cctgctgga caggtttctg ctctccacca tgcaagactc 6360
acttagtccc tctcctccag tctcttccca cccgctggac ggggatgggc acgtgtcact 6420
ggaacacagt agtccggaca aagactggta cgttcactct gtcaaacc acgtgttgac 6480
caggtcagat tctgcactgc tgggaaggtc agagctggtg aatcggattc ctgctgaaga 6540
tatgaatgcc ttcatgatga actcggagtt caacctaac ctgctagctc catgcttaag 6600
cctagggatg agtgaaattt ctggtggcca gaagagtgc ctttttgaag cagcccgta 6660
ggtgactctg gccctgtgta gcggcaccgt gcagcagctc cctgctgtcc atcatgtctt 6720
ccagcccgag ctgcctgcag agccggcggc ctactggagc aagttgaatg atctgtttgg 6780
ggatgctgca ctgtatcagt cctgcccac tctggcccg gccctggcac agtacctggt 6840
ggtggtctcc aaactgccc gtcatttgca ccttctcct gagaaagaga aggacattgt 6900
gaaattcgtg gtggcaaccc ttgaggccct gtcttgcat ttgatccatg agcagatccc 6960
gctgagtctg gatctccag cagggtgga ctgctgctgc ctggccctgc agctgcctgg 7020
cctctggagc gtggtctcct ccacagagtt tgtgaccac gccctgctcc tcatctactg 7080
tgtgcacttc atcctggag cgttgacgt gcagcctgga gagcagcttc ttagtccaga 7140
aagaaggaca aataccccaa aagccatcag cgaggaggag gaggaagtag atccaaacac 7200
acagaatcct aagtatatca ctgcagcctg tgagatggtg gcagaaatgg tggagtctct 7260
gcagtcgggt ttggccttgg gtcataaaa gaatagcggc gtgcggcgct ttctcagccc 7320
attgctaagg aacatcatca tcagcctggc ccgcctgccc cttgtcaaca gctacacacg 7380

tgtgccccca ctggtgtgga agcttggatg gtcacccaaa ccgggagggg attttggcac 7440
agcattccct gagatccccg tggagtccct ccaggaaaag gaagtcttta aggagttcat 7500
ctaccgcac aacacactag gctggaccag tctactcag tttgaagaaa cttggggccac 7560
cctccttgggt gtctcgtgta cgcagccct cgtgatggag caggaggaga gccaccaga 7620
agaagacaca gagaggcccc agatcaacgt cctggcgtg caggccatca cctcactggt 7680
gctcactgca atgactctgc ctctggcccg caaccagct ctactctct tggaggaga 7740

```

gctcagctgca aggactctgc ctctggccgg caccaccagc gtaagctgct tggagcagca 7750
 gccccggaac aagcctctga aagctctcga caccagggtt gggaggaagc tgagcattat 7800
 cagagggatt gtggagcaag agattcaagc aatggtttca aagagagaga atattgccac 7860
 ccatcattta tatcaggcat gggatcctgt cccttctctg tctccggcta ctacagggtgc 7920
 cctcatcagc caccagaagc tgctgctaca gatcaacccc gagcgggagc tggggagcat 7980
 gagctacaaa ctccggccagg tgtccataca ctccgtgtgg ctggggaaca gcatcacacc 8040
 cctgagggag gaggaatggg acgaggaaga ggaggaggag gccgacgcc ctgcaccttc 8100
 gtcaccaccc acgtctccag tcaactccag gaaacaccgg gctggagttg acatccactc 8160
 ctgttcgcag tttttgcttg agttgtacag ccgctggatc ctgccgtcca gctcagccag 8220
 gaggaccccg gccatcctga tcagtggagt ggtcagatcc cttctagtgg tctcagactt 8280
 gttcacccag cgaaccagc ttgagctgat gtatgtgacg ctgacagaac tgcgaagggt 8340
 gcacccttca gaagacgaga tcctcgctca gtacctggtg cctgccacct gcaaggcagc 8400
 tgccgtcctt gggatggaca aggcctggc ggagcctgtc agccgcctgc tggagagcac 8460
 gctcaggagc agccacctgc ccagcagggt tggagccctg caccgcctcc tctatgtgct 8520
 ggagtgcgac ctgctggacg acactgccaa gcagctcacc ccggtcatca gcgactatct 8580
 cctctccaac ctgaaaggga tcgcccactg cgtgaacatt cacagccagc agcacgtact 8640
 ggtcatgtgt gccactgcgt ttacctcat tgagaactat cctctggacg tagggccgga 8700
 attttcagca tcaataatac agatgtgtgg ggtgatgctg tctggaagtg aggagtccac 8760
 cccctccatc atttaccact gtgccctcag aggcctggag ccctcctgc tctctgagca 8820
 gctctccgc ctggatgcag aatcgctggc caagctgagt gtggacagag tgaacgtgca 8880
 cagcccgcac cgggccatgg cggctctggg cctgatgctc acctgcatgt acacaggaaa 8940
 ggagaaagtc agtccgggta gaacttcaga ccctaactct gcagccccc acagcgagtc 9000
 agtgattgtt gctatggagc gggatatctg tctttttgat aggatcagga aaggctttcc 9060
 ttgtgaagcc agagtgtgg ccaggatcct gcccagttt ctgacgact tcttcccacc 9120
 ccaggacatc atgaacaaag tcatcggaga gtttctgtcc aaccagcagc catacccca 9180
 gtteatggcc accgtggtgt ataagtggt tcagactctg caccagccc ggcagtcgtc 9240
 catggtccgg gactgggtca tgctgtccct ctccaactc acgcagaggg ccccggtcgc 9300

 catggccacg tggagcctct cctgcttctt tgctcagcgc tcaccagcc cgtgggtcgc 9360
 ggcgatcctc ccacatgtca tcagcaggat gggcaagctg gagcagggtg acgtgaacct 9420
 tttctgctg gtgccacag acttctacag acaccagata gaggaggagc tcgaccgag 9480
 ggccttcag tctgtgcttg aggtggttgc agcccagga agccatata accggtgct 9540
 gacttgttta cgaaatgtcc acaaggtcac cactgctga gcgccatggt gggagagact 9600
 gtgaggcggc agctggggcc ggagccttg gaagtctgc ccttgtgccc ctgcctccac 9660
 cgagccagct tggtcctat gggcttccgc acatgccgc ggcggccagg caacgtgct 9720
 gtctctgcca tgtggcagaa gtgctctttg tggcagtggc caggcaggga gtgtctgcag 9780
 tcctgggtgg gctgagcctg aggccttcca gaaagcagga gcagctgtgc tgcaccccat 9840
 gtgggtgacc aggtcctttc tcctgatagt cactgctgg ttgttgccag gttgcagctg 9900
 ctcttgcatc tgggccagaa gtcctccctc ctgcaggctg gctgttggcc cctctgctgt 9960
 cctgagctag agctggctt caggagctt tggagagctt agctgctc tggctgctg 10020

cctgcagtag aagctgctgc gagcaggtcc tgggaacacc ggccctgggtc cccctggctg 10020
 ggtgtgcatg ccacgccccg tgtctggatg cacagatgcc atggcctgtg ctgggccagt 10080
 ggctgggggt gctagacacc cggcaccatt ctccctcttc tcttttcttc tcaggattta 10140
 aaatttaatt atatcagtaa agagattaat tttaacgtaa ctctttctat gccctgttaa 10200
 agtatgtgaa tcgcaaggcc tgtgtgcat gcgacagcgt ccgggggtgtt ggacagggcc 10260
 cccggccacg ctccctctcc tgtagccact ggcatagcc ccttgagcac ccgtgacat 10320
 ttccgttgta catgttcttg tttatgcatt cacaagggtga ctgggatgta gagaggcgtt 10380
 agtgggcagg tggccacagc aggaactgag acaggccccc attatcctag ggtgtgcttc 10440
 acctgcagcc cctcctcttc gggcacagac gactgtcgtt ctccaccac cagtcaggga 10500
 cagcagcttc cctgtcactc agctgagaag gccagccctc cctggctgtg agcagcctcc 10560
 actgtgtcca gagacatggg cctccactc ctgttcttg ctagccctgg ggtggcgtct 10620
 gcctaggagc tggctggcag gtgttgggac ctgctgctcc atggatgcat gccctaagag 10680
 tgtcactgag ctgtgttttg tctgagcctc tctcgggtcaa cagcaaagct tgggtgtcttg 10740
 gcactgttag tgacagagcc cagcatccct tctgcccccg ttccagctga catcttgac 10800
 ggtgaccctt tttagttagg agagtgcaga tctgtgctca tcggagactg cccacaggcc 10860
 ctgtcagagc cgcactcct atcccaggc caggtccctg gaccagcctc ctgtttgcag 10920
 gcccagagga gccaaagtc taaaatggaa gtggattctg gatggccggg ctgctgctga 10980
 tgtaggagct ggatttggga gctctgcttg ccgactggt gtgagacgag gcaggggctc 11040
 tgcttctca gccctagagg cgagccaggc aaggttggcg actgtcatgt ggcttggttt 11100
 ggtcatgcc gtcatgttt tgggtattga atgtggtaag tggaggaaat gttggaactc 11160

 tgtgcagggt ctgccttgag accccaagc ttccacctgt ccctctccta tgtggcagct 11220
 ggggagcagc tgagatgtgg acttgatgc tgccacata cgtgaggggg agctgaaagg 11280
 gagccctcc tctgagcagc ctctgccagg cctgtatgag gcttttccca ccagctccca 11340
 acagaggcct ccccagcca ggaccactc gtccctctgg cggggcagca ggagcggtag 11400
 aaaggggtcc gatgtttgag gaggccctta agggaagcta ctgaattata acacgtaaga 11460
 aaatcaccat tccgtattgg ttgggggctc ctgtttctca tctagcttt ttccctggaa 11520
 gcccgctaga aggtttggga acgaggggaa agttctcaga actgttggct gctccccacc 11580
 cgcctccgc ctccccgcga ggttatgtca gcagctctga gacagcagta tcacaggcca 11640
 gatgttgttc ctggctagat gtttacattt gtaagaaata aactgtgaa tgtaaaacag 11700
 agccattccc ttggaatgca tatcgtggg ctcaacatag agtttgtctt cctcttgttt 11760
 acgacgtgat ctaaaccagt ccttagcaag gggctcagaa cccccctc tggcagtagg 11820
 tgtcccccac ccccaaagc ctgcctgtgt gctccggaga tgaatatgag ctccattagta 11880
 aaaatgactt caccacgca tatacataaa gtatccatgc atgtgcatat agacacatct 11940
 ataattttac acacacacct ctcaagacgg agatgcatgg cctctaagag tgccctgttc 12000
 ggttcttctt ggaagttgac tttccttaga cccgccaggt caagtttagc gcgtgacgga 12060
 catccaggcg tgggacgtgg tcagggcagg gctcattcat tgccactag gatccactg 12120
 gcgaagatgg tctccatata agctctctgc agaaggagg aagactttat catgttctta 12180
 aaaatctgtg gcaagcacc atcgtattat ccaaattttg ttgcaaagt gattaatttg 12240

gttgtcaagt tttgggggtg ggctgtgggg agattgcttt tgttttcctg ctggtaatat 12300
 cgaggaaagat tttaatgaaa ccagggtaga attgtttggc aatgcactga agcgtgtttc 12360
 tttcccaaaa tgtgcctccc ttccgctgcg gggccagctg agtctatgta ggtgatgttt 12420
 ccagctgcc aagtctcttt gttactgtcc accctcattt ctgccagcgc atgtgtcctt 12480
 tcaaggggaa aatgtgaagc tgaacccctt ccagacaccc agaatgtagc atctgagaag 12540
 gccctgtgcc ctaaaggaca cccctcgccc ccctcttcat ggagggggtc atttcagagc 12600
 cctcggagcc aatgaacagc tctcctctt ggagctgaga tgagcccccac gtggagctcg 12660
 ggacggatag tagacagcaa taactcgggtg tgtggccgcc tggcaggtgg aacttcctcc 12720
 cgttgccggg tggagtgagg ttagttctgt gtgtctggtg ggtggagtca ggttctctt 12780
 gctacctgtg agcatccttc ccagcagaca tctcctcctg gctttgtccc tccccgctt 12840
 cctccctctg cggggaggac cggggaccac agctgctggc cagggtagac ttggagctgt 12900
 cctccagagg ggtcacgtgt aggagtgaga agaaggaaga tcttgagagc tgetgagggg 12960
 ccttgagag ctcaggatgg ctcagacgag gacactcgtg tgccgggctt gggcctctg 13020
 ggaaggagg agctgctcag aatgcgcgat gacaactgaa ggcaacctgg aaggttcagg 13080

 ggccgctctt ccccatgtg cctgtcacgc tctggtgcag tcaaaggaac gccttccctt 13140
 cagttgtttc taagagcaga gtctcccgct gcaatctggg tggtaactgc cagccttggg 13200
 ggatcgtggc caacgtggac ctgcctacgg aggggtgggt ctgacccaag tggggcctcc 13260
 ttgtccaggt ctactgctt tgcaccgtgg tcagagggac tgtcagctga gcttgagctc 13320
 ccctggagcc agcagggtg tgatgggcca gtcccggagc cccaccaga cctgaatgct 13380
 tctgagagca aaggaagga ctgacgagag atgtatattt aattttttaa ctgctgcaa 13440
 cattgtacat ccaaattaaa ggaaaaaat ggaaaccatc a 13481

<210> 81

<211> 10636

<212> DNA

<213> Homo sapiens

<400> 81

gaggagagag cagagtatac cgcagacatc atttctacta cagtggcgga gccgtacagg 60
 acctgtttca ctgcaggggg atccaaaaca agccccgtgg agcagcagcc agagcaacag 120
 cagccgcaag acattgtttc tctccctctg ccccccttc cccacgcaac ccagatcca 180
 tttaacttt acagttttac ctacaaaaa ctactacaag caccaagctc cctgatggaa 240
 aggagcatcg tgcataaagt caccagggtg gtccattcaa gctgcagatt tgtttgtcat 300
 cctgttacag caatctctc ctccactgcc actacaggga agtgcacac atgtcagcat 360
 actggagcat agtgaagag tctattttga agcttcaaac ttagtgctgc tgcagaccag 420
 gaacaagaga gaaagagtgg atttcagcct gcacggatgg tcttgaaaca caaatggtt 480
 ttggtctagg cgttttacac tgagattctc cactgccacc ctttctactc aagcaaatc 540
 ttctgaaaa gatctgctgc aaggaaactga tagcttatgg ttctccattg tgatgaaagc 600
 acatgggtaca gttttccaaa gaaattagac cattttcttc gtgagaaaga aatcgacgtg 660
 ctcttttact cctcttttct tctcttttct ctctctctct ctctctctct ctctctctct 720

ctgttttcat aggggtatttc tcaacttctct gtgaaaggaa gaaagaacac gcttgagccc 120
 aagagccctc agggagccctc cagagcctgt gggaagtctc catgggtgaag tataggctga 780
 ggctacctgt gaacagtacg cagtgaatgt tcatccagag ctgctgttgg cggattgtac 840
 ccacggggag atgattcctc atgaagagcc tggatccctt acagaaatca aatgtgactt 900
 tccgtttatc agactaaaat cagagccatc cagacagtga aacagtcacc gtggaggggg 960
 gacggcgaaa aatgaaatcc aaccaagagc ggagcaacga atgcctgcct cccaagaagc 1020
 gcgagatccc cgccaccagc cggctcctcg aggagaaggc ccctaccctg cccagcgaca 1080
 accaccgggt ggagggcaca gcatggctcc cgggcaaccc tgggtggcgg ggccacgggg 1140
 gcgggaggca tgggcccggc gggacctcgg tggagcttgg tttaaacag ggaataggtt 1200
 tacacaaagc attgtccaca gggctggact actccccgc cagcgtccc aggtctgtcc 1260

 ccgtggccac cagctgcct gccggtacg ccaccccgca gccagggacc ccgtgtccc 1320
 ccgtgcagta cgctcacctg ccgcacacct tccagttcat tgggtcctcc caatacagt 1380
 gaacctatgc cagcttcac ccatcacagc tgatccccc aaccgccaac ccgtcacca 1440
 gtgcagtggc ctcgcccgca ggggccacca ctccatcca gcgctcccag ctggaggcct 1500
 attccactct gctggccaac atgggcagtc tgagccagac gccgggacac aaggctgagc 1560
 agcagcagca gcagcagcag cagcagcagc agcagcatca gcatcagcag cagcagcagc 1620
 agcagcagca gcagcagcag cagcagcacc tcagcagggc tccggggctc atcaccocgg 1680
 ggtccccccc accagcccag cagaaccagt acgtccacat ttccagttct ccgcagaaca 1740
 ccggccgcac cgcctctcct ccggccatcc ccgtccacct ccacccccc cagacgatga 1800
 tcccacacac gtcacccctg gggccccct cccaggtcgt catgcaatac gccgactccg 1860
 gcagccactt tgtccctcgg gaggccacca agaaagctga gagcagccgg ctgcagcagg 1920
 ccatccaggc caaggaggtc ctgaacggtg agatggagaa gagccggcgg tacggggccc 1980
 cgtcctcagc cgacctgggc ctgggcaagg caggcggcaa gtcggttcct caccogtacg 2040
 agtccaggca cgtgggtggtc caccogagcc cctcagacta cagcagtcgt gatccttcgg 2100
 gggtcggggc ctctgtgatg gtcttgccca acagcaacac gcccgagct gacctggagg 2160
 tgcaacaggc cactcatcgt gaagcctccc cttctaccct caacgacaaa agtggcctgc 2220
 atttagggaa gcctggccac cggtoctacg cgctctcacc ccacacggtc attcagacca 2280
 cacacagtgc ttcagagcca ctcccggtg gactgccagc caccgccttc tacgcaggga 2340
 ctcaaccccc tgtcatcggc taactgagcg gccagcagca agcaatcac taogccggca 2400
 gcctgcccga gcacctggtg atccccggca cacagcccct gtcctatccg gtcggcagca 2460
 ctgacatgga agcgtcgggg gcagccccg ccatagtcac gtcctatcccc cagtttgctg 2520
 cagtgcctca caggttcgtc accaocggcc ttccaagag cgagaacttc aacctgagg 2580
 ccctgggtcac ccaggccggc taccagcca tgggtcaggc ccagatccac ctgcctgtgg 2640
 tgcagtccgt ggctccccg gcggcggctc cccctacgct gcctccctac ttcatgaaag 2700
 gctccatcat ccagttggcc aacggggagc taaagaaggt ggaagactta aaaacagaag 2760
 atttcatcca gagtgcagag ataagcaacg acctgaagat cgactccagc accgtagaga 2820
 ggattgaaga cagccatagc ccgggcgtgg ccgtgatata gttcgccgtc ggggagcacc 2880

gagcccaggt cagcgttgaa gttttggtag agtatccttt ttttgtgttt ggacagggct 2940
 ggtcatcctg ctgtccggag agaaccagcc agctctttga tttgccgtgt tccaaactct 3000
 cagttgggga tgtctgcac tcgcttaccc tcaagaacct gaagaacggc tctgttaaaa 3060
 agggccagcc cgtggatccc gccagcgtcc tgcgaagca ctcaaaggcc gacggcctgg 3120

 cgggcagcag acacaggtat gccgagcagg aaaacggaat caaccagggg agtgcccaga 3180
 tgctctctga gaatggcgaa ctgaagtttc cagagaaaat gggattgcct gcagcgccct 3240
 tcctcaccaa aatagaaccc agcaagcccg cggcaacgag gaagaggagg tggcggcgc 3300
 cagagagccg caaactggag aagtcagaag acgaaccacc tttgactctt cctaagcctt 3360
 ctctaattcc tcaggaggtt aagatttgca ttgaaggccg gtctaataga ggcaagtaga 3420
 ggcagcgtgg gggaaaggaa acgtggctct cccttatcat ttgtatccag attactgtac 3480
 tgtaggctaa aataacacag tatttcatg ttatcttctt aatttttagt ttctgttcta 3540
 acctgtcat tagagttaca gcaggttgtt cgcaggagac tgggtgcata gctttttcca 3600
 cgagtgtctg tcagtgcgc ggcgggagga agggcacagc aggagcggc agggctccag 3660
 gcatccccgg ggaagaaagg aacggggctt cacagtgcct gccttctcta gcggcacaga 3720
 agcagccggg ggcgctgact ccgcctagt tgcaggagaa agtcccgtgg gaagggtcct 3780
 gcaggggtgc aggggtgcac gcatgtggg gtgcacagc gctgtggcg cgagtgcagg 3840
 tctcttttcc tctgcctccc tctgcctcac tctcttgcta tcggcatggg ccgggggggt 3900
 tcagagcagt gtccctctgg ggttcccacg tgcaaatca acatcaggaa cccagcttca 3960
 gggcatcgcg gagacgcgtc agatggcaga tttggaaagt taaccattta aaagaacatt 4020
 tttctctcca acatatttta caataaaagc aacttttaat tgtatagata tatatttccc 4080
 cctatggggc ctgactgcac tgatatatat tttttttaa gagcaactgc cacatgcggg 4140
 atttcatttc tgctttttac tagtgcagcg atgtcaccag ggtgttgtgg tggacaggga 4200
 agcccctgct gtcatggccc cacatggggg aaggggggtt ggggtgggg gagagggaga 4260
 gagcgaacac ccacgctggt ttctgtgcag tgttaggaaa accaatcagg ttattgcatt 4320
 gacttcactc ccaagaggta gatgcaaac gcccttcagt gagagcaaca gaagctcttc 4380
 acgttgagtt tgcgaaatct ttttgtctt gaactctagt actgtttata gttcatgact 4440
 atggacaact cgggtgccac ttttttttt ttccagatc cagtgtgaca tgaggaatta 4500
 gattttgaag atgagcatat attactatct ttaagcattt aaaaatactg ttcacacttt 4560
 attaccaagc atcttggtct ctcatccaac aagtaactga tctcacttta aactctttgg 4620
 ggaaaaaaca aaaacaaaa aactaagtt gctttctttt ttccaact gtaactacat 4680
 ttcagctctg cagaattgct gaagagcaag atattgaaag tttcaatgtg gtttaaaggg 4740
 atgaatgtga attatgaact agtatgtgac aataaatgac caccaagtac tacctgacgg 4800
 gaggcacttt tcactttgat gtctgagaat cagttcaagg catatgcaga gttggcagag 4860
 aaactgagag aaaagggatg gagaagagaa tactcatttt tgtccagtgt ttttcttttt 4920
 aagatgaact tttaaagaac cttgcgattt gcacatattg agtttataac ttgtgtgata 4980
 ttcctgcagt ttttatocaa taacattgtg ggaaagggtt gggggactga acgagcataa 5040

 ataaatgtag caaaatttct ttctaacctg ctaaaactct aggccatttt ataaggttat 5100
 gttcctttga aaattcattt tggctttttt accacatctg tcacaaaaag ccaggtctta 5160

gcgggctctt agaaactctg agaattttct tcagattcat tgagagagtt ttccataaag 5220
 acatttatat atgtgagcaa gatttttttt aaacaattac tttattattg ttgttattaa 5280
 tgttattttt agaatggctt ttttttttct attcaaaatc aaatcgagat ttaatgtttg 5340
 gtacaaaccc agaaagggta tttcatagtt tttaaacctt tcattcccag agatccgaaa 5400
 tatcatttgt gggttttgaa tgcattctta aagtgcctta aaaaaagtt ttataagtag 5460
 ggagaaattt ttaaatattc ttacttggat ggctgcaact aaactgaaca aatacctgac 5520
 ttttctttta cccattgaa aatagtactt tcttcgtttc acaaattaaa aaaaaatct 5580
 ggtatcaacc cacattttgg ctgtctagta ttcatttaca tttagggttc accaggacta 5640
 atgattttta taaaccgttt tctggggtgt accaaaaaca tttgaatagg tttagaatag 5700
 ctagaatagt tccttgactt tcctcgaatt tcattaccct ctcagcatgc ttgcagagag 5760
 ctgggtgggc tcattcttgc agtcatactg cttatttagt gctgtatttt ttaaactgtt 5820
 ctgttcagag aacttgctta atcttccata tattctgctc agggcacttg caattattag 5880
 gttttgtttt tctttttgtt ttttagcctt tgatggtaag aggaatacgg gctgccacat 5940
 agactttgtt ctcatataa tcaactattt caactcatgt ggactcagaa aaacacacac 6000
 caccttttgg cttacttoga gtattgaatt gactggatcc actaaaccaa cactaagatg 6060
 ggaaaacaca catggtttgg agcaatagga acatcatcat aatttttgtg gttctatttc 6120
 aggtatagga attataaaat aattggttct ttctaacac ttgtccatt tcattctctt 6180
 gcttttttag catgtgcaat actttctgtg ccaatagagt ctgaccagtg tgctatatag 6240
 ttaaagctca ttcccttttg gctttttcct tgtttggtt atcttccca ttctggccag 6300
 agcagggctg gaggaagga gccaggagg agagagcctc ccacctttcc cctgtgtcgg 6360
 atgctgagt ctggggcgg gagccttcag gagccccgtg cgtctgccgc cactgtgcag 6420
 aaagagccag ccaaggagac ccgggggagg aaccgcagt tcccctgtca ccacacggaa 6480
 tagtgaatgt ggagtgtgga gaggaaggag gcagattcat ttctaagacg cactctggag 6540
 ccatgtagcc tggagtcaac ccattttcca cgtcttttc tgcaagtggg caggcccctc 6600
 ctcggggtct gtgtccttga gacttggagc cctgcctctg agcctggagc ggaagtgtgg 6660
 cctgttgtgt gtgtgcgttc tgagcgtgtt ggccagtggc tgtggagggg accacctgcc 6720
 acccaccgtc accactccct tgtggcagct ttctcttcaa ataggaagaa cgcacagagg 6780
 gcaggagcct cctgtttgca gacgttggcg ggccccgagg ctcccagagc agcctctgtc 6840
 accgcttctg tgtagcaaac attaacgatg acaggggtag aaattcttcg gtgccgttca 6900

 gcttacaagg atcagccatg tgcctctgta ctatgtccac ttgcaatat ttaccgacag 6960
 ccgtcttttg ttctttcttt cctgttttcc atttttaaac tagtaacagc aggccttttg 7020
 cgtttacaat ggaacacaat caccaagaaa ttagtcaggg cgaaaagaaa aaaataatac 7080
 tattaataag aaaccaacaa acaagaacct ctctttctag ggatttctaa atatataaaa 7140
 tgactgttcc ttagaatgtt taacttaaga attatttcag tttgtctggg ccacactggg 7200
 gcagaggggg gagggagggg tacagagatg gatgccactt acctcagatc ttttaagtg 7260
 gaaatccaaa ttgaattttc atttggactt tcaggataat tttctatgtt ggtcaacttt 7320
 tcgttttccc taactcacc agtttagttt gggatgattt gatttctgtt gttgttgatc 7380
 ccatttctaa cttgaattg tcagcctctc tttttctct tagctgactc ttttagttt 7440

```

ccccccaa cccggaaatg cagccctcca cgtccctcgc caggcagatg cgtccggccc 7540
tttcccccca ccaggaagtg gcagcatccc tccttctccc cttaaaggac tctgcggaac 7500
ctttcacacc tctttctcag ggacggggca ggtgtgtgtg tggtaactg acgtgtccag 7560
aagcagcact ttgactgctc tggagtaggg ttgtacaatt tcaaggaatg tttggatttc 7620
ctgcatcttg tggattactc cttagatacc gcatagattg caatataatg ctgcatgttc 7680
aagatgaaca gtagctccta gtaatcataa aatccactct ttgcacagtt tgatctttac 7740
tgaaatatgt tgccaaaatt tatttttgtt gttgtagctc tggattttgt tttgttttgt 7800
tttttaagga aacgattgac aatacccttt aacatctgtg actactaagg aaacctattt 7860
ctttcataga gagaaaaatc tccaatgctt ttgaagacac taataccgtg ctatttcaga 7920
tatgggtgag gaagcagagc tctcggtagc gaaggccggg cttcttgagc tgtgttggtt 7980
gtcatggcta ctgtttcatg aaccacaagc agctcaacag actggtctgt tgccttctga 8040
aaccctttgc acttcaattt gcaccaggtg aaaacagggc cagcagactc catggcccaa 8100
ttcgggttct tcgggtgtga tgtgaaagga gagaattaca cttttttttt ttttaagtgg 8160
cgtggaggcc tttgcttcca catttgtttt taaccagaa tttctgaaat agagaattta 8220
agaacacatc aagtaataaa tatacagaga atatactttt ttataaagca catgcatctg 8280
ctattgtgtt ggggttggtt cctctctttt ccacggacag tgttgtgttt ctggcatagg 8340
gaaactccaa acaacttgca cacctctact ccggagctga gatttctttt acatagatga 8400
cctcgttcca aatacgttac ctactgatg ataggatctt ttctttagc actatacctt 8460
gtgggaattt ttttttaaat gtacacctga tttgagaagc tgaagaaaac aaaattttga 8520
agcactcact ttgaggagta caggtaatgt tttaaaaaat tgcacaaaag aaaaatgaat 8580
gtcgaaatga ttcattcagt gtttgaaaga tatggctctg ttgaaacaat gagtttcata 8640
ctttgtttgt aaaaaaaaaa aagcagagaa ggggtgaaag ttacatgttt ttttgtatat 8700
agaaatttgt catgtctaaa tgatcagatt tgtatggtta tggcctggaa gaattactac 8760
gtaaaaggct cttaaactat acctatgctt attgttattt ttgttacata tagccctcgt 8820

ctgagggagg ggaactcggc attctgcgat ttgagaatac tgttcattcc tatgctgaaa 8880
gtacttctct gagctccctt cttagtctaa actcttaagc cattgcaact tcttttctt 8940
cagagatgat gtttgacatt ttcagcactt cctgttccta taaacccaaa gaatataatc 9000
ttgaacacga agtgtttgta acaagggatc caggctacca atcaaacagg actcattatg 9060
gggacaaaaa aaaaaattat ttcaccttct tccccccac acctcattta aatgggggga 9120
gtaaaaacat gatttcaatg taaatgcctc attttatttt agttttattt tgatttttat 9180
ttaatatata gaggccagaa taaatacggg gcactctctc agaatagtat tcctgtccaa 9240
aaatcaagcc ggacagtgga aactggacag ctgtggggat attaagcacc cccacttaca 9300
attcttaaat tcagaatctc gtccctccc ttctcgttga aggcaactgt tctggtagct 9360
aactttctcc tgtgtaatgg cgggagggaa caccggcttc agtttttcat gtcccatga 9420
cttgcataca aatgggttcaa ctgtattaaa attaagtgc tttggccaat aggtagtatc 9480
tatacaataa caacaatctc taagaatttc cataactttt ctatctgaa aggactcaag 9540
tcttccactg cagatacatt ggaggcttca cccacgtttt ctttcccttt agtttggttg 9600
ctgtctggat ggccaatgag cctgtctcct tttctgtggc caatctgaag gccttcgttg 9660

```

```

gaagtgttgt ttacagtaat ccttaccgaag ataacataact gtcctccaga ataccaagta 9720
ttaggtgaca ctagctcaag ctgttgtctt cagagcagtt accaagaagc tcggtgcaca 9780
ggttttctct ggttcttaca ggaaccacct actctttcag tttcttgcc caggagtggg 9840
gtaaatcctt tagttagtgc atttgaactt gatacctgtg cattcagttc tgtgaatact 9900
gccctttttg gcgggggttt ctcctctccc cagcctgaac tgctcaactc taaacccaaa 9960
ttagtgtcag ccgaaggag gtttcaagat agtcctgtca gtatttgtgg tgaccttcag 10020
attagacagt cttcatttcc agccagtga gtcctggctc cagagccatc tctgagactc 10080
gtactactgg atgttttaat atcagatcat taccaccat atgcctcca caggccaagg 10140
gaaaacagac accagaactt ggggttgagg cactaccaga ctgacatggc cagtacagag 10200
gagaactagg gaaggaatga tgttttgac cttattgaaa agaaaatttt aagtgcatac 10260
ataatagtta agagctttta ttgtgacagg agaacttttt tccatatgag tgcatactct 10320
ctgtaattcc agtgtaaaat attgtacttg cactagcttt tttaaacaaa tattaaaaaa 10380
tggaagaatt catattctat tttctaactg tgggtgtgtct attttagga tacaactcag 10440
tctgtttatt gaatttatg gtccctttct ttgatgggtc ttgcagggtt tctaggtaga 10500
aattatttca ttattataat aaaacaatgt ttgattcaaa atttgaacaa aattgtttta 10560
aataaattgt ctgtatacca gtacaagttt attgtttcag tataactcgt ctaataaaat 10620
aacagtgcc attgca 10636

```

<210> 82

<211> 4712

<212> DNA

<213> Homo sapiens

<400> 82

```

acccccgaga aagcaaccca gcgcgcgcgc cgtcctcac gtgtccctcc cggccccggg 60
gccacctcac gttctgcttc cgtctgacct ctccgacttc cggtaaagag tcctatccg 120
cacctccgct cccaccgggc gcctcggcgc gccgcctc cgatgcgctc agcggccgca 180
gtcctcgga gtcccgcggt ggccaccgag tctcgcgct tcgccgcagc cagggtggcc 240
gggtggcgct cgtccagcg gccggcgcg cggagcgggc ggggcggcg tggcgcgcc 300
cggggacgt atccctccgc cgcctctccc cgcctgggc cgggcccccc tcctcccg 360
cagagctgc ctccctccgc ctgagctgt tttgtagca acggcaacgg cggcgcgcg 420
tttcggcccg gtcacggcg gtccttgggt ctggcgggc ctcccgccc attcgtcgtc 480
ctccttctcc cctcgcag ccggggcgcc cctcggcg cgcaccccg cgcctccc 540
ctcggcgccc gcgcgtccc gccgcgttcc ggcgtctct tggcgcgccc ggcctccggc 600
tgtccccgcc cggcggtgca gccggtgtat gggccctca ccatgtcgt gaagccccag 660
cagcagcagc agcagcagca gcagcagcag cagcagcaac agcagcagca gcagcagcag 720
cagcagcgc cgcgcgggc tgccaatgtc cgcgaagccg gggcagcgg ccttctagcg 780
tcgccgcg cgcgccttc gccgtcctc tcctcgggt cctcgtcctc ggccacggct 840
cctcctcgg tggtcgggc gacctcggc ggcgggagc cggcctggg cagaggtcga 900
aacagtaaca aaggactgcc tcagtctacg atttctttg atggaatcta tgcaaatacg 960

```

aggatggttc atatacttac atcagttggt ggctccaaat gtgaagtaca agtgaaaaat 1020
 ggaggtatat atgaaggagt ttttaaaact tacagtccga agtgtgattt ggtacttgat 1080
 gccgcacatg agaaaagtac agaatccagt tcggggccga aacgtgaaga aataatggag 1140
 agtattttgt tcaaatgttc agactttggt gtggtacagt ttaaagatat ggactccagt 1200
 tatgcaaaaa gagatgcttt tactgactct gctatcagtg ctaaagtga tggcgaacac 1260
 aaagagaagg acctggagcc ctgggatgca ggtgaactca cagccaatga ggaacttgag 1320
 gctttggaaa atgacgtatc taatggatgg gatcccaatg atatgtttcg atataatgaa 1380
 gaaaattatg gtgtagtgtc tacgtatgat agcagtttat cttcgtatac agtgccctta 1440
 gaaagagata actcagaaga atttttaaaa cgggaagcaa gggcaaacca gttagcagaa 1500
 gaaattgagt caagtgccca gtacaaagct cgagtggccc tggaaaatga tgataggagt 1560
 gaggaagaaa aatacacagc agttcagaga aattccagtg aacgtgaggg gcacagcata 1620
 aacactaggg aaaataaata tattcctcct ggacaaagaa atagagaagt catatcctgg 1680

 ggaagtggga gacagaattc accgcgtatg ggccagcctg gatcgggctc catgccatca 1740
 agatccactt ctcacacttc agatttcaac ccgaattctg gttcagacca aagagtagtt 1800
 aatggaggtg ttccctggcc atcgccctgc ccctctcctt cctctcgccc acctctcgc 1860
 taccagtcag gtcccaactc tcttcacct cgggcagcca cccctacacg gccgccctcc 1920
 agggcccccct cgcggccatc cagacccccg tctcaccct ctgctcatgg ttctccagct 1980
 cctgtctcta ctatgcctaa acgcatgtct tcagaagggc ctccaaggat gtcccaaaag 2040
 gcccagcgac atcctcgaaa tcacagagtt tctgctggga ggggttccat atccagtggc 2100
 ctagaatttg tatcccaaaa cccaccaggt gaagcagcta ctctccagt agcaaggacc 2160
 agtccctcgg ggggaacgtg gtcatcagtg gtcagtgggg ttccaagatt atcccctaaa 2220
 actcatagac ccaggtctcc cagacagaac agtattggaa atacccccag tgggccagtt 2280
 cttgtctctc cccaagctgg tattattcca actgaagctg ttgcatgcc tattccagct 2340
 gcatctccta cgctgctag tctgcatcg aacagagctg ttacccttc tagtgaggct 2400
 aaagattcca ggcttcaaga tcagaggcag aactctcctg cagggaataa agaaaatatt 2460
 aaaccaatg aaacatcac tagcttctca aaagctgaaa acaaaggat atcaccagtt 2520
 gtttctgaac atagaaaaca gattgatgat ttaagaaat ttaagaatga ttttaggtta 2580
 cagccaagtt ctacttctga atctatggat caactactaa acaaaaatag agaggagaa 2640
 aaatcaagag atttgatcaa agacaaaatt gaaccaagtg ctaaggattc ttccattgaa 2700
 aatagcagca gcaactgtac cagtggcagc agcaagccga atagccccag catttccct 2760
 tcaatactta gtaacacgga gcacaagagg ggacctgagg tcaactccca aggggttcag 2820
 acttcagcc cagcatgtaa acaagagaaa gacgataagg aagagaagaa agacgcagct 2880
 gagcaagtta ggaaatcaac attgaatccc aatgcaaagg agttcaaccc acgttccttc 2940
 tctcagcaa agccttctac taccocaaact tcacctcggc ctcaagcaca acctagccca 3000
 tctatggtgg gtcacaaaca gccaaactca gtttatactc agcctgtttg ttttgacca 3060
 aatatgatgt atccagtcac agtgagccca ggcgtgcaac ctttataccc aatacctatg 3120
 acgcccctgc cagtgaatca agccaagaca tatagagcag taccaaaatg gccccaacag 3180

cggaagacc agcatcatca gaggccatg atgcaccag cgtcagcagc gggcccaccg 3240
 attgcagcca ccccaccagc ttactccaag caatatgttg cctacagtcc tcagcagttc 3300
 ccaaatcagc cccctgttca gcatgtgcca cattatcagt ctcagcatcc toatgtatat 3360
 agtcctgtaa tacagggtaa tgctagaatg atggcaccac caacacacgc ccagcctggt 3420
 ttagtatctt cttcagcaac tcagtacggg gctcatgagc agacgcatgc gatgtatgca 3480
 tgtcccaaat taccatacaa caaggagaca agcccttctt tctactttgc catttccacg 3540
 ggctcccttg ctcagcagta tgccgaccct aacgtatccc tgcaccacaa tactccacac 3600

 cctcagcctt cagctacccc cactggacag cagcaaagcc aacatggtgg aagtcaccc 3660
 gcaccagtc ctgttcagca ccacagcac caggccgccc aggtctctca tctggccagt 3720
 ccacagcagc agtcagccat ttaccacgcg gggcttgccg caactccacc ctccatgaca 3780
 cctgcctcca acacgcagtc gccacagaat agtttcccag cagcacaaca gactgtcttt 3840
 acgatccatc cttctcacgt tcagccggcg tataccaacc caccacacat ggcccacgta 3900
 cctcaggctc atgtacagtc aggaatggtt ccttctcatc caactgccc tgcgccaatg 3960
 atgctaata gaacacagcc acccgccggt cccagggccg ccctcgctca aagtgcacta 4020
 cagcccattc cagtctcgac aacagcgcat ttccctata tgacgcaccc ttccagtaca 4080
 gccaccacc aacagcagtt gtaaggctgc cctggaggaa ccgaaaggcc aaattccctc 4140
 ctcccttcta ctgctctac caactggaag cacagaaaac tagaatttca tttattttgt 4200
 ttttaaata tatatgttg tttctttaa catccaatag gaatgctaac agttcacttg 4260
 cagtggaga tacttggacc gaggtagggc atttaggaac ttgggggcta ttccataatt 4320
 ccataatgctg tttcagagtc ccgcaggtag cccagctctg cttgccgaaa ctggaagtta 4380
 tttatttttt aataaccctt gaaagtcag aacacatcag ctagcaaaag aagtaacaag 4440
 agtgattctt gctgctatta ctgctaaaaa aaaaaaaaaa aaaaaatcaa gacttggaac 4500
 gcccttttac taaacttgac aaagtttcag taaattctta ccgtcaaaact gacggattat 4560
 tatttataaa tcaagtttga tgagtgatc actgtctaca gtggttcaac ttttaagtta 4620
 agggaaaaac ttttactttg tagataatat aaaataaaaa cttaaaaaaa atttaaaaaa 4680
 taaaaaaagt tttaaaaact gaaaaaaaaa aa 4712

<210> 83

<211> 6923

<212> DNA

<213> Homo sapiens

<400> 83

gagaggggca gggggcggag ctggaggggg tgggtcggcg tgggggccgt tggctccaga 60
 caaataaaca tggagtccat cttccacgag aaacaagaag gctcactttg tgctcaacat 120
 tgcctgaata acttattgca aggagaatat tttagccctg tggaattatc ctcaattgca 180
 catcagctgg atgaggagga gaggatgaga atggcagaag gaggagttag tagtgaagat 240
 tatgcacagt ttttacagca gccttctgga aatatggatg acagtgggtt tttctctatt 300
 cagggtataa gcaatgcctt gaaagtttgg ggtttagaac taatcctgtt caacagtcca 360

gagtatcaga ggctcaggat cgatcctata aatgaaagat catttatatg caattataag 420
 gaacactggg ttacagttag aaaattagga aaacagtggg ttaacttgaa ttctctcttg 480
 acgggtccag aattaatatc agatacatat ctgacacttt tcttggtcca attacaacag 540

 gaaggttatt ctatatttgt cgttaagggt gatctgccag attgogaagc tgaccaactc 600
 ctgcagatga ttaggggtcca acagatgcat cgacccaaac ttattggaga agaattagca 660
 caactaaaag agcaaagagt ccataaaaca gacctggaac gagtgttaga agcaaatgat 720
 ggctcaggaa tgttagacga agatgaggag gatttgacga gggctctggc actaagtgcg 780
 caagaattg acatggaaga tgaggaagca gatctccgca gggctattca gctaagtatg 840
 caaggtagtt ccagaaacat atctcaagat atgacacaga catcaggtag aaatcttact 900
 tcagaagagc ttcggaagag acgagaagcc tactttgaaa aacagcagca aaagcagcaa 960
 cagcagcagc agcagcagca gcagggggac ctatcaggac agagttcaca tccatgtgaa 1020
 aggccagcca ccagttcagg agcacttggg agtgatctag gtgatgctat gagtgaagaa 1080
 gacatgcttc aggcagctgt gaccatgtct ttagaaactg tcagaaatga ttgaaaaca 1140
 gaaggaaaaa aataatacct ttaaaaaata atttagatat tcatacttcc caacattatc 1200
 ctgtgtgatt acagcatagg gtccactttg gtaatgtgtc aaagagatga ggaaataaga 1260
 cttttagcgg ttgcaaaaca aaatgatggg aaagtggaac aatgggtcgg ttgtaggact 1320
 aaataatgat cttccaaaata ttagccaaag aggcattcag caattaaaga catttaaaat 1380
 agttttctaa atgtttcttt ttcttttttg agtgtgcaat atgtaacatg tctaaagtta 1440
 gggcattttt cttggatctt ttgcagact agctaattag ctctgcctc aggttttttc 1500
 catatagttt gttttctttt tctgtcttgt aggtaagttg gctcacatca tgtaatagtg 1560
 gctttcattt cttattaacc aaattaacct ttcaggaaag tatctctact ttctgatgt 1620
 tgataatagt aatggttcta gaaggatgaa cagttctccc ttcaactgta taccgtgtgc 1680
 tccagtgttt tcttgtgttg tttctctgta tcacaacttt tctgtacct ggttttcatt 1740
 attttccac aattcttttg aaagatggta atcttttctg aggttttagcg ttttaagccc 1800
 tacgatggga tcattatttc atgactgggt cgttctctaaa ctctgaaatc agccttgcac 1860
 aagtacttga gaataaatga gcatttttta aaatgtgtga gcagtgtctt tccagatgc 1920
 tttatgaatg tcttttctact tatatcaaaa ccttacagct ttgttgcaac ccttcttcc 1980
 tgcgccttat ttttctctt cttctccaat tgagaaaact aggagaagca tagtatgcag 2040
 gcaagtctcc ttctgttaga agactaaaca tacgtacca ccatgaatgt atgatacatg 2100
 aaatttggcc ttcaatttta atagcagttt tattttattt tttctcctat gactggagct 2160
 ttgtgttctc ttacagttg agtcatggaa tgtagggtgc tgcttcacat cttttagtag 2220
 gtatagcttg tcaagatgg tgatctggaa catgaaaata atttactaat gaaaatatgt 2280
 ttaaatttat actgtgattt gacacttgca tcatgttttag atagcttaag aacaatggaa 2340
 gtcacagtag ttagtggatc tataaataag aaagtcata gttttgataa atattctctt 2400

 taattgagat gtacagagag tttcttgctg ggtcaatagg atagtatcat ttgggtgaaa 2460
 accatgtctc tgaaattgat gttttagttt cagtgttccc tatccctcat tctccatctc 2520
 cttttgaagc tcttttgaat gttgaattgt tcataagcta aaatccaaga aatttcagct 2580

gacaacttcg aaaattataa tatggtatat tgcctcctcg gtgtgtggct gcacacattt	2640
tatcaggga agttttttga tctaggattt attgctaact aactgaaaag agaagaaaaa	2700
atatctttta tttatgatta taaaatagct ttttcttcga tataacagat tttttaagtc	2760
attattttgt gccaatcagt tttctgaagt ttcccttaca caaaaggata gctttatttt	2820
aaaatctaaa gtttctttta atagttaaaa atgtttcaga agaattataa aactttaaaa	2880
ctgcaaggga tgttgagtt tagtactact cctcaagat ttaaaaagct aaatatttta	2940
agactgaaca tttatgttaa ttattaccag tgtgtttgtc atattttcca tggatatttg	3000
ttcattacct ttttccattg aaaagttaca ttaaaacttt catacacttg aattgatgag	3060
ctaccttaata taaaaatgag aaaaccaata tgcattttta agttttaact ttagagttta	3120
taaagttcat atatacccta gttaaagcac ttaagaaaat atggcatgtt tgacttttag	3180
ttcctagaga gtttttgtt ttgtttttgt tttttttga gacggagtct tgctatgtct	3240
cccaggctgg agggcagtgg catgatctcg gctcactaca acttccacct cccgggttca	3300
agcaattctc ctgcctcagc ctccagagta gctgggatta caggcgccca ccaccacacc	3360
cggcagattt ttgtattttt ggtagagacg cggtttcac atgtttggcc aggctggctc	3420
cgaactcctg acctcaggtg atccgcctgc cttggcctcc caaagtgtt ggattacagg	3480
catgagccac tgcgcctggc cagctagaga gtttttaag cagagctgag cacacactgg	3540
atgcgtttga atgtgtttgt gtagtttgt gtgaaattgt tacatttagc aggcagatcc	3600
agaagcacta gtgaactgtc atcttgggtg ggttggctta aatttaattg actgtttaga	3660
ttccatttct taattgattg gccagtatga aaagatgcc gtgcaagtaa ccatagtatc	3720
aaaaaagta aaaattattc aaagctatag ttataacatc aggtactgcc atttactgta	3780
aaccacctgc aagaaagtc ggaacaacta aattcacaag aactgtcctg ctaagaagtg	3840
tattaaagat ttccattttg ttttactaat tgggaacatc ttaatgttta atatttaaac	3900
tattggatc atttttctaa tgtataattt gtattactgg gatcaagtat gtacagtgg	3960
gatgctagta gaagttaag ccttggaat accactttca tattttcaga tgtcatggat	4020
ttaatgagta atttatgtt ttaaaattca gaatagttaa tctctgatct aaaaccatca	4080
atctatgtt tttacgtaa tcatgtaaat atttcagtaa tataaactgt ttgaaaaggc	4140
tgtgcagggt aaactctata ctaggatctt ggccaaataa ttacaattc acagaatatt	4200
ttatttaagg tgggtgcttt ttttttgtc cttaaaactt gatttttctt aactttattc	4260
atgatgccaa agtaaatgag gaaaaaact caaaaccagt tgagtatcat tgcagacaaa	4320
actaccagta gtccatattg tttaatatta agttgaataa aataaatttt atttcagtca	4380
gagcctaaat cacattttga ttgtctgaat ttttgatact atttttaaaa tcatgctagt	4440
ggcggctggg cgtggtagct cagcctgta atcccagcat ttggggaggc cgaagtgggt	4500
ggatcacgag gtccggagtt cgagaccagc ttggccaaaa tggtgaaacc ccattctgtac	4560
taaaaactac aaaaattagc tgggcgcggt ggcagggtgc tgtaatcca gctacctggg	4620
agtctgaggc aggagaattg cttgaaccct ggcgacagag gatgcagtga gccaagatgg	4680
tgccactgta ctccagactg ggcgacagag tgagactctg tctcaaaaaa aaaaaaaaaa	4740
tcatgctagt gccaaagact actaaattct taaaaccggc ccattggacc tgtacagata	4800
aaaaatagat tcagtgcata atcaaatat gataatttta aaatcttaag tagaaaaata	4860

aatcttgatg ttttaaattc ttacgaggat tcaatagtta atattgatga tctcccggt 4920
gggtgcagtg gctcacgcct gtaatcccag cagttctgga ggctgagggtg ggcgaaacac 4980
ttcaggccag gagttaaga ccagtctggg caacatggtg aaacctcgtt tctactaaaa 5040
atacaaaaat tagccgggcg tggttgcaca cacttgtaat ccagctact caggaggcta 5100
agaatcgcat gagcctagga ggcagagggtt gcagagtgcc aagggtcac cactgcattc 5160
cagcctgccc aacagagtga gacactgttt ctgaaaaaa aaaatatata tatatatata 5220
tatatgtgtg tatatatata tgtatatata tatgacttcc tattaaaaac tttatcccag 5280
tcgggggcag tggctcacgc ctgtaatccc aacactttgg gaggtgagg caggtggatc 5340
acctaagtc cggagtttga gaccagcctg gccaacatgg tgaaaccca tctctactaa 5400
aaatacaaaa cttaagccag gtatggtggc gggcacctgt aatcccagtt acttgggagg 5460
ctgaggcagg agaatcgttt aaaccagga ggtggagggtt gcagtgagct gagatcgtgc 5520
cattgcactc tagcctgggc aacaagagta aaactccatc ttaaaggttt gtttgttttt 5580
ttttaatccg gaaacgaaga ggcgttgggc cgctattttc tttttcttct tttcttctct 5640
tctttttttt tttttctgag acggagtcta gctctgctgc ccaggctgga gtacaatgac 5700
acgatgttgg ctactgcaa cctccacctc ctgggttcaa gcgattctcc tgcctcagcc 5760
tccaagtac ctgggattac aggcacctgc cactacacct ggcgaaatatt tgtttttttt 5820
agtagagacg ggcttttacc atgttaggct ggtctcaaac tcctgacctc aggtgatctg 5880
cctgccttgg cctcccaaag tgctgggatt acagggtgcag gccaccacac ccggccttgg 5940
gccactgttt tcaaagtga ttgtttgttg tatcgagtcc ttaagtatgg atatatatgt 6000
gaccttaatt aagaactacc agattggatc aactaatcat gtcagcaatg taaataactt 6060
tatttttcat attcaaaata aaaactttct tttatttctg gcccttttat aaccagcatc 6120
tttttgcttt aaaaaatgac ctggctttgt atttttttag tcttaaacat aataaaaata 6180

tttttgttct aatttgcttt catgagtga gattattgac atcgttggta aattctagaa 6240
ttttgatttt gttttttaat ttgaagaaaa tctttgctat tattattttt tccaagtggc 6300
ctggcatttt aagaattagt gctaataacg taacttctaa atttgcgta attggcatgt 6360
ttaatagcat atcaaaaaac attttaagcc tgtggattca tagacaaagc aatgagaaac 6420
attagtaaaa tataaatgga tattcctgat goatttagga agctctcaat tgtctcttgc 6480
atagttcaag gaatgttttc tgaatttttt taatgctttt tttttttttg aaagaggaaa 6540
acatacattt ttaaatgtga ttatctaatt tttaaacac tgggctatta ggaataactt 6600
tttaaaaatt actgttctgt ataaatattt gaaattcaag tacagaaaat atctgaaaca 6660
aaaagcattg ttgtttggcc atgatacaag tgcactgtgg cagtgccgct tgctcaggac 6720
ccagccctgc agcccttctg tgtgtgctcc ctggttaagt tcatttgctg ttattacaca 6780
cacaggcctt cctgtctggc cgttagaaaa gccgggcttc caaagcactg ttgaacacag 6840
gattctgttg ttagtgtgga tgttcaatga gttgtatttt aaatatcaaa gattattaaa 6900
taaagataat gtttgctttt cta 6923

<210> 84

<211> 8646

<212> DNA

<213> Homo sapiens

<400> 84

```

gatgtcccga gctgctatcc ccggctcggc ccgggcagcc gccttctgag cccccgaccc      60
gaggcgccga gccgcgccg ccgatgggc tgggccgtgg agcgtctccg cagtcgtagc      120
tccagccgcc gcgtccccag ccccggcagc ctcagcatca gggcgggcgg cgccggcggc      180
ggcgtcttcc gcacgttccg ccgcagcgta acccgagacc ctttgcctct tgcagaatgg      240
cccgcttcgg agacgagatg ccggcccgct acgggggagg aggcctccggg gcagccgccg      300
gggtggctgt gggcagcgga ggcggcgag gagccggggg cagccggcag ggcgggcagc      360
ccggggcgca aaggatgtac aagcagtaa tggcgcgag agcgcggacc atggcactct      420
acaaccccat ccccgctccg cagaactgcc tcacggttaa ccggtctctc ttctcttcca      480
gcgaagacaa cgtggtgaga aaatacgcca aaaagatcac cgaatggcct ccctttgaat      540
atatgatttt agccaccatc atagcgaatt gcacgtcctc cgcactggag cagcatctgc      600
ctgatgatga caagaccccg atgtctgaac ggctggatga cacagaacca tacttcattg      660
gaattttttg ttctgaggct ggaattaaaa tcattgccct tgggtttgcc ttccacaaag      720
gctcctactt gaggaatggc tggaatgtca tggactttgt ggtgggtgta acgggcatct      780
tggcgacagt tgggacggag tttagacctac ggacgctgag ggcagttcga gtgctgcggc      840
cgctcaagct ggtgtctgga atcccaagtt tacaagtcgt cctgaagtcg atcatgaagg      900

cgatgatccc ttgctgcag atcggcctcc tcctattttt tgcaatcctt atttttgcaa      960
tcataggggt agaattttat atgggaaaat ttcataccac ctgctttgaa gaggggacag     1020
atgacattca gggtagtctc ccggctccat gtgggacaga agagcccgcc cgcacctgcc     1080
ccaatgggac caaatgtcag ccctactggg aaggggccaa caacgggata actcagttcg     1140
acaacatcct gtttgacgtg ctgactgttt tccagtgcac aacctggaa gggtaggactg     1200
atctcctcta caatagcaac gatgcctcag ggaacacttg gaactggttg tacttcatcc     1260
ccctcatcat catcggtccc ttttttatgc tgaaccttgt gctgggtgtg ctgtcagggg     1320
agttttgcaa agaaagggaa cgggtggaga accggcgggc ttttctgaag ctgaggcggc     1380
aacaacagat tgaacgtgag ctcaatgggt acatggagtg gatctcaaaa gcagaagagg     1440
tgatcctcgc cgaggatgaa actgacgggg agcagaggca tccctttgat ggagctctgc     1500
ggagaaccac cataaagaaa agcaagacag atttgcctca cccgaagag gctgaggatc     1560
agctgggtga tatagcctct gtgggttctc ccttcggccg agccagcatt aaaagtgcga     1620
agctggagaa ctgcaccttt ttccacaaaa aggagaggag gatgcgtttc tacatccgcc     1680
gcctgggtcaa aactcaggcc ttctactgga ctgtactcag tttggtagct ctcaacacgc     1740
tgtgtgttgc tattgttccac tacaaccagc ccgagtggct ctccgacttc ctttactatg     1800
cagaattcat tttcttagga ctctttatgt ccgaaatgtt tataaaaatg tacgggcttg     1860
ggacgcggcc ttacttccac tcttccttca actgctttga ctgtgggggt atcattggga     1920
gcactcttga ggtcatctgg gctgtcataa aacctggcac atcctttgga atcagcgtgt     1980
tacgagccct caggttattg cgtattttca aagtcacaaa gtactgggca tctctcagaa     2040
acctgctcct ctctctctc aactccatga aatccatcat caacctctta tttctccttt     2100

```

```

-----
tcctgttcat tgtcgtcttc gcccttttgg gaatgcaact cttcggcggc cagttaaatt 2160
tcgatgaagg gactcctccc accaacttcg atacttttcc agcagcaata atgacgggtgt 2220
ttcagatcct gacgggcgaa gactggaacg aggtcatgta cgacgggatc aagtctcagg 2280
ggggcggtgca gggcggcatg gtgttctcca tctatttcat tgtactgacg ctctttggga 2340
actacaccct cctgaatgtg ttcttgcca tcgctgtgga caatctggcc aacgcccagg 2400
agctcaccaa ggtggaggcg gacgagcaag aggaagaaga agcagcgaac cagaaacttg 2460
ccctacagaa agccaaggag gtggcagaag tgagtctctt gtccgcggcc aacatgtcta 2520
tagctgtgaa agagcaacag aagaatcaa agccagccaa gtccgtgtgg gacgagcgga 2580
ccagtggatg gcgaaagcag aacttgctgg ccagccggga ggccctgtat aacgaaatgg 2640
acccggacga gcgtggaag gctgcctaca cgcggcacct gggccagac atgaagacgc 2700
acttgaccg gccgctggtg gtggaccgc aggagaaccg caacaacaac accaacaaga 2760
gccggggcgc cgagcccacc gtggaccagc gcctcggcca gcagcgcgc gaggacttcc 2820

tcaggaaaca ggcccgctac cacgatcggg cccgggacc cagcggctcg gcgggcctgg 2880
acgcacggag gccctgggcg ggaagccagg aggcgagct gagccgggag ggacctacg 2940
gcccgagtc ggaccaccac gcccgggagg gcagcctgga gcaaccggg ttctgggagg 3000
gcgaggccga gcgaggcaag gccggggacc cccaccggag gcacgtgcac cggcaggggg 3060
gcagcaggga gagccgcagc ggttccccgc gcacgggccc ggacggggag catcgacgtc 3120
atcgcgcgca ccgagggccc ggggaggagg gtccggaggga caaggcggag cggagggcgc 3180
ggcaccgcga gggcagccgg ccggcccggg gcggcgaggg cgagggcgag ggccccgacg 3240
ggggcgagcg caggagaagg caccggcatg gcgtccagc cactaacgag ggggacgcgc 3300
ggaggggagg caaggagcgg aggcacgga ggaggaaaga gaaccagggc tccgggggtc 3360
ctgtgtcggg ccccaacctg tcaaccacc gcccaatcca gcaggacct ggccgccaag 3420
acccacccct ggacagaggat attgacaaca tgaagaacaa caagctggcc accgcggagt 3480
cggccgctcc ccacggcagc cttggccacg ccggcctgcc ccagagccca gccaaagtgg 3540
gaaacagcac cgaccccgcc cccatgctgg ccacccctgc catggccacc aacccccaga 3600
acgcgcgac cgccgggacg cccaacaacc cggggaacct atccaatcc gggccccca 3660
agacccccga gaatagcctt atcgtacca accccagcgg caccagacc aattcagcta 3720
agactgccag gaaacccgac cacaccacag tggacatccc cccagcctgc cccccccc 3780
tcaaccacac cgtcgtacaa gtgaacaaaa acgccaacct agaccactg ccaaaaaaag 3840
aggaagagaa gaaggaggag gaggaagacg accgtgggga agacggccct aagccaatgc 3900
ctccctatag ctccatgttc atcctgtcca cgaccaacc ccttcgccc ctgtgccatt 3960
acatcctgaa cctgcgctac tttgagatgt gcacccctcat ggtcattgcc atgagcagca 4020
tcgccttgcc cgcgaggac cctgtgcagc ccaacgcacc tcggaacaac gtgctgcgat 4080
actttgacta cgtttttaca ggcgtcttta cctttgagat ggtgatcaag atgattgacc 4140
tggggctcgt cctgcacag ggtgcctact tccgtgacct ctggaatatt ctgacttca 4200
tagtggctag tggggccctg gttagccttg ccttacttg caatagcaa ggaaaagaca 4260
tcaacacgat taaatccctc cgagtccctc ggggtctacg acctcttaa accatcaagc 4320

```

ggctgccaaa gctcaaggct gtgtttgact gtgtggtgaa ctcacttaaa aacgtcttca 4380
 acatcctcat cgtctacatg ctattcatgt tcatcttcgc cgtggtggct gtgcagctct 4440
 tcaaggggaa attcttcac tgcactgacg agtccaaaga gtttgagaaa gattgtcgag 4500
 gcaaatacct cctctacgag aagaatgag tgaaggcgcg agaccgggag tggaagaagt 4560
 atgaattcca ttacgacaat gtgctgtggg ctctgctgac cctcttcacc gtgtccacgg 4620
 gagaaggctg gccacaggtc ctcaagcatt cgggtggacgc cacctttgag aaccagggcc 4680

 ccagccccgg gtaccgcatg gagatgtcca tttctacgt cgtctacttt gtggtgttcc 4740
 ccttcttctt tgtcaatata tttgtggcct tgatcatcat caccttcacg gagcaagggg 4800
 acaagatgat ggaggaatac agcctggaga aaaatgagag ggcctgcatt gatttcgcca 4860
 tcagcgccaa gccgctgacc cgacacatgc cgcagaacaa gcagagcttc cagtaccgca 4920
 tgtggcagtt cgtggtgtct ccgcctttcg agtacacgat catggccatg atcgccctca 4980
 acaccatcgt gcttatgatg aagtcttatg gggcttctgt tgcttatgaa aatgccctgc 5040
 ggggtgttcaa catcgtcttc acctccctct tctctctgga atgtgtgctg aaagtcattg 5100
 cttttgggat totgaattat ttccgcgatg cctggaacat ctccgacttt gtgactgttc 5160
 tgggcagcat caccgatata ctctgactg agtttgggaa tccgaataac ttcataaacc 5220
 tgagctttct ccgcctcttc cgagctgccc ggcctcatca acttctccgt cagggttaca 5280
 ccatccgcat tcttctctgg acctttgtgc agtccctcaa ggcctgcct tatgtctgtc 5340
 tgctgatogc catgctcttc ttcatctatg ccatcattgg gatgcagggtg tttggttaaca 5400
 ttggcatcga cgtggaggac gaggacagt atgaagatga gttccaaatc actgagcaca 5460
 ataacttccg gaccttcttc caggccctca tgcttctctt ccggagtgc accggggaag 5520
 cttggcacia catcatgctt tctgcctca gcgggaaacc gtgtgataag aactctggca 5580
 tctgactcag agagtgtggc aatgaatttg cttattttta ctttgtttcc ttcattctcc 5640
 tctgctcgtt tctgatgctg aatctctttg tcgccgtcat catggacaac tttgagtacc 5700
 tcacccgaga ctctccatc ctgggcccc accacctgga tgagtacgtg cgtgtctggg 5760
 ccgagtatga cccgcagct tggggccgca tgccttacct ggacatgtat cagatgctga 5820
 gacacatgtc tccgccccg ggtctgggga agaagtgtcc ggccagagtg gcttacaagc 5880
 ggcttctcgc gatggacctg cccgtcgag atgacaacac cgtccacttc aattccaccc 5940
 tcatggctct gatccgcaca gccctggaca tcaagattgc caagggagga gccgacaaac 6000
 agcagatgga cgtgagctg cgggaaggaga tgatggcgat ttggccaat ctgtcccaga 6060
 agacgctaga cctgctggtc acacctcaca agtccacgga cctcaccgtg gggaagatct 6120
 acgcagccat gatgatcatg gactactacc ggcagagcaa ggccaagaag ctgcaggcca 6180
 tgcgcgagga gcaggaccgg acacctcaca tgttccagcg catggagccc ccgtcccaa 6240
 cgcaggaagg gggacctggc cagaacgcc tccctccac ccagctggac ccaggaggag 6300
 cctgatggc tcacgaaagc ggcctcaagg agagcccgtc ctgggtgacc cagcgtgcc 6360
 aggagatgtt ccagaagacg ggcacatgga gtccggaaca agccccct accgacatgc 6420
 ccaacagcca gcctaactct cagtccgtgg agatgcgaga gatgggcaga gatggctact 6480
 ccgacagcga gcaactacct cccatggaag gccagggccg ggtgcctcc atgcccgc 6540
 tccctgcaga gaaccagagg agaaggggcc ggccacgtgg gaataacctc agtaccatct 6600

cagacaccag ccccatgaag cgttcagcct ccgtgctggg ccccaaggcc cgacgcctgg 6660
 acgattactc gctggagcgg gtcccgcccg aggagaacca gcggcaccac cagcggcgcc 6720
 gcgaccgcag ccaccgcgcc tctgagcgct ccctggggcg ctacaccgat gtggacacag 6780
 gcttggggac agacctgagc atgaccaccc aatccgggga cctgccgtcg aaggagcggg 6840
 accaggagcg gggccggccc aaggatcgga agcatcgaca gcaccaccac caccaccacc 6900
 accaccacca tcccccgccc ccgcacaagg accgctatgc ccaggaacgg ccggaccacg 6960
 gccgggcacg ggctcgggac cagcgtggt cccgctcgcc cagcgagggc cgagagcaca 7020
 tggcgaccg gcaggcgagt agttccgtaa gtggaagccc agccccctca acatctggta 7080
 ccagcactcc gcggcggggc cgccgccagc tccccagac cccctccacc ccccgccac 7140
 acgtgtccta ttcctctgtg atccgtaagg ccggcggtc ggggcccccg cagcagcagc 7200
 agcagcagca gcagcagcag cagcagcagg cggtaggcag gccgggcccg gcggccacca 7260
 gcggccctcg gaggtacca ggccccacgg ccgagcctct ggccggagat cggccgccc 7320
 cggggggcca cagcagcggc cgtcgcgcca ggatggagag gcgggtccca ggccccggcc 7380
 ggagcgagtc ccccggggccc tgtcgacacg gcggggcccg gtggccggca tctggcccg 7440
 acgtgtccga ggggcccccg ggtccccggc accatggcta ctaccggggc tccgactacg 7500
 acgaggccga tggccccggc agcggggggc gcgaggaggc catggccggg gcctacgacg 7560
 cgccaccccc cgtacgacac gcgtcctcgg gcgccaccgg gcgctcgccc aggactcccc 7620
 gggcctcggg cccggcctgc gcctcgcctt ctcggcacgg ccggcgactc cccaacggct 7680
 actaccggc gcacggactg gccaggcccc gcgggcccgg ctccaggaag ggctgcacg 7740
 aaccttacag cgagagtac gatgattggt gctaagcccg ggcgaggtgg cgcccgccc 7800
 gccccccacg caccaccgc acacaccca ccgaggagc cgcgcagagg ccgcgggggc 7860
 ccagcacaga gggcccgga gagggccagc cgggagacc cagactctgg agaggccagg 7920
 gctgggccac aagggtgtcc cgcagagacc ctcgccaaa agagaccctc ctgggcagcc 7980
 acggcgcccc ccaaccagcc ccgatcccc caccacgac aggggctctc gggtaggag 8040
 caggagcag acaaaccaca cagccaagg atttgaatta actcagccat ttttgagaa 8100
 ctttgggaa catgaaaaaa aaaaaaaaaa aaaaaaaaaa aaacattttt aaaagaaaa 8160
 acggggagaa aaaaatagct tctattgatg agttttatca tctcaattga atctttcctt 8220
 tccctgatga agacagctgg tggccgagtg cggcaaagaa gccagaagga accagaatcc 8280
 cagtgccta caccaccac cagacacact cacaccaca cacgttctca gacacacaca 8340
 agagtgcctg ccggttatac caaacctac tattactgcc tgcagaaatc aatttaaaaa 8400
 aataataata acaataaaca attttaaaaa ggacaaaaaa attaattgatt gagaaaagag 8460
 gcattttttt ctgacatttg gtctgcttg aaacaacaaa agaagaagaa aaaccacca 8520
 tcaccaccga ttcctttgct tcttttttcc ttttttcta cttgtttga aaaccgtggg 8580
 cttgggactg tgaattattg catgacattc aaaaagaaaa aaaaaataaa aaaaagtga 8640
 atcaaa 8646

<210> 85

<211> 7242

<212> DNA

<213> Homo sapiens

<400> 85

```

gaaaaagggt gaaagagaaa cttggcgacc tcccggagga gttcgcgaag cgaccaggag      60
cgtgttgcca tcgtcctcac ccggcaccca attccaccac agagtcggga ttctcgtcgg      120
gatcgtgatg ggggtgctttt atttttctct ttgattttca aaaaatgtct atgtgactgt      180
ccctatctta aggggaagtt gaaagtgggg gcgggggtgc tcaatgagaa acgttgccct      240
gtgtgtagtt gtttgagca cactgcaaat tatattggca tctctttcca aaagtcactt      300
tgattcaact tcgatagctt tctcgtaaat ggcacgttta ggtggtgaga ggtggatgag      360
gaaacaggca ccagtgcagc tgatttgacc tccagtggga tagatacgat tagcaccagg      420
atcgtgtctc attttgaacc cagatctgaa cagaattaag acgaacgagc tttcacaatt      480
gcagcagatg aagatccatt ggtaaattga tcaggatttt tggcctaccc tccaaagaaa      540
aggagcggaa agaattgtcg agcgggccgc ggatgacgtc aggggggagc cgcgcgcgc      600
ggcggcggcg gcgggcggag cagcggccgc ggccgcgccg cagcagcagc agcagcagca      660
gcagcagcag ccgccgcctc cgcagcccca gcggcagcag caccgcgccac cgcgcgccag      720
gcgcacacgg ccggaggacg gcgggccccg cgcgcgcctc acctcgcccg ccgcaatggc      780
gacggtcggg gagcgcaggc ctctgccag tctgaagtg atgctgggac agtcgtggaa      840
tctgtgggtt gaggttcca aacttcctgg gaaggacggg acagaattgg acgaaagttt      900
caaggagttt gggaaaaacc gcgaagtcac ggggctctgt cgggaagaca tgccaatatt      960
tggtttctgt ccagcccatg atgatttcta cttggtggtg tgtaacgact gtaatcaggt      1020
tgtcaaaccg caggcatttc aatcacatta tgaaagaaga catagctcat ccagcaagcc      1080
gcctttggcc gttcctccca cttcagtatt ttcttcttc ccttctctgt ccaaaagcaa      1140
aggaggcagt gcaagtggaa gcaaccgttc ttccagtgga ggtgttctta gcgcattctc      1200
atcaagttcc aagtgttg aatcacccaa agagaaactg cagctcaggg ggaacaccag      1260
gccaatgcat ccatttcagc aaagtagagt tccccatggt agaatcatga caccctctgt      1320
gaaagtggaa aagattcatc cgaaaatgga tggcacacta ctgaaatctg cgggtggggc      1380
aacctgtcct gctactgtga gttccttagt caagcctggc cttaactgcc cctcaatacc      1440

aaagccaacc ttgccttcac ctggacagat tctgaatggc aaaggccttc ctgcaccgcc      1500
cactctggaa aagaaacctg aagacaattc caataatagg aaatttttaa ataagagatt      1560
atcagaaaga gagtttgatc ctgacatcca ctgtggggtt attgatctcg acaccaagaa      1620
gccctgcacc cggctcttga catgcaagac acattcctta acccagcgca gggctgtcca      1680
gggtagaaga aaacgatttg atgtgttatt agccgagcac aaaaacaaaa ccagggaaaa      1740
ggaattgatt cgccatccgg actctcagca accaccgcag cctctcaggg acccgcatcc      1800
cgccctcctc agaacgtcac aggagccgca ccaaaaccct caccgagtga ttcttccga      1860
atcaaagcct ttgtagcta gtaaacctaa acctcacacc ccagtcctc caaggcctcc      1920
aggctgccct gtcagcaag gtgggagtgc cccattgac cctcctccag tccatgaatc      1980
tccacaccct cccctgcctg ccactgagcc agcttctcgg ttatccagtg aggaggcgga      2040

```

aggcgatgac aaagaagagt ctgttgaaaa actggactgt cattattcag gtcacatccc 2100
 tcagccagca tcttttttga catttgggag cgggcagata ggaagaggct attacgtgtt 2160
 tgaactccagg tggaaatcgac ttccgtgcgc cctcaacctc atggtggaga agcatctgaa 2220
 tgcacagcta tgggaagaaaa tcccaccagt gcccagtacc acctcaccca tctccacacg 2280
 tattcctcac cggacaaact ctgtgccgac atcacaatgt ggagtcagct atctggcagc 2340
 agccaccgtc tctacatccc cagtccgtct ctcactctacc tgcactctcc caaatagcaa 2400
 atcggtagca gctcatggaa ccacactaaa tgcacagcct gctgcttcag gggcgatgga 2460
 tctctgtgtc agtatgcaat ccagacaagt gtctctttca tctcactccc ctccacggcc 2520
 ctctggcctt tctcgtgttc ctctcctccc catgtccagg aaacctcaga aattgaaatc 2580
 cagcaaatct ttgaggccca aggagtcttc tggtaacagc actaactgtc aaaatgccag 2640
 tagcagtacc agtggcggct caggaaagaa acgcaaaaac agttcccccac tgttggttca 2700
 ctcttctctc tctcttctct cctcctctctc ttcttctcat tccatggagt cttttaggaa 2760
 aaactgtgtg gctcactctg ggcctcccta cccctcaacg gtaacatctt cccatagcat 2820
 cggcctcaac tgtgtgaaga ataaagcaaa tgcgggtgaac gtcgggcatg accagtcagg 2880
 gaggggcccc cccaccggga gccctgctga atccatcaag aggatgagtg tgatggtgaa 2940
 cagcagtgat tctactcttt ctcttggggc attcattcac cagtccaatg aactgcctgt 3000
 caactccac ggagttttt cccactcaca cactcctcta gacaaactca taggaaagaa 3060
 aagaaagtgc tcaccacgct cgagcagcat caacaacagc agcagcaaac ccacaaaggt 3120
 tgccaaagtg ccagccgtga acaatgtcca catgaaacac acaggcacca tcccaggggc 3180
 acaaggactg atgaacagtt cctccttca tcagccaaag gcacgtccct gacagctgaa 3240
 aatagcacgg ggaggaataa tgcggacact tttgaggaca agttacacct ccactcagca 3300
 ctctggactc cagcatgcct ttgagtctgt tttcccaacc tctgtgggc ctcaagggtg 3360

 gaaacctgcc gggctgttgt tttaacgagg atttccctga agctatgtct ctagecagtga 3420
 gtactcataa aggacactgg atcaagttca gccaccgaat tgcttttacc agtgtaaaag 3480
 tggcttgaac tgcttgctac caatctgtga gaagtttttg tttttgtttt gttttttaac 3540
 ttgcagtata tcacagagcc actcttcaag tagattggct gggcaaaaga atgttttggc 3600
 aagagcgtta ctgtagacct ttctccctcc ttctttttac taccattttt ttttaacact 3660
 gtcactctga ggtcactctc cagcagttag gcaccttaac tggagaccag aaaccttcca 3720
 gagaacacag ggctgcatcc cgagcaaccc tctgaagaag ggaattaggc tttagatttt 3780
 gatagcaatg ttccaggaat gaaatataga tgtagccca agacaccatg acaaaatagc 3840
 ccagcctttt gagagtaatt tgggaaaaga agctgtcaga agtttctaac ttacaaactg 3900
 gtttgaaatt tttgatgcc agacagcaag tataaatcat tttggaggct tacttttcat 3960
 gatacaaaaag caattctgtg tgattttttt ttttaagaag aaagaaaatg caagctagtt 4020
 ttgagaaaag aaggccaaat tgggtcgggg gaggtggga gtgaggaagt taaaatcact 4080
 ataggagaaa aaaacttttt tcaagatttc caaagagatg aaattttctt aatcctttta 4140
 agttttcata gtaaacagta tggcagattg ggttggttgt cctacctggt ctatttttaa 4200
 aagtcacctt ttaaagtga attattagat acacttaa atgttccaagg cactctctac 4260
 attacccttg tttttctctt tggatactgt cctgggacta agttagatt tctgcttcaa 4320

gcacttctgg cattgtgtgt ttttgtatgc actccccctc atgccacttc agatgtttat 4380
ttggatgtgg ttggggacga gacgacacac caaggaaagg gagttggaga gaatgtaagt 4440
cctgacctga aggtcttttg tgatgcatgt ataggattgc cctgacacac accctccttt 4500
cttgggatta taccagccat cttcctgaga gttttggagc cctctaggat attttttcta 4560
gtaccccacc cccacccct aaagaaagac cttaatatgt taaaacagca ttgcttgag 4620
aaggtgtcat tgaattccgg gacgagccgg agcctttaaa tgggtgcttc caccactaca 4680
ggctcctgac acgagtaaca ggcaactgtt cttagaagaa cacacgaagt tgccgaacac 4740
agggtaaaat ttccaaggcg ctgatcgtt cctgggccag ggcctgatga gagccagtca 4800
gtacattctt tttttctac agttcttggg tttcaactt cagtttcagg gaatttcaag 4860
tcaacaacag gtagaatgaa taaacttggg taccagccta ataattgtgaa ttgctacaga 4920
attattctta ttatgtaaga aaacaaaaac tttatgcaga tacttttagct ataaattgat 4980
gtaaaatact gattttttta aaggaaggag agaacagtat cttgttcaat tattatgcaa 5040
tcaatcagta aatgttttta aatgatact acaggagagc ttagtaagga gagggcatgg 5100
atgggccagt ttggcatagt tgggagaaat cagtctggtt tccatcccag tcggggaaga 5160
gagaggtgag agggaatcag aacgtaccta gttgattcct tggtgacaag tgcaatgggg 5220

tatgggtaga atttattttc agagccaaga ggacttcatg gttataaata aagttgcctt 5280
tagcaatgga atttacagat cgatcatgtt gttccgaaag atgtgaatag gatccacaat 5340
aacaagttga ttcagactaa tgtagatatt tagattagca agtattgaac atttgatttc 5400
ttagactgag gttttaaatg aatttcatta tttctccgg taatacacag agcatcgga 5460
ttaggaaatt agccattttg gattctgtct gccacaaaca gacctattct aaacagtgtc 5520
attaaatttt agactgttgt tcaaatattt tattttctcc taaactactt tttatggtga 5580
tgaataatta agaccattta aaacacggga gtacaagtat ttttttgaat taaattaact 5640
tgcaaaaacc aaatttgacg tggttgggtt gttctagac agactttggt atcaatttaa 5700
aaccaagata atttttatat tctttccaat agaatttcat gacaactcct gcagttttct 5760
taacctacaa aaaaaaaaaa aaagtgtgtc aatgatgaac aaagaattat acaaaacctt 5820
cttttgtatc tttatttttg aatttcttgt tctattataa atatggaagt atccctattt 5880
cagaagacat attttgttaa aatgaattg tacatattta aatatgtatt ttgacacagg 5940
tctttttttc tgatatcctg ttttggtaca attgagatca tctagtattt atttattaat 6000
taataaaaagt aaataccttt ttataatttg aagtggttca ctgccaagcc aatagttcta 6060
gaacctgcct cctttacagt ttttaagggt gcctctgttc tgtgaaaagt ctttgtccct 6120
tttagtgtct cgggagtgga ttcatacaga tgaagtgggc attgcttctt cctggttgcc 6180
tggtttcccg atagactaca tgtaactaag tgacacactg cttttctttt gttagtattt 6240
tatgtgtggg agtatgtgac tgcgtgtgtg tgtgcctgtg cgtgtgtgtg tatactcagc 6300
acatgtatgt tactatgtga tgtggtttta aactaatgga aaaaactgaa agtgcctgaa 6360
actagtttta agcttagaca gaatctcttt aaaaagactt gaatgttcag ttgaactttt 6420
ggagtttgct ttttccacct aaatatgtt tctaaaattt taggggcgga gttgaaaacc 6480
accaatgtcg gtaattttat aaggtatttt aaaattaaga cctcttggtt catagtaatt 6540
caattggtga tggattgcct ggtggcacca agggttacag atctttttgt cagccagcaa 6600

```

cttacacgat gtgtccgttt tgttattcac tcatgaaata caatttaaaa tattttaaatt 6660
atatttgatt ccaaaaatat aatacaaga agtacctctg agaacattga aaaaaatgta 6720
taatttgaaa aatgtaactt ataagggcag ctgtcttcct gcaagagttc tgttgccaag 6780
gaattttcta atgtcgctca ttctgtccag ggggtttggg gcgattgggc tttgaaaaaa 6840
tattottaaa agtttgttta gcagaaaata atcactttta cathttgtgc aaaacatttt 6900
acattttcag ataatttaaa tgagcactac atactgtcag tgtgaatgta gggccttgaa 6960
agcattttgc tttttttttt tttttttttt ttttgagctt ggttataaaa gcaatctcct 7020
gtgttaaaaa cgtgtgaata gtttgataat ttgtacacat aatcaagagc atctcagctg 7080
gactttgtgt tggctgctgt atagaacatg aacaaatgtc aagggataga aaattacttt 7140

ggatatttaa aagagaagaa atatatagtc tatttgtttt gtaacaagtt tctgtaaaata 7200
aaataattta tactatttat aagaaaaaaa aaaaaaaaaa aa 7242

```

<210> 86

<211> 2300

<212> DNA

<213> Homo sapiens

<400> 86

```

ggccaggcaa gcctgaatcc tgtccctgcc atctcgccac tgcagctcgg gtccagaaag 60
gcaccatttt gtgcgggctg cccgctctcc cagggggagg agggatcttt tttgcatttt 120
ggagcggctg ccaaggaggg gaacctgttg ggcactctcc cagaccgctt tgtgagcgcc 180
tccggggcgg gcggggcgga ccagaccctc cggggcacgg cgtatcttgg caccggagg 240
cagcggaggc aggcgcagca tcctcgctgg gaactggagc tggagtgagc gcaccgcgg 300
ggaggagccg ccgcagcctc gcagaaccgc agtggaggag gtgacagctc cattgccggg 360
tttttatttt tttctctccc gcctcccgct ctctctctca ggctcggacc atgggtgcagt 420
cccactggct cccctgcccc cctctcctgt gagactggct gcggggaggg atcatggata 480
cttgtctgcc ggcttctggt tcccacgcaa gtaagcctgc tgtcaatgga ggaggacatt 540
gatacccgca aaatcaacaa cagtttctgt cgcgaccaca gctatgcgac cgaagctgac 600
attatctcta cggtagaatt caaccacacg ggagaattac tagcgacagg ggacaagggg 660
ggtcgggttg taatatttca acgagagcag gagagtaaaa atcaggttca tcgtaggggt 720
gaatacaatg tttacagcac attccagagc catgaaccgc agttcgatta cctgaagagt 780
ttagaaatag aagaaaaaat caataaaata agatggctcc cccagcagaa tgcagcttac 840
tttcttctgt ctactaatga taaaactgtg aagctgtgga aagtcagcga gcgtgataag 900
aggccagaag gctacaatct gaaagatgag gagggccggc tccgggatcc tgccaccatc 960
acaaccctgc gggtgctgt cctgagaccc atggacctga tgggtggagg caccacacga 1020
agagtatttg ccaacgcaca cacatatcac atcaactoca tatctgtcaa cagcgactat 1080
gaaacctaca tgtccgctga tgacctgagg attaacctat ggaactttga aataaccaat 1140
caaagtttta atattgtgga cattaagcca gccaacatgg aggagctcac ggaggtgatc 1200
acagcagccg agttccaccc ccatcattgc aacaccttcg tgtacagcag cagcaaaggg 1260

```

```

acaatccggc tgtgtgacat gcgggcatct gccctgtgtg acaggcacac caaatttttt 1320
gaagagccgg aagatccaag caacagatca tttttctctg aaattatctc ttogatttgg 1380
gatgtgaagt tcagccacag tgggaggtat atcatgacca gggactactt gaccgtcaaa 1440
gtctggggtc tcaacatgga aaaccgcccc atcgagactt accaggttca tgactacctc 1500
cgcagcaagc tgtgttcctt ctatgaaaat gactgcattt ttgataaatt tgagtgtgtg 1560

tggaatgggt cagacagtgt catcatgaca ggctcctaca acaacttctt caggatgttc 1620
gacagaaaca ccaagcgtga tgtgacctt gaggcctcga gggaaaacag caagccccgg 1680
gctatcctca aaccccgaaa agtgtgtgtg gggggcaagc ggagaaaaga cgagatcagt 1740
gtcgacagtc tggacttttag caaaaagatc ttgcatacag cttggcatcc ttcagaaaat 1800
attatagcag tggcggctac aaataaccta tatatattcc aggacaaggt taactaggtg 1860
gacaagttat tacttaataa tctcacatac tgaatactag tcaaacaagt ttttaaatgt 1920
ttctttgggt cttcatttga tgcattgact ttaatttccc tatacaggaa atgattggaa 1980
tagaattaaa aggagtccaa cattcccagc tcccagttc taagaaactt ttgtcaaac 2040
caatagggtt gggacacttc tgtttagaat tgaaagctgc cagctaacag taattcttcc 2100
atagttgact tgaacttctg atgcttttat tgcccagttt tctctggtgg gtccagtggt 2160
ttgttcctag gtgtctgctg cgataaaatg aggttgtctg tagtatttaa ggagaaaaga 2220
gataagtttt ttttaattaa gcaattccat ttgattgaaa aaaatcaaca aaaaataaac 2280
accgtttact cttagacaaa 2300

```

<210> 87

<211> 1921

<212> DNA

<213> Homo sapiens

<400> 87

```

ggcgggaagt acattatcaa cgcgcgccag gggttcagtg aggtcgggca ggttcgctgt 60
ggcggggcgc tgggcccgcg gctgtttaac ttcgcttcgc ctggcccata gtgatctttg 120
cagtgaacca gcatcactgt ttcttgccgt gtgaagataa cccaaggaat tgagggaagt 180
gctgagaaga gtgtgctgga gatgctctag gaaaaaattg aatagtgaga cgagttccag 240
cgcaagggtt tctggtttgc caagaagaaa gtgaacatca tggatcagaa caacagcctg 300
ccaccttacg ctcagggtt ggctccctt cagggtgcca tgactcccg aatccctatc 360
tttagtccaa tgatgcctta tggcactgga ctgacccac agcctattca gaacaccaat 420
agtctgtcta ttttggaaga gcaacaagc cagcagcagc aacaacaaca gcagcagcag 480
cagcagcagc agcaacagca acagcagcag cagcagcagc agcagcagca gcagcagcag 540
cagcagcagc agcagcagca acaggcagtg gcagctgcag ccgttcagca gtcaacgtcc 600
cagcaggcaa cacagggaac ctcaggccag gcaccacagc tcttccactc acagactctc 660
acaactgcac ccttgccggg caccactcca ctgtatccct ccccatgac tcccatgacc 720
cccatcactc ctgccacgcc agcttcggag agttctggga ttgtaccgca gctgcaaaat 780

```

```

attgtatcca cagtgaatct tgggtgtaaa cttgacctaa agaccattgc acttcgtgcc      840
cgaaacgcgcg aatataatcc caagcgggtt gctgcggtaa tcatgaggat aagagagcca      900
cgaaccacgcg cactgatttt cagttctggg aaaatggtgt gcacaggagc caagagtga      960
gaacagtcca gactggcagc aagaaaatat gctagagttg tacagaagtt gggttttcca     1020
gctaagttct tggacttcaa gattcagaat atggtgggga gctgtgatgt gaagtttctt     1080
ataaggttag aaggccttgt gctcaccac caacaattta gtagttatga gccagagtta     1140
tttcttggtt taatctacag aatgatcaaa cccagaattg ttctccttat ttttgtttct     1200
ggaaaagttg tattaacagg tgctaaagtc agagcagaaa tttatgaagc atttgaaaac     1260
atctacccta ttctaaaggg attcaggaag acgacgtaat ggctctcatg tacccttgcc     1320
tccccacccc ccttcttttt ttttttttaa acaaatcagt ttgttttggg acctttaaat     1380
gggtggtgtt tgagaagatg gatgttgagt tgcagggtgt ggcaccagggt gatgcccttc     1440
tgtaagtgcc caccgcggga tgccgggaag gggcattatt tgtgactga gaacaccgcg     1500
cagcgtgact gtgagttgct cataccgtgc tgctatctgg gcagcgtgc ccatttattt     1560
atatgtagat tttaaacact gctgttgaca agttggtttg agggagaaaa ctttaagtgt     1620
taaagccacc tctataattg attggacttt ttaattttta tgtttttccc catgaaccac     1680
agtttttata tttctaccag aaaagtaaaa atctttttta aaagtgtgtt ttttctaatt     1740
tataactcct aggggttatt tctgtgccag acacattcca cctctccagt attgcaggac     1800
agaatatatg tgttaatgaa aatgaatggc tgtacatatt tttttctttc ttcagagtac     1860
tctgtacaat aaatgcagtt tataaaagtg ttagattggt gttaaaaaaa aaaaaaaaaa     1920
a                                                                 1921

```

<210> 88

<211> 10661

<212> DNA

<213> Homo sapiens

<400> 88

```

cgagatcccc gggagccagc ttgctgggag agcgggacgg tccggagcaa gccagaggc      60
agaggaggcg acagagggaa aaagggccga gctagccgct ccagtgtgtt acaggagccg     120
aagggaacga ccacgccagc cccagcccgg ctccagcgac agccaacgcc tcttgacagc     180
cggcggcttc gaagccgcgc cccggagctg ccctttcttc ttcgggtgaag tttttaaag     240
ctgctaaaga ctcgaggagaa gcaaggaaag tgcctggtag gactgacggc tgcctttgtc     300
ctcctcctct ccaccccgcc tccccccacc ctgccttccc cccctccccc gtcttctctc     360
ccgcagctgc ctcagtcggc tactctcagc caacccccct caccaccctt ctccccaccc     420
gcccccccgcc ccccgctggc ccagcgtgac cagcccagat ttgcagagag gtaactccct     480
ttggctgcga gcgggcgagc tagctgcaca ttgcaaagaa ggctcttagg agccaggcga     540
ctggggagcg gcttcagcac tgcagccacg acccgctggg ttaggctgca cggggagaga     600
accctctgtt ttccccact ctctctccac ctctcctgc cttccccacc ccgagtgcgg     660
agccagagat caaaagatga aaaggcagtc aggtcttcag tagccaaaaa aaaaaacaaa     720

```

caaaaacaaa aaagccgaaa taaaagaaaa agataataac tcagttctta tttgcaccta	780
cttcagtgga cactgaattt ggaaggtgga ggattttgtt tttttctttt aagatctggg	840
catcttttga atctaccctt caagtattaa gagacagact gtgagcctag cagggcagat	900
cttgctccacc gtgtgtcttc ttctgcacga gactttgagg ctgtcagagc gctttttgcg	960
tgggtgctcc cgcaagtttc cttctctgga gcttcccgca ggtgggcagc tagctgcagc	1020
gactaccgca tcatcacagc ctgttgaact cttctgagca agagaagggg aggcggggta	1080
agggaagtag gtggaagatt cagccaagct caaggatgga agtgcagtta gggctgggaa	1140
gggtctaccc tcggccgcgcg tccaagacct accgaggagc tttccagaat ctgttccaga	1200
gcgtgcgcga agtgatccag aacccggggc ccaggcaccg agaggccgcg agcgcagcac	1260
ctcccgccgc cagtttgctg ctgtctgcagc agcagcagca gcagcagcag cagcagcagc	1320
agcagcagca gcagcagcag cagcagcagc agcaagagac tagccccagg cagcagcagc	1380
agcagcaggg tgaggatggt tctccccaag cccatcgtag aggccccaca ggctacctgg	1440
tcctggatga ggaacagcaa ccttcacagc cgcagtcggc cctggagtgc caccgccaga	1500
gaggttgctt cccagagcct ggagccgcgcg tggccgcag caaggggctg ccgcagcagc	1560
tgccagcacc tcgggacgag gatgactcag ctgcccctc caggttgctc ctgctgggcc	1620
ccactttccc cggcttaagc agctgctccg ctgaccttaa agacatcctg agcagggcca	1680
gcaccatgca actccttcag caacagcagc aggaagcagt atccgaagc agcagcagcg	1740
ggagagcgag ggaggcctcg ggggctccca cttcctccaa ggacaattac ttagggggca	1800
cttcgaccat ttctgacaac gccaaaggagt tgtgtaaggc agtgtcggtg tccatgggcc	1860
tgggtgtgga ggcgttgag catctgagtc caggggaaca gcttcggggg gattgcatgt	1920
acgccccact tttgggagtt ccacccgctg tgcgtccac tccttgtgcc ccattggccg	1980
aatgcaaagg ttctctgcta gacgacagcg caggcaagag cactgaagat actgctgagt	2040
attccccctt caagggaggt tacaccaaag ggctagaagg cgagagccta ggctgctctg	2100
gcagcgctgc agcagggagc tccgggacac ttgaactgcc gtctaccctg tctctctaca	2160
agtccggagc actggacgag gcagctgctg accagagtcg cgactactac aactttccac	2220
tggctctggc cggaccgcgc cccctccgc cgcctccca tccccacgt cgcataagc	2280
tggagaaccc gctggactac ggcagcgctt gggcggctgc ggcggcgag tgcgcctatg	2340
gggacctggc gagcctgcat ggcgcggtg cagcgggacc cggttctggg tcacctcag	2400
ccgccgcttc ctcatcctgg cacactctct tcacagccga agaaggccag ttgtatggac	2460
cgtgtggtgg tgggtggggg ggtggcggcg gcggcgcgcg cgcgcgcgcg ggcggcgcg	2520
gcggcgcgcg cgcgagggcg ggagctgtag cccctacgg ctacactcg cccctcagg	2580
ggctggcgcg ccaggaaagc gacttcaccg cacctgatgt gtggtacctt ggcggcatgg	2640
tgagcagagt gccctatccc agtcccactt gtgtcaaaag cgaaatgggc cctggatgg	2700
atagctactc cggaccttac ggggacatgc gtttggagac tgccagggac catgttttgc	2760
ccattgacta ttactttcca cccagaaga cctgcctgat ctgtggagat gaagcttctg	2820
ggtgtcacta tggagctctc acatgtggaa gctgcaaggt cttottcaaa agagccgctg	2880
aagggaacaa gaagtacctg tgcgccagca gaaatgattg cactattgat aaattccgaa	2940

ggaaaaattg tccatcttgt cgtcttcgga aatgttatga agcagggatg actctgggag 3000
 cccggaagct gaagaaactt ggtaatctga aactacagga ggaaggagag gcttccagca 3060
 ccaccagccc cactgaggag acaaccaga agctgacagt gtcacacatt gaaggctatg 3120
 aatgtcagcc catctttctg aatgtcctgg aagccattga gccaggtgta gtgtgtgctg 3180
 gacacgacaa caaccagccc gactcctttg cagccttgct ctctagcctc aatgaactgg 3240
 gagagagaca gcttgtacac gtggtcaagt gggccaaggc cttgcctggc ttccgcaact 3300
 tacacgtgga cgaccagatg gctgtcattc agtactcctg gatggggctc atgggtgtttg 3360
 ccatgggctg gcgatccttc accaatgtca actccaggat gctctacttc gccctgctc 3420
 tggttttcaa tgagtaccgc atgcacaagt cccggatgta cagccagtgt gtccgaatga 3480
 ggcacctctc tcaagagttt ggatggctcc aaatcacccc ccaggaattc ctgtgcatga 3540
 aagcactgct actcttcagc attattccag tggatgggct gaaaaatcaa aaattctttg 3600
 atgaacttcg aatgaactac atcaaggaac tcgatcgtat cattgcatgc aaaagaaaaa 3660
 atcccacatc ctgctcaaga cgcttctacc agctcaccaa gctcctggac tccgtgcagc 3720
 ctattgcgag agagctgcat cagttcactt ttgacctgct aatcaagtca cacatgggtga 3780
 gcgtggactt tccggaaatg atggcagaga tcactctctg gcaagtgcc aagatccttt 3840
 ctgggaaagt caagcccatc tatttcacac ccagtgaaag cattggaaac cctatttccc 3900
 caccacagct catgccccct ttccagatgtc ttctgcctgt tataactctg cactactcct 3960
 ctgcagtgcc ttggggaatt tcctctattg atgtacagtc tgtcatgaac atgttcctga 4020
 attctatttg ctgggctttt tttttctctt tctctccttt ctttttcttc ttccctccct 4080
 atctaaccct cccatggcac cttcagactt tgcttcccat tgtggctcct atctgtgttt 4140
 tgaatggtgt tgtatgcctt taaatctgtg atgatcctca tatggcccag tgtcaagttg 4200
 tgcttgttta cagcactact ctgtgccagc cacacaaaag tttacttacc ttatgccacg 4260
 ggaagttag agagctaaga ttatctgggg aaatcaaaac aaaaacaagc aaacaaaaaa 4320
 aaaaagcaaa aacaaaacaa aaaataagcc aaaaaacctt gctagtgttt ttccctcaa 4380

 aataaataaa taaataaata aatacgtaca tacatacaca catacataca aacatataga 4440
 aatcccaaaa gaggccaata gtgacgagaa ggtgaaaatt gcaggcccat ggggagttac 4500
 tgattttttc atctcctccc tccacgggag actttatttt ctgccaatgg ctattgccat 4560
 tagagggcag agtgacccca gagctgagtt gggcaggggg gtggacagag aggagaggac 4620
 aaggagggca atggagcatc agtacctgcc cacagccttg gtccctgggg gctagactgc 4680
 tcaactgtgg agcaattcat tatactgaaa atgtgcttgt tgttgaaaat ttgtctgcat 4740
 gttaatgcct ccccccaaaa cccttttctc tctcactctc tgccctcaac ttccagattga 4800
 ctttcaatag tttttctaag acctttgaac tgaatgttct cttcagccaa aacttggcga 4860
 cttccacaga aaagtctgac cactgagaag aaggagagca gagatttaac cttttgtaag 4920
 gccccatttg gatccaggtc tgctttctca tgtgtgagtc agggaggagc tggagccaga 4980
 ggagaagaaa atgatagctt ggctgttctc ctgcttagga cactgactga atagttaaac 5040
 tctcactgcc actacctttt ccccacctt aaaaagacctg aatgaagttt tctgccaaac 5100
 tccgtgaagc cacaagcacc ttatgtcctc ccttcagtgt tttgtgggcc tgaatttcat 5160
 cacactgcat ttccagccatg gtcacaaagc ctgtttgctt cttttgggca tgttcacaga 5220

ttctctgtta agagccccc aaccaagaa ggtagcagg ccaacagctc tgacatctat 5280
 ctgtagatgc cagtagtcac aaagatttct taccactct cagatcgctg gagcccttag 5340
 acaaactgga aagaaggcat caaagggatc aggcaagctg ggcgtcttg ccttgctccc 5400
 cagagatgat accctcccag caagtggaga agttctcact tccttcttta gagcagctaa 5460
 aggggctacc cagatcaggg ttgaagagaa aactcaatta ccaggggtggg aagaatgaag 5520
 gcactagaac cagaaacct gcaaatgctc ttcttgctac ccagcatatc cactgcaga 5580
 agtcatgaga agagagaagg aacaagagg agactctgac tactgaatta aaatcttcag 5640
 cggcaaagcc taaagccaga tggacacat ctggtgagtt tactcatcat cctcctctgc 5700
 tgctgattct ggcctctgac attgccata ctactcaga tccccacct ttgttgctgc 5760
 ctcttagtca gagggaggcc aaaccattga gactttctac agaaccatgg cttctttcgg 5820
 aaaggctctg ttggtgtggc tccaatactt tgccacctat gaactcaggg tgtgccctgg 5880
 gacactgggt ttatatagtc ttttggcaca cctgtgttct gttgacttcg ttcttcaagc 5940
 ccaagtgcaa gggaaaatgt ccactactt tctcatcttg gcctctgcct ccttacttag 6000
 ctcttaatct catctgttga actcaagaaa tcaagggcca gtcatacagc tgccatttt 6060
 aattgattca ctctgtttgt tgagaggata gttctgagt gacatgatat gatccacaag 6120
 ggtttccttc cctgatttct gcattgatat taatagccaa acgaacttca aaacagcttt 6180
 aaataacaag ggagagggga acctaagatg agtaatatgc caatccaaga ctgctggaga 6240

 aaactaaagc tgacaggttc ctttttggg gtgggataga catgttctgg ttttctttat 6300
 tattacacaa tctggctcat gtacaggatc acttttagct gttttaaaac gaaaaaata 6360
 tccaccactc ttttcagtta cactaggtta cttttaata ggtcctttac atctgtttg 6420
 gaatgatttt catcttttgt gatacacaga ttgaattata tcattttcat atctctcctt 6480
 gtaataacta gaagctctcc ttacatttc tctatcaaat ttttcatctt tatgggtttc 6540
 ccaattgtga ctcttgctt catgaatata tgtttttcat ttgcaaaagc caaaatcag 6600
 tgaacagca gtgtaattaa aagcaacaac tggattactc caaatttcca aatgacaaaa 6660
 ctagggaaaa atagcctaca caagccttta ggcctactct ttctgtgctt gggtttgagt 6720
 gaacaaagga gattttagct tggctctgtt ctcccatgga tgaaaggagg aggatttttt 6780
 ttttcttttg gccattgatg ttctagccaa tgtaattgac agaagtctca ttttgcagc 6840
 gctctgctct acaaacagag ttggtatggt tggatactg tactcacctg tgagggactg 6900
 gccactcaga cccacttagc tggtagctga gaagatgagg atcactcact ggaaaagtca 6960
 caaggaccat ctccaaacaa gttggcagtg ctcgatgtgg acgaagagtg aggaagagaa 7020
 aaagaaggag caccagggag aaggctcctg ctgtgctggg cagcagacag ctgccaggat 7080
 cacgaactct gtagtcaaag aaaagagctg tgtggcagtt tcagctctcg ttcattgggc 7140
 agctcgccta gcccagcct ctgagctgac atgggagttg ttggattctt tgtttcatag 7200
 cttttctat gccataggca atattgttgt tcttgaaag tttattattt ttttaactcc 7260
 cttactctga gaaagggata tttgaagga ctgtcatata tctttgaaa aagaaaatct 7320
 gtaatacata ttttttatg tatgttact ggcactaaaa aatatagaga gcttcattct 7380
 gtcccttggg tagttgtga ggtaattgtc caggttgaaa aataatgtgc tgatgctaga 7440
 gtccctctct gtccatactc tacttctaaa tacatatagg catacatagc aagttttatt 7500

tgacttgtac ttttaagagaa aatatgtcca ccatccacat gatgcacaaa tgagctaaca	7560
ttgagcttca agtagcttct aagtgtttgt ttcattaggc acagcacaga tgtggccttt	7620
cccccttct ctccttgat atctggcagg gcataaaggc ccaggccact tcctctgcc	7680
cttcccagcc ctgcacaaaa gctgcatttc aggagactct ctccagacag cccagtaact	7740
acccgagcat ggcccctgca tagccctgga aaaataagag gctgactgtc tacgaattat	7800
cttgtgccag ttgcccaggt gagaggcac tgggccaagg gagtggtttt catgtttgac	7860
ccactacaag gggtcatggg aatcaggaat gccaaagcac cagatcaaat ccaaaactta	7920
aagtcaaaat aagccattca gcatgttcag tttcttgaa aaggaagttt ctaccctga	7980
tgcccttcta ggcagatctg ttctcaccat taatcttttt gaaaatcttt taaagcagtt	8040
tttaaaaaga gagatgaaag catcacatta tataaccaa gattacattg tacctgctaa	8100
gataccaaaa ttcataaggg caggggggga gcaagcatta gtgcctcttt gataagctgt	8160
ccaaagacag actaaaggac tctgctggtg actgacttat aagagctttg tgggtttttt	8220
tttcccta atatacatg tttagaagaa ttgaaaataa tttcgggaaa atgggattat	8280
gggtccttca ctaagtatt ttataagcag aactggcttt ccttttctct agtagttgct	8340
gagcaaattg ttgaagctcc atcattgcat ggttggaat ggagctgttc ttagccactg	8400
tgtttgctag tgcccatgtt agcttatctg aagatgtgaa acccttgctg ataaggagc	8460
atataagta ctgattttg cactagaggg acagcaggca gaaatcctta tttctgcca	8520
ctttggatgg cacaaaaagt tatctgcagt tgaaggcaga aagttgaaat acattgtaa	8580
tgaatatttg tatccatgtt tcaaaattga aatatatata tatatatata tatatatata	8640
tatatatata tagtgtgtgt gtgtgttctg atagctttta ctttctctgc atctttatat	8700
ttggttccag atcacacctg atgccatgta cttgtgagag aggatgcagt tttgttttg	8760
aagctctctc agaacaaaca agacacctgg attgatcagt taactaaaag tttctcccc	8820
tattgggttt gaccacaggt tcctgtgaag gagcagagg ataaaaagag tagaggacat	8880
gatacattgt actttactag ttcaagacag atgaatgtgg aaagcataaa aactcaatgg	8940
aactgactga gatttaccac aggaaggcc caaacttggg gccaaaagcc tacccaagt	9000
attgaccagt gggcccctaa tgggacctga gctgttgaa gaagagaact gttccttgg	9060
cttcaccatc cttgtgagag aagggcagtt tcctgcattg gaacctggag caagcgtct	9120
atctttcaca caaattccct cacctgagat tgaggtgctc ttgttactgg gtgtctgtgt	9180
gctgtaattc tggttttgga tatgttctgt aaagattttg acaaatgaaa atgtgtttt	9240
ctctgttaaa acttgtcaga gtactagaag ttgtatctct gtaggtgcag gtccatttct	9300
gccacaggt aggggttttt tctttgatta agagattgac acttctgttg cctaggacct	9360
cccaactcaa ccatttctag gtgaaggcag aaaaatccac attagttact cctcttcaga	9420
catttcagct gagataacaa atcttttgga attttttcac ccatagaaag agtggttagat	9480
atttgaattt agcaggtgga gtttcatagt aaaaacagct tttgactcag ctttgattta	9540
tcctcatttg atttggccag aaagtaggta atatgcattg attggcttct gattccaatt	9600
cagtatagca aggtgctagg ttttttcctt tcccacctg tctcttagcc tggggaatta	9660
aatgagaagc cttagaatgg gtggcccttg tgacctgaaa cacttcccac ataagctact	9720

```

taacaagatt gtcattggagc tgcagattcc attgccacc aaagactaga acacacacat 9780
atccatacac caaaggaaag acaattctga aatgctgttt ctctgggtgtg tccctctctg 9840
gctgctgcct cacagtatgg gaacctgtac tctgcagagg tgacaggcca gatttgcatt 9900
atctcacaac cttagccctt ggtgctaact gtcctacagt gaagtgcctg ggggggtgtc 9960
ctatcccata agccacttgg atgctgacag cagccaccat cagaatgacc cagcaaaaa 10020

aaagaaaaaa aaaattaaaa agtccctca caaccagtg acaccttct gctttcctct 10080
agactggaac attgattagg gagtgcctca gacatgacat tcttgtgtg tccttggaat 10140
taatctggca gcaggaggga gcagactatg taaacagaga taaaaattaa ttttcaatat 10200
tgaaggaaaa aagaaataag aagagagaga gaaagaaagc atcacacaaa gatitttctta 10260
aaagaaacaa ttttgcttga aatctcttta gatggggctc atttctcacg gtggcacttg 10320
gcctccactg ggcagcagga ccagctccaa gcgctagtgt tctgttctct ttttgtaatc 10380
ttggaatctt ttgttgtctt aaatacaatt aaaaatggca gaaacttgtt tgttggaacta 10440
catgtgtgac tttgggtctg tctctgcctc tgctttcaga aatgtcatcc attgtgtaaa 10500
atattggctt actggtctgc cagctaaaac ttggccacat cccctgttat ggctgcagga 10560
tcgagttatt gttaacaaag agaccaaga aaagctgcta atgtcctctt atcattgttg 10620
ttaatttgtt aaacataaa gaaatctaaa atttcaaaaa a 10661

```

<210> 89

<211> 4367

<212> DNA

<213> Homo sapiens

<400> 89

```

gacgccatac tggacgccaa gtgggaggaa cttcaaggct gtccctgctg ggccctccgc 60
tctgcttctg cgaaggtttc attgaaaaca gatcctgcaa aagttccagg tgcccacact 120
ggaaaacttg agatcctgct tcccagacca cagctgtggg gaacttgggg tggagcagag 180
aagtttctgt attcagctgc ccaggcagag gagaatgggg tctccacagc ctgaagaatg 240
aagacacgac agaataaaga ctcgatgtca atgaggagtg gacggaagaa agaggccct 300
gggccccggg aagaactgag atcgaggggc cgggcctccc ctggaggggt cagcacgtcc 360
agcagtgatg gcaaagctga gaagtccagg cagacagcca agaaggcccg agtagaggaa 420
gcctccaccc caaagggtcaa caagcagggt cggagtgagg agatctcaga gagtgaaagt 480
gaggagacca atgcacaaa aaagacaaa actgagcagg aactccctcg gccacagtct 540
ccctccgata tggatagctt ggacgggctg agccttaatg atgatggcag cagcgaccct 600
agggatatcg accaggacaa ccgaagcacg tccccagta tctacagccc tggaaagtgtg 660
gagaatgact ctgactcact ttctggcctg tccagggccc cagcccgccc ctaccaccca 720
cctccactct ttctccttc ccctcaaccg ccagacagca cccctcgaca gccagaggct 780
agctttgaac cccatccttc tgtgacaccc actggatata atgctcccat ggagcccccc 840
acatctcgaa tgttccaggc tctcctggg gccctcccc ctacccaca gctctatcct 900
gggggcaact gtggagtttt gtctggaccc ccaatgggtc ccaagggggg aggggctgcc 960

```

tcatcagtgg ggggccctaa tgggggtaag cagcaccccc caccactac tcccatttca 1020

gtatcaagct ctggggctag tgggtctccc ccaacaaagc cgctaccac tccagtgggt 1080

ggtgggaacc tacctttctg tocaccacca gccaaattcc cccatgtgac accgaacctg 1140

cctccccac ctgcctgag accctcaac aatgcatcag cctctcccc tggcctgggg 1200

gccaaccac tacctggtca tctgcctct cccacgcca tgggacagg tatgggtgga 1260

cttctctctg gccagagaa gggcccaact ctggctcctt caccacctc tctgcctcct 1320

gttctctctt ctgctccagc gcccccatg aggtttcctt attcatctc tagtagtagc 1380

tctgcagcag cctcctcttc cagttcttcc tctcttctct ctgcctccc ctteccagct 1440

tcccaggcat tgccagcta cccccactct ttccctcccc caacaagct ctctgtctcc 1500

aatcagcccc ccaagtatac tcagccttct cctccatccc aggtgtgtg gagccagggt 1560

ccccaccac ctctccta tggccgctc ttagccaaca gcaatgcca tccaggcccc 1620

ttcctcctct ctactggggc ccagtcacc gccaccacc cagtctcaac acatcaccat 1680

aacaccagc aacagcaaca gcagcagcag cagcagcagc agcagcagc gcagcagcag 1740

cagcatcacg gaaactctgg gccccctcct cctggagcat ttccccccc actggagggc 1800

ggtagctccc accacgcaca cccttacgcc atgtctcctt cctggggtc tctgaggccc 1860

taccaccag gccagcaca cctgccccca cctcacagc aggtgtccta cagccaagca 1920

ggcccaatg gccctcagc ctcttctctt tccaactctt cctcttccc ttctcaagg 1980

tcctaccat gttcacacc ctcccttcc cagggcctc aaggggccc ctacccttc 2040

ccacgggtgc ctacggtcac cactctctcg gctacccttt ccacggtcac tgccaccgtg 2100

gttctctcgc cagcagcta caaacggcc tccccacctg gccccccacc gtacggaaag 2160

agagccctgt ccccgggggc ctacaagaca gccaccacc ccggatacaa acccggtcg 2220

cctccctcct tccgaacggg gacccaccg ggctatcgag gaacctcgc acctgcaggc 2280

ccaggacct tcaagccggg ctgcgccacc gtgggacctg ggcctcgc acctgcgggg 2340

ccctcaggcc tgccatcgt gccaccacca cctgcggccc ctgcctcagg gccgcccctg 2400

agcgccacgc agatcaaca ggagcgggt gaggagtatg agaccccga gagcccggtg 2460

ccccagccc gcagccctc gccccctccc aagtggttag atgtaccag ccatgccagt 2520

cagtctgcca ggttcaacaa acacctggat cgcggcttca actcgtcgc gcgcagcgac 2580

ctgtactctg tgccactgga gggctccaag ctggccaaga agcgggcca cctggtggag 2640

aagtgcggc gcgagcgga gcagcgcg gcggaagaa aggagcgga gcgcgagcg 2700

gaacgcgaga aagagcgga gcgcgaga gagcgagc ttgaacgag cgtgaagttg 2760

gctcaggagg gccgtgctcc ggtggaatgc ccatctctgg gccagtgcc ccatcgccct 2820

ccatttgaac cgggcagtgc ggtggtaca gtgccccct acctgggtcc tgacactcca 2880

gccttgcgca ctctcagtga atatgcccg cctcatgtca tgtctcctgg caatcgcaac 2940

catccattct acgtgcccct gggggcagtg gaccggggc tctgggtta caatgtccc 3000

gccctgtaca gcagtgatcc agctgcccg gagagggaac ggaagccc tgaacgagac 3060

ctccgtgacc gcctcaagcc tggctttgag gtgaagccta gtgagctgga accctacat 3120

ggggtccctg ggccgggctt ggatcccttt ccccgacatg ggggcctggc tctgcagcct 3180

ccccaccta acctacacc ttctcccttt catccaccc tccccccct aaacagaa 3240

```

cgtctagcgc tggcagctgg gccagccctg cggcctgaca tgtcctatgc tgagcggetg 3300
gcagctgaga ggcagcacgc agaaagggtg gggcccttgg gcaatgaccc actggcccgg 3360
ctgcagatgc tcaatgtgac tccccatcac caccagcact cccacatcca ctgcacacctg 3420
cacctgcacc agcaagatgc tatccatgca gcctctgocct cgggtgcaccc tctcattgac 3480
cccctggcct cagggtctca ccttaccctg atccccctacc cagctggaac tctccctaac 3540
cccctgcttc ctcaccctct gcacgagaac gaagttcttc gtcaccagct ctttgctgcc 3600
ccttaccggg acctgcgggc ctccctttct gcccgatgt cagcagctca tcagctgcag 3660
gccatgcacg cacagtcagc tgagctgcag cgcttggcgc tggaacagca gcagtggctg 3720
catgccatc acccgctgca cagtgtgccg ctgcctgccc aggaggacta ctacagtcac 3780
ctgaagaagg aaagcgacaa gccactgtag aacctgcgat caagagagca ccatggctcc 3840
tacattggac cttggagcac ccccaccctc ccccaccgt gcccttggcc tgccaccacg 3900
agccaagagg gtgctgctca gttgcagggc ctccgcagct ggacagagag tgggggaggg 3960
agggacagac agaaggccaa ggcccgatgt ggtgtgcaga ggtggggagg tggcgaggat 4020
ggggacagaa agcgcacaga atcttggacc aggtctctct tccttgtccc cctgctttt 4080
ctcctcccc atgcccaacc cctgtggccg ccgcccctcc cctgcccctg tgggtgtgatt 4140
atctcatctg ttagatgtgg ctgttttgcg tagcatcgtg tgccaccctt gccctcccc 4200
gatccctgtg tgcgcgcccc ctctgcaatg tatgccctt gcccttccc cactactaata 4260
atttatatat ataaatatct atatgacgct cttaaaaaaa catcccaacc aaaaccaacc 4320
aaacaaaaac atcctcacia ctcccagga aaaaaaaaa aaaaaaa 4367

```

<210> 90

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<400> 90
 nugnugnugn ugnugnugn g 21

<210> 91
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<400> 91
 nugcugcugc ugcugcugc g 21

<210> 92
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

 <400> 92
 cugnugcugn ugcugnugcu g 21

 <210> 93
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

 <400> 93

nugcugnugc ugnugcugnu g 21

<210> 94

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<400> 94

cugcugnugn ugnugcugcu g 21

<210> 95

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<400> 95

cugcugcugn ugcugcugcu g 21

<210> 96

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<400> 96

nugcugcugc ugcugcugnu g 21

<210> 97

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<400> 97

cngcngcngc ngcngcngcn g 21

<210> 98

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<400> 98

cngcugcugc ugcugcugcu g 21

<210> 99

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methyluracil

 <400> 99
 cugcngcugc ngcugcngcu g 21

 <210> 100
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methyluracil

 <400> 100
 cngcugcngc ugcngcugcn g 21

 <210> 101
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

 <400> 101
 cugcugcngc ngcngcugcu g 21

 <210> 102
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methyluracil

 <400> 102
 cngcugcugc ugcugcugcn g 21

 <210> 103
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>

<221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

 <400> 103
 cugcugcngc ugncgcugcu g 21

 <210> 104
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (7).. (7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<400> 104

nngnngnngn ngngnngnngn g

21

<210> 105

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<400> 105

cugcugnnngn ngngcugcu g 21

<210> 106

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methylcytosine

 <400> 106
 nngcugcugc ugcugcugnn g 21

 <210> 107
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4).. (4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7).. (7)
 <223> n is 5-methylcytosine

 <220>

<221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<400> 107
 nugnugnugn ugnugnugnu g 21

<210> 108
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature

<222> (19) .. (19)
 <223> n is 5-methylcytosine

 <400> 108
 nugcugnugc ugnugcugnu g 21

 <210> 109
 <211> 24
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<400> 109

nugnugnugn ugnugnugnu gnug 24

<210> 110

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methyluracil

<400> 110

cngcngcngc ngcngcngcn gcng 24

<210> 111

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is 5-methylcytosine

<400> 111
 nugnugnugn ugnugnugnu gnugnug 27

<210> 112
 <211> 27
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methyluracil

<400> 112

cngcngcngc ngcngcngcn gcngcng 27

<210> 113

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16) .. (16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (28) .. (28)

<223> n is 5-methylcytosine

<400> 113

nugnugnugn ugnugnugnu gnugnugnug

30

<210> 114

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is 5-methyluracil

<220>

<221> misc_feature
 <222> (26)..(26)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (29) .. (29)
 <223> n is 5-methyluracil

<400> 114
 cngcngcngc ngcngcngcn gcngcngcng 30

<210> 115
 <211> 33
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature

<222> (16) .. (16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (28) .. (28)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is 5-methylcytosine

<400> 115

nugnugnugn ugnugnugnu gnugnugnug nug 33

<210> 116

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is 5-methyluracil

<400> 116
cngcngcngc ngcngcngcn gcngcngcng cng 33

<210> 117
<211> 36
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (19) .. (19)
<223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (28) .. (28)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (31)..(31)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (34)..(34)
 <223> n is 5-methylcytosine

<400> 117
 nugnugnugn ugnugnugnu gnugnugnug nugnug 36

<210> 118
 <211> 36
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is 5-methyluracil

<400> 118
cngcngcngc ngcngcngcn gcngcngcng cngcng 36

<210> 119
<211> 12
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (6) .. (6)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<400> 119
 ngnnngnnngnn gn 12

<210> 120
 <211> 12
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<400> 120
 ngcngcngcn gc 12

<210> 121
 <211> 15
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature

<222> (1) .. (1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (4).. (4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (6) .. (6)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is 5-methylcytosine

<400> 121
ngnngnngnn gnn gn 15

<210> 122
<211> 15
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7).. (7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<400> 122
ngcngcngcn gcngc 15

<210> 123
<211> 18
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1) .. (1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (6) .. (6)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature

<222> (15)..(15)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (16).. (16)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

 <400> 123
 ngnnngnnngnn gnnngnnn 18

 <210> 124
 <211> 18
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16).. (16)

<223> n is 5-methylcytosine

<400> 124

ngcngcngcn gcngcngc 18

<210> 125

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

<400> 125
 ngnnngnnngnn gnnngnnngng n 21

<210> 126
 <211> 21
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16).. (16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<400> 126

ngcngcngcn gcngcngcng c 21

<210> 127

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24) .. (24)
 <223> n is 5-methylcytosine

<400> 127
 ngngngngnn gngngngng ngng 24

<210> 128
 <211> 24
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide
 <220>

<221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7).. (7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16).. (16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<400> 128
 ngcngcngcn gcngcngcng cngc 24

<210> 129
 <211> 27
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7).. (7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24) .. (24)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25)..(25)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27) .. (27)
 <223> n is 5-methylcytosine

<400> 129
 ngngngngnn gngngngng nngngngn 27

<210> 130

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is a, c, g, or u

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methylcytosine

<400> 130

ngcngcngcn gcngcngcng cngcngc 27

<210> 131

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (19) .. (19)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (21) .. (21)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (22).. (22)
<223> n is 5-methylcytosine

<220>
<221> misc_feature

<222> (24) .. (24)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is 5-methylcytosine

<400> 131

ngnngnngnn gnnngnngng nngnngnngn 30

<210> 132

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is 5-methylcytosine

<400> 132

ngcngcngcn gcngcngcng cngcngcngc 30

<210> 133

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7).. (7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methylcytosine

<400> 133
 nngnngnngn ng 12

<210> 134
 <211> 12
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<400> 134

cngcngcngc ng 12

<210> 135

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<400> 135

nngnngnngn ngngg 15

<210> 136

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methylcytosine

<400> 136
 cngcngcngc ngcng 15

<210> 137
 <211> 18
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methylcytosine

<220>

<221> misc_feature
<222> (4)..(4)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)

<223> n is 5-methylcytosine

<400> 137

nngnngnngn ngngnng 18

<210> 138

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<400> 138

cngcngcngc ngcngcng 18

<210> 139

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methylcytosine

<400> 139
 nngnngnngn ngngnngnngn g 21

<210> 140
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methylcytosine

<400> 140

cngcngcngc ngcngcngcn g 21

<210> 141

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20).. (20)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is 5-methylcytosine

<400> 141
 nngnngnngn ngngnngnngn gnng 24

<210> 142
 <211> 24
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20)..(20)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (23) .. (23)
 <223> n is 5-methylcytosine

<400> 142
 cngcngcngc ngcngcngcn gcng 24

<210> 143
 <211> 27
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20).. (20)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22).. (22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (23) .. (23)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (26)..(26)
 <223> n is 5-methylcytosine

<400> 143
 nngnngnngn ngnngnngnn gnnngng 27

<210> 144
 <211> 27
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide
 <220>

<221> misc_feature
 <222> (2)..(2)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (20).. (20)
 <223> n is a, c, g, or u

<220>
 <221> misc_feature
 <222> (23) .. (23)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (26)..(26)
 <223> n is 5-methylcytosine

<400> 144

<210> 145

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (23) .. (23)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (25) .. (25)
<223> n is 5-methylcytosine

<220>
<221> misc_feature

<222> (26)..(26)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (28) .. (28)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methylcytosine

<400> 145

nngnngnngn ngnngnngnn gnnngnngng 30

<210> 146

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (20).. (20)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methylcytosine

<400> 146

cngcngcngc ngcngcngcn gcngcngcng 30

<210> 147

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<400> 147
 uuuuuuuuuu un 12

<210> 148
 <211> 12
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (4).. (4)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methyluracil

<220>

<221> misc_feature
<222> (8)..(8)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 5-methyluracil

<400> 148
nncnncnncn nc 12

<210> 149
<211> 15
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is 5-methylcytosine

<220>
<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<400> 149

uuuuuuuuuu unuun 15

<210> 150

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<400> 150

nnnnnnnnnn ncnncc 15

<210> 151

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is a, c, g, or u

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

 <400> 151
 uuuuuuuuuu unuuuuun 18

 <210> 152
 <211> 18
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (2) .. (2)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methyluracil

 <220>

<221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methyluracil

<400> 152
 nncnncnncn ncnncnnc 18

<210> 153
 <211> 21
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<400> 153

uuuuuuuuuu unuuuuuuu n 21

<210> 154

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<400> 154

nncnncnncn ncnnncnn c 21

<210> 155

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature
<222> (4)..(4)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7)..(7)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20).. (20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<400> 155

nnnnnnnnnnnn nnnnnnnnnnn n 21

<210> 156

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 5-methylcytosine

<400> 156

nnnuucuucu ucuucuucnn n 21

<210> 157

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature
<222> (1) .. (1)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (7).. (7)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (19)..(19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<400> 157

nnnuucnnnu ucnnnuucnn n 21

<210> 158

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 5-methylcytosine

<400> 158

uuuuuuuuuu unuuuuuuu nuun 24

<210> 159

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature
<222> (7).. (7)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (19) .. (19)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methyluracil

<400> 159

nncnncnncn ncnnncnnnn cnc 24

<210> 160

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (27) .. (27)

<223> n is 5-methylcytosine

<400> 160

uuuuuuuuuu unuuuuuuuu nuuuun 27

<210> 161

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2) .. (2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methyluracil

<220>

<221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is a, c, g, or u

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (17)..(17)
 <223> n is 5-methyluracil

<220>
 <221> misc_feature
 <222> (19) .. (19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methyluracil

<400> 161

nnncnncnncn ncnnncnncn cncnnc 27

<210> 162

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24) .. (24)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27) .. (27)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (30)..(30)
 <223> n is 5-methylcytosine

<400> 162
 uuuuuuuuuu unuuuuuuuu nuuuuuuuuu 30

<210> 163
 <211> 30
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (23) .. (23)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (25) .. (25)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (26)..(26)
<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methyluracil

<400> 163

nnnnnnnnnn nnnnnnnnnn cnnnnnnnnn 30

<210> 164

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (27)..(27)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is 5-methylcytosine

<400> 164

uuuuuuuuuu uuuuuuuuuu uuuuuuuuuu uun 33

<210> 165

<211> 33

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (19) .. (19)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (20)..(20)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (22)..(22)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (23)..(23)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (25) .. (25)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (26)..(26)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (28) .. (28)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (29) .. (29)
<223> n is 5-methyluracil

<220>
<221> misc_feature

<222> (31)..(31)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is 5-methyluracil

<400> 165

nnnnnnnnnn nnnnnnnnnn cnnnnnnnnn nnc 33

<210> 166

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<220>
<221> misc_feature
<222> (2) .. (2)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (4).. (4)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (7).. (7)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methyluracil

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 5-methyluracil

<220>
<221> misc_feature

<222> (16)..(16)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (20)..(20)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (29) .. (29)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (32)..(32)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is 5-methyluracil

<220>

<221> misc_feature

<222> (35)..(35)

<223> n is 5-methyluracil

<400> 167

nnnnnnnnnn nnnnnnnnnn cnnnnnnnnn nnnnnn 36

<210> 168

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<400> 168
 ggnggnggng gn 12

<210> 169
 <211> 15
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6) .. (6)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<400> 169
 ggnggnggng gnggn 15

<210> 170
 <211> 18
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<400> 170

ggnggnggng gnggnggn 18

<210> 171

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12) .. (12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15) .. (15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18) .. (18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<400> 171

ggnggnggng gnggnggngg n 21

<210> 172

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3) .. (3)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

 <400> 172
 ggnggcggcg gcggcggcgg n 21

 <210> 173
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

 <400> 173
 ggnggcggng gcggnggcgg n 21

 <210> 174
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>

<221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<400> 174
 ggcggcggng gnggnggcgg c 21

<210> 175
 <211> 24
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is 5-methylcytosine

<400> 175

ggnggnggng gnggnggngg nggn 24

<210> 176

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (27) .. (27)

<223> n is 5-methylcytosine

<400> 176

ggngngngng gngngngng ngngngn 27

<210> 177

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (15)..(15)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21) .. (21)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24)..(24)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (27) .. (27)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (30)..(30)
 <223> n is 5-methylcytosine

<400> 177
 ggnggnggng gnggnggngg nggnggnggn 30

<210> 178
 <211> 12
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7).. (7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<400> 178

nggnggnggn gg 12

<210> 179

<211> 15

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<400> 179

nggnggnggn ggngg 15

<210> 180

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

 <400> 180
 nggnggnggn ggnggngg 18

 <210> 181
 <211> 21
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

 <220>

<221> misc_feature
 <222> (19)..(19)
 <223> n is 5-methylcytosine

 <400> 181
 nggnggnggn ggnggngng g 21

 <210> 182
 <211> 24
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (10)..(10)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

 <220>
 <221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22).. (22)

<223> n is 5-methylcytosine

<400> 182

nggngggnggn gggngggngng gngg 24

<210> 183

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7)..(7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25) .. (25)

<223> n is 5-methylcytosine

<400> 183

nggngggnggn ggngggnggng gnggngg 27

<210> 184

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7).. (7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (25) .. (25)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (28) .. (28)
 <223> n is 5-methylcytosine

<400> 184
 ngngngngngn ggngngngng gngngngngg 30

<210> 185
 <211> 15
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 2,6-diaminopurine

<220>

<221> misc_feature
 <222> (3)..(3)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (4).. (4)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (6) .. (6)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (9) .. (9)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (14)..(14)
 <223> n is 2,6-diaminopurine

<400> 185
 ngnnungnnu ngnnu 15

<210> 186
 <211> 20
 <212> RNA
 <213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 2,6-diaminopurine

<400> 186

ngnnungnnu ngnnungnnu 20

<210> 187

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature
 <222> (18)..(18)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (19) .. (19)
 <223> n is 2,6-diaminopurine

 <400> 187
 ngnnuagaau agaaungnu 20

 <210> 188
 <211> 20
 <212> RNA
 <213> Artificial

 <220>
 <223> Oligonucleotide

 <220>
 <221> misc_feature
 <222> (1) .. (1)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (11)..(11)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 2,6-diaminopurine

 <220>
 <221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<400> 188

ngnnuagaau ngnnuagaau 20

<210> 189

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 2,6-diaminopurine

<400> 189

ngaauaggnu ngaauaggnu 20

<210> 190

<211> 25

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1) .. (1)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6) .. (6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19) .. (19)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (21) .. (21)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (24) .. (24)

<223> n is 2,6-diaminopurine

<400> 190

ngnnungnnu ngnnungnnu ngnnu 25

<210> 191

<211> 30

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature
<222> (1) .. (1)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (4)..(4)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (8)..(8)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (9) .. (9)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (16)..(16)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (28)..(28)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is 2,6-diaminopurine

<400> 191

ngnnungnnu ngnnungnnu ngnnungnnu

30

<210> 192

<211> 35

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (8)..(8)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature
<222> (14)..(14)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (19)..(19)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (21)..(21)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (23)..(23)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (24)..(24)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (26)..(26)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (28)..(28)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (29)..(29)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (31)..(31)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (34)..(34)

<223> n is 2,6-diaminopurine

<400> 192

ngnnungnnu ngnnungnnu ngnnungnnu ngnnu 35

<210> 193

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<400> 193

naggnaggna gg 12

<210> 194

<211> 12

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<400> 194

cnggcngggcn gg 12

<210> 195

<211> 16

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature
 <222> (14)..(14)
 <223> n is 2,6-diaminopurine

<400> 195
 cnggcnggcg ggcngg 16

<210> 196
 <211> 16
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (1)..(1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (5)..(5)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (9)..(9)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<400> 196
 naggaggga ggnagg 16

<210> 197
 <211> 20
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<400> 197

naggnaggna ggnaggnagg 20

<210> 198

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<400> 198

cnnggcnggc n ggcnggcngg 20

<210> 199

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<400> 199

naggcaggna ggcaggnagg 20

<210> 200

<211> 20

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<400> 200

cnggcaggcn ggcaggcngg 20

<210> 201

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature
<222> (17)..(17)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)
<223> n is 5-methylcytosine

<400> 201
naggnagгна ggnaggnagg nagg 24

<210> 202
<211> 24
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (2)..(2)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (14)..(14)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is 2,6-diaminopurine

<220>
<221> misc_feature

<222> (22)..(22)

<223> n is 2,6-diaminopurine

<400> 202

cnggcnggcgcn ggcnnggcngg cngg 24

<210> 203

<211> 28

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is 5-methylcytosine

<400> 203

naggnaggnna ggnaggnagg naggnagg 28

<210> 204

<211> 28

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 2,6-diaminopurine

<400> 204
cnggcngggcn ggcnggcngg cnggcngg 28

<210> 205
<211> 32
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (13)..(13)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)
<223> n is 5-methylcytosine

<220>
<221> misc_feature
<222> (25)..(25)
<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is 5-methylcytosine

<400> 205

naggnaggna ggnaggnagg naggnaggna gg 32

<210> 206

<211> 32

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (26)..(26)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (30)..(30)

<223> n is 2,6-diaminopurine

<400> 206

cnggcnggc n ggcnggcngg cnggcnggc n gg 32

<210> 207

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (29)..(29)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (33)..(33)

<223> n is 5-methylcytosine

<400> 207

naggnaggna ggnaggnagg naggnaggna ggnagg 36

<210> 208

<211> 36

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (2)..(2)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 2,6-diaminopurine

<220>

<221> misc_feature

<222> (14)..(14)

<223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (26)..(26)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (30)..(30)
 <223> n is 2,6-diaminopurine

<220>
 <221> misc_feature
 <222> (34)..(34)
 <223> n is 2,6-diaminopurine

<400> 208
 cnggcnggc n ggcnnggcngg cnggcnggc n ggcnngg 36

<210> 209
 <211> 17
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (6)..(6)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (12)..(12)
 <223> n is 5-methylcytosine

<400> 209

ggcucnggcu cnggcuc 17

<210> 210

<211> 18

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<400> 210

ggcncnggcnc cnggcncn 18

<210> 211

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<400> 211

ggcucnggcu cnggcucn 18

<210> 212

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 5-methylcytosine

<400> 212

ggcucnggcu cnggcucngg cucn 24

<210> 213

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 5-methylcytosine

<400> 213

ggcncnggcncnnggcncnggcncn 24

<210> 214

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is inosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is inosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is inosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is inosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 5-methylcytosine

<400> 214

ggcncnggcnc cnggcncngg cncn 24

<210> 215

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is 5-methylcytosine

<400> 215

ggccunggcc ungccungg ccun 24

<210> 216

<211> 18

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (6)..(6)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (9)..(9)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (11)..(11)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (12)..(12)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (15)..(15)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (17)..(17)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (18)..(18)

<223> n is C or 5-methylcytosine

<400> 216
ggunnnggnu nnggnunn 18

<210> 217
<211> 24
<212> RNA
<213> Artificial

<220>
<223> Oligonucleotide

<220>
<221> misc_feature
<222> (3)..(3)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
 <222> (17)..(17)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (18)..(18)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (21)..(21)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (24)..(24)
 <223> n is C or 5-methylcytosine

<400> 217
 ggnunnggnu nnggnunngg nunn 24

<210> 218
 <211> 24
 <212> RNA
 <213> Artificial

<220>
 <223> Oligonucleotide

<220>
 <221> misc_feature
 <222> (3)..(3)
 <223> n is C or 5-methylcytosine

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n is inosine

<220>
 <221> misc_feature

<222> (5)..(5)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is inosine

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is inosine

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is inosine

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<400> 218

ggnnnnngggn nnggnnnnngg nnnn 24

<210> 219

<211> 24

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (3)..(3)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (4)..(4)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (5)..(5)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature
<222> (6)..(6)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (9)..(9)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is an abasic monomer

<220>
<221> misc_feature
<222> (11)..(11)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (12)..(12)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (15)..(15)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (16)..(16)
<223> n is an abasic monomer

<220>
<221> misc_feature
<222> (17)..(17)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (18)..(18)
<223> n is C or 5-methylcytosine

<220>
<221> misc_feature
<222> (21)..(21)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is C or 5-methylcytosine

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is C or 5-methylcytosine

<400> 219

ggnnnnngggn nnggnnnnngg nnnn 24

<210> 220

<211> 25

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (4).. (4)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (7).. (7)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (10)..(10)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (13)..(13)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (16)..(16)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is 5-methylcytosine

<220>

<221> misc_feature

<222> (22)..(22)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (23)..(23)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (24)..(24)

<223> n is an abasic monomer

<220>

<221> misc_feature

<222> (25)..(25)

<223> n is an abasic monomer

<400> 220

nugnugnugn ugnugnugnu gnnnn 25

<210> 221

<211> 25

<212> RNA

<213> Artificial

<220>

<223> Oligonucleotide

<220>

<221> misc_feature
 <222> (1)..(1)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (7)..(7)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (19)..(19)
 <223> n is 5-methylcytosine

<220>
 <221> misc_feature
 <222> (22)..(22)
 <223> n is an abasic monomer

<220>
 <221> misc_feature
 <222> (23)..(23)
 <223> n is an abasic monomer

<220>
 <221> misc_feature
 <222> (24)..(24)
 <223> n is an abasic monomer

<220>
 <221> misc_feature
 <222> (25)..(25)
 <223> n is an abasic monomer

<400> 221

nugcugnugc ugnugcugnu gnnnn 25

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2011097614A](#) [0010]
- [US6683173B](#) [0019]
- [US13530218B](#) [0022]
- [WO2011097641A](#) [0022]
- [WO2011150408A](#) [0022]
- [WO2007089611A](#) [0029]
- [EP12165139A](#) [0100]
- [US61636914B](#) [0100]

Non-patent literature cited in the description

- Chem. Commun., 2007, 3765- [0022]
- **KIEBURTZ K. et al.**Huntington Study Group, 1996, vol. 11, 136-142 [0060]
- **REMINGTON**Science and Practice of PharmacyLippincott Williams & Wilkins20000000 [0062]
- **AARTSMA-RUS et al.**Hum Mol Gen, 2003, vol. 12, 8907-14 [0099]
- **ARAI K et al.**Bioorg. Med. Chem., 2011, vol. 21, 6285- [0099]
- **BAUER et al.**J Neurochem., 2009, vol. 110, 1737-65 [0099]
- **BRAIDA C. et al.**Human Molecular Genetics, 2010, vol. 9, 1399-1412 [0099]
- **BRUNO et al.**Adv Drug Deliv Rev., 2011, vol. 63, 131210-26 [0099]
- **DIEBOLD et al.**Eur J Immunol, 2006, vol. 36, 123256-67 [0099]
- **EVERS et al.**PLoS ONE, 2011, vol. 6, 9e24308- [0099]
- **HUANG et al.**Somat Cell Molec Gen, 1998, vol. 24, 217-33 [0099]
- **KRIEG AM. et al.**Nature, 1995, vol. 374, 546-549 [0099]
- **KRIEG, A. M.**Curr. Opin. Immunol., 2000, vol. 12, 35-43 [0099]
- **KUMAR L**Pharm. Technol., 2008, vol. 3, 128- [0099]
- **MUCHOWSKI et al.**PNAS, 2002, vol. 99, 727-32 [0099]
- **MULDERS et al.**PNAS, 2009, vol. 106, 3313915-20 [0099]
- **PEACOCK H et al.**J. Am. Chem. Soc., 2011, vol. 133, 9200- [0099]
- **POPOVIC PJ. et al.**J of Immunol, 2006, vol. 177, 8701-8707 [0099]
- **ROON-MOM et al.**Mol Brain Res, 2002, vol. 109, 1-10 [0099]

- **ROPPER AH.BROWN RH.**Principles of neurologyMcGraw-Hill20050000 [0099]
- **ROSS et al.**Lancet Neurol., 2011, vol. 10, 83-98 [0099]
- **RIGO, F et al.**Nature chemical biology, 2012, vol. 8, 555-561 [0099]
- **STEFFAN et al.**PNAS, 2000, vol. 97, 6763-68 [0099]
- **VON HORSTEN S. et al.**Hum Mol Genet., 2003, vol. 12, 6617-24 [0099]
- **WAGNER, H.**Adv. Immunol., 1999, vol. 73, 329-368 [0099]
- **YU RZ.**Anal Biochem, 2002, vol. 304, 19-25 [0099]

P a t e n t k r a v

- 5 **1.** Oligonukleotid bestående af 2'-O-methyl RNA-nukleotidrester med en hovedkæde, hvor alle phosphat-dele er erstattet af phosphorothioat-dele, hvilken oligonukleotid har en basesekvens bestående af (XYG)₇, hvor hvert X er 5-methylcytosin, og hvert Y er uracil (SEQ ID NO:90).
- 10 **2.** Oligonukleotid ifølge krav 1, hvor oligonukleotidet er et enkeltstrenget oligonukleotid.
- 3.** Sammensætning omfattende et oligonukleotid ifølge krav 1 eller 2.
- 15 **4.** Sammensætning ifølge krav 3, hvor den omfatter mindst ét excipiens, der yderligere kan understøtte forstærkning af targetering og/eller afgivelse af sammensætningen og/eller oligonukleotidet til et væv og/eller en celle og/eller i et væv og/eller en celle.
- 20 **5.** Oligonukleotid ifølge krav 1 eller 2, eller sammensætning ifølge krav 3 eller 4, til anvendelse som et medikament til forebyggelse, forsinkelse og/eller behandling af en human genetisk sygdom forbundet med cis-element repeat-instabilitet.

DRAWINGS

Fig. 1a




Fig. 1b




Fig. 2a




Fig. 2b




Fig. 2c




Fig. 2d

